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ABSTRACT
5 Fluorouracil (5FU) chemotherapy is widely used in the treatment of colorectal
cancer (CRC), and has been the first-choice chemotherapy drug for CRC for many years.
However, nearly 10% of patients receiving chemotherapy die during the first 30 days of
treatment. Further, it is estimated that 70% of surviving patients will develop non-specific
toxicities as a result of chemotherapy treatment. We characterize these toxicities in an
animal model of chemotherapy treatment and show that perturbations in the gut
microbiome might be exacerbate the prolonged effects of chemotherapy. A compound
that could attenuate the multiple non-selective toxicities associated with chemotherapy
could have great clinical potential. Emodin is a trihydroxy-anthraquinone found in
several Chinese herbs, including Rheum palmatum and Polygonum multiflorum. Emodin
has been shown to attenuate the severity of multiple experimental disease models
including arthritis, liver damage, atherosclerosis, myocardial ischemia, and cancer by
reducing the inflammatory cascades associated with these conditions. We illustrate that
emodin is poorly absorbed when given orally or intraperitoneally and is cleared from
systemic circulation by 12 hours. However, we did discover that emodin is more
bioavailable in female mice 1 hour after dosing. We also demonstrate that emodin is safe
in mice when given through the diet for 3 months and does not cause any physiological or
pathological perturbations. When pairing emodin with 5FU, we were able to attenuate
functional toxicities associated with chemotherapy and ameliorate the lymphocytopenia
associated with chronic and acute chemotherapy. Further, we demonstrate that emodin
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can improve gut resilience to 5FU and reduce aberrations in bacterial spatial
arrangement. In addition, we examined the ability for emodin to be used as a preventative
treatment for colorectal and intestinal cancer. We show that emodin treatment reduces
tumor burden in both the AOM/DSS and Apcmin/+ models of sporadic cancer
development. In the AOM/DSS model we show that emodin reduces pro-tumorigenic
M2-type macrophages in the colon. Further, we show that there is amelioration of the
pro-inflammatory niche that exists in the bone marrow which might contribute to the
improved survival outcome and quality of life during cancer treatment. The findings
presented in this document show significant promise for the potential use of emodin as a
primary and complementary therapeutic in the treatment of colorectal cancer.
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PREFACE
The need for physician-scientists has never been greater. As the world enters the
next industrial revolution, biomedicine will be at the forefront of the most unprecedented
discoveries. With new medical technology and an evolving understanding of nature, so
must come a new approach to medicine. Chemically derived therapeutic interventions
will be able to optimize physiological interactions to achieve the maximal result during
treatment. The goal of this dissertation is to investigate the interaction between three
characters in medical treatment; the inflammatory response, the gut microbiota, and the
drug itself. Through the course of my work, I will demonstrate how all three of these
components of medicine can interact to improve the efficacy, fine tune the
pharmacokinetics, and reduce non-specific toxicity to idealize the personalized approach
to medicine. While I know that I am not the only one to propose this approach to
medicine, I hope these ideas will prove to be fruitful in the evolution of modern medicine
and lead to safer and more effective treatments in all fields of medicine.

Figure P1.1 The microbiota-immune-drug axis in the development of personalized
medicine.
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CHAPTER 1
INTRODUCTION AND AIMS
The WHO has reported cancer as the second leading cause of death, accounting
for nearly 9.6 million deaths worldwide per year. This amounts to nearly 1 in 6 deaths
being due to cancer. In the United States, the National Cancer Institute estimates that over
1.7 million new cases of cancer will be diagnosed in 2020 and over 600 thousand people
will die from the disease. Within this statistic, the American Cancer Society estimated
that in 2019 there were over 100 thousand new cases of colon cancer and over 40
thousand new cases of rectal cancer while there were over 51 thousand deaths associated
to colorectal cancer alone. It is estimated that the average American has a 5% lifetime
risk of developing colorectal cancer (CRC) with men having a greater mortality rate of 59
per 100 thousand versus 44 per 100 thousand in women. The incidence of colorectal
cancer increases with advancing age in both genders, with the highest risk occurring in
those over 69 years of age. The financial burden of colorectal cancer has had a large
impact on the current health care system. In 2010, the estimated direct cost of colorectal
cancer was over $14 billion, with over $11 billion resulting from lost productivity and
premature death. Thus, colorectal cancer has had, and is continuing, to have a major
impact on both the population and economy of the United States.1
5 Fluorouracil (5FU) chemotherapy is widely used in the treatment of CRC and
has been the first-choice chemotherapy drug for CRC for many years. However, its
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clinical utility remains hampered by acquired resistance and hematopoietic and
gastrointestinal toxicities resulting from its non-selectivity. 5FU functions as a
thymidylate synthase inhibitor with a half-life of approximately 15 min when injected
intravenously (IV).
When used in the treatment of CRC, it is estimated that approximately 1% of the
injected compound reaches the colon to induce a potential anti-tumor effect. This
translates to a 10-15% success rate in the clinic. Currently, there is no standard
prescription of 5FU therapy. The most common regimen involves 4 consecutive days of a
moderate dose with daily monitoring of behavior and phenotypic changes in the patient.
If the patient is described as well adapted and responsive to the treatment, a fifth day of
treatment will be given and then will be delivered every other day until the patient begins
to show symptoms of non-specific toxicity. As such, many side effects are associated
with 5FU treatment; the most common including fatigue, loss of appetite, and diarrhea,
all of which can lead to a reduced quality of life. Beyond this, it is estimated that over 7%
percent of cancer patients treated with chemotherapy die as a result of non-selective
toxicities rather than the cancer itself.
Alternative and complementary medicine has been used in many aspects of both
western and eastern medicine. Attenuating inflammation and disease pathology with
these compounds is an age-old practice but has recently entered the spotlight in modern
experimental medicine. Unfortunately, many natural compounds are sold as supplements
and are therefore at risk for being improperly used. This, however, presents the
opportunity to investigate the efficacy and applicability of these natural compounds to
clinical settings as potential primary or complementary therapeutics.
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Emodin (1,3,8-trihydroxy-6-methylanthraquinone), is a natural anthraquinone that
has recently entered the spotlight of natural compounds with potential anti-tumor and
anti-inflammatory properties. Isolated from several Chinese herbs, including Rheum
palmatum, Polygonum cuspidatum, and Polygonum multiflorum, emodin has been
regularly used in traditional Chinese medicine. Multiple pre-clinical investigations have
demonstrated emodin to contain a wide spectrum of pharmacological benefits, including;
anti-viral, anti-bacterial, anti-allergic, anti-osteoporotic, anti-diabetic, anti-inflammatory,
neuroprotective, hepatoprotective, and anti-tumorigenic properties. Utilizing these
potential properties, our ultimate aim is to establish emodin as a safe compound to be
used as potentially both a primary and complementary therapeutic.
The overall goal of this proposal is to determine the pre-clinical effectiveness of
emodin in attenuating the toxicities associated with chemotherapy treatment and the
potential for emodin to prevent the onset of colorectal cancer. Our central hypothesis is
that emodin will reduce the inflammation associated with both chemotherapy toxicity and
colorectal cancer burden through mechanisms involving the inactivation of macrophages
leading to reduced inflammatory burden, better quality of life, and prolonged survival.
This hypothesis will be tested in the following three aims:
Specific Aim #1 will evaluate the effect of 5 fluorouracil chemotherapy on inflammation,
functional parameters, and gut microbiota.
Specific Aim #2 will determine the effects of dietary emodin on reducing toxicity of 5
fluorouracil chemotherapy.
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Specific Aim #3 will determine the efficacy of dietary emodin on preventing colorectal
cancer.
Working Model: Initially, this proposal will examine the overall toxic characteristics of
5FU chemotherapy both in the absence and presence of colorectal cancer (AIM 1). Next,
this proposal will investigate the pharmacological properties of natural anthraquinone
emodin and its ability to be used as a complementary therapeutic to reduce the toxic
properties associated with 5-FU chemotherapy (AIM 2). Finally, this proposal will also
evaluate the use emodin to prevent the onset of colorectal cancer (AIM 3). Overall, this
proposal will provide a comprehensive understanding of 1) the toxicities associated with
current cancer treatments, 2) the potential use of emodin to reduce toxicities associated
with current cancer treatments, and 3) the potential for emodin to be used as a dietary
therapeutic to prevent colorectal cancer. The results of the above described aims will
serve as an important step for progression of emodin to human trials in addition to
furthering our understanding of the role of natural anthraquinones in the prevention and
treatment of colorectal cancer.
Specific Aim #1 will evaluate the effect of 5 fluorouracil chemotherapy on
inflammation, functional parameters, and gut microbiota.
Rationale: It has been previously established that 5FU chemotherapy causes
severe adverse reactions and non-selective toxicities in cancer patients. Side effects
include fatigue, loss of appetite, and diarrhea among others, all of which can lead to a
reduced quality of life and premature death. Identifying strategies to increase efficacy and
reduce toxicity of chemotherapy are of significant public health importance. Further, 5FU
has been reported to cause disturbances in the gut microbiome, which can further
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influence the outcome of cancer therapy. Thus, the goal of this aim is to perform a
comprehensive analysis of the physiological effects of 5FU therapy on inflammation,
functional parameters, and gut microbiota.
Aim 1.1: We will observe the effects of 5FU on local and systemic inflammation
in non-tumor burdened mice and in the AOM/DSS model of colorectal cancer.
We will use a low dose regime of 5FU therapy (40 mg/kg) which is most
comparable to the commonly prescribed dose in clinical medicine.
Aim 1.2: To observe the effects of 5FU on quality of life, we will employ a
battery of functional tests to investigate fatigue, muscular strength, and peripheral
nociception.
Aim 1.3: We will observe and characterize the changes in the gut microbiomeimmune system using 16S rRNA sequencing and PICRUSt analysis. We will then
utilize fecal microbial transplantation to characterize the changes in microbial
composition and their effects on host physiology.
Specific Aim #2 will determine the effects of dietary emodin on reducing toxicity of 5
fluorouracil chemotherapy.
Rationale: Emodin is a natural anthraquinone derivative found in various Chinese
medicinal herbs. Recent evidence has shown emodin to have many health benefits
including anti-inflammatory, anti-viral, and anti-bacterial properties among others. In this
aim we will first characterize the safety and pharmacodynamics of emodin and then use
emodin as a complementary therapeutic to attenuate the toxicities of 5FU chemotherapy.
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Aim 2.1: We will perform a standard pharmacokinetics study by giving emodin
via IP and oral gavage to assay the clearance of emodin in the plasma over time.
Aim 2.2: To observe the potential long-term effects of emodin, we will feed male
and female an emodin infused diet for three months.
Aim 2.3: Emodin will be given 3x/week at a dose of 40 mg/kg complementary to
our 35 mg/kg 5FU regime and observed at an acute and chronic timepoint to
observe the potential to ameliorate 5FU-associated toxicities.
Specific Aim #3 will determine the efficacy of dietary emodin on preventing
colorectal cancer.
Rationale: There is emerging evidence that emodin may have anti-tumor
properties. We will use the AOM/DSS and Apcmin/+ models of colorectal cancer to
investigate the potential for emodin to be given as a preventative agent to patients at risk
for developing colorectal cancer.
Aim 3.1: We will investigate the potential for emodin to reduce the tumor burden
in both models of CRC when used as a preventative therapeutic.
Aim 3.2: We will investigate the ability for emodin to reduce the chronic
inflammation associated with CRC.
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Figure 1.1 Research Model
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CHAPTER 2
REVIEW OF LITERATURE
2.1 Colorectal Cancer
The WHO has reported cancer as the second leading cause of death, accounting
for nearly 9.6 million deaths worldwide per year. The American Cancer Society
estimated that in 2019 there were over 100 thousand new cases of colon cancer and over
40 thousand new cases of rectal cancer, while there were over 51 thousand deaths
associated to colorectal cancer alone. It is estimated that the average American has a 5%
lifetime risk of developing colorectal cancer (CRC) with men having a greater mortality
rate of 59 per 100 thousand versus 44 per 100 thousand in women. The incidence of
colorectal cancer increases with advancing age in both genders, with the highest risk
occurring in those over 69 years of age. The financial burden of colorectal cancer has had
a large impact on the current health care system. In 2010, the estimated direct cost of
colorectal cancer was over $14 billion, with over $11 billion resulting from lost
productivity and premature death. Thus, colorectal cancer has had, and is continuing, to
have a major impact on both the population and economy of the United States.1
Clinical Symptoms of Colorectal Cancer
Colorectal cancer is a degenerative disease that takes years to develop in humans.
The incidence of colorectal cancer is suggested to be onset by chronic stress and poor
lifestyle management, the latter of which is typically a lack of physical activity and poor
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diet. In the early stages of the disease, symptoms of colorectal cancer may be minimal or
not present at all. The quantity and severity of symptoms associated with colorectal
cancer typically accompany the progression of the disease.
In a clinical setting, symptoms of colorectal cancer are typically broken-down into
two categories: local and systemic. Local symptoms are those which have a direct effect
on the colon or rectum. These symptoms include changes in bowel habits, constipation,
diarrhea, alternating diarrhea and constipation, rectal bleeding or bloody stools,
abdominal bloating or cramping, incomplete bowel emptying, and narrower stools.
Systemic symptoms are those that affect the entire body and are typically seen in the later
stages of the disease. These symptoms typically include unexplained weight loss,
unexplained loss of appetite, nausea or vomiting, anemia, jaundice, and weakness and
fatigue. Due to the delayed onset of both local and systemic symptoms past the initial
onset of the disease, the American Cancer Society recommends that the average
American should start regular screening at age 45. Typical screening procedures can be
done either with a sensitive stool-based test or with a physical exam consisting of a
colonoscopy. Persons in good health are recommended to undergo a colonoscopy every
10 years or flexible sigmoidoscopy (FSIG) every 5 years.
The Two-Faced Future of Colorectal Cancer
The next 50 years will be challenged with a two-faced future of colorectal cancer.
On the dark side of this face we see the frightening reality that Millennials and Gen Xers
have twice the incidence of colorectal cancer. A study by Siegel et. al, 2017 reported the
striking increase in colorectal cancer incidence rates among patients aged 20-39.2
Although socially, this age group has been shown to be the most active and health
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conscious group of Americans, the prevalence of preservatives and poor environmental
health has been attributed to this increase of cancer incidence. This further provides
rationale to develop a greater understanding of the etiology of colorectal cancer and to
develop better preventative therapeutics to lower this increasing burden.
Whereas increased incidence will cause a heavy burden on the healthcare of the
American people, improved screening and detection methods for colorectal cancer has
been improving survival rates. This has included improved technological advancements
in colonoscopy. Colonoscopy is the accepted gold standard for detecting and diagnosing
colorectal adenomas and cancers. The Third Eye® Retroscope® and Third Eye®
Panoramic™ are two recently developed colonoscopes that allow for a full 1800 retroflex
to provide a more complete view of the colonic folds and can improve polyp detection by
up to 80%.3 Another recent development, pioneered by Check Cap Ltd, has combined Xray imaging with microtechnology to improve capture of gastrointestinal images. Check
Cap’s C-Scan® capsule utilizes a capsule size tablet taken with contrast agent. Over 2472 hours the C-Scan capsule will pass through the gastrointestinal system and generate
3D images of the enteric system which can be assessed by physicians.
2.2 Models of Studying and Investigating Colorectal Cancer
There are many models of studying colorectal cancer that are being utilized to
understand the development, progression, and potential therapies of the disease. Utilizing
both sexes in multiple models is the gold standard to performing a comprehensive
investigation of CRC. Cell culture methods have also been utilized, especially for drug
development, to understand a direct impact of a compound on murine and human cells.
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Human models are only used in later progressions of drug development, and therefore
many investigators use rodent and in-vitro models to study colorectal cancer.
Non-rodent species
Canine use has become an attractive model for comparative oncology research.
Similar to rodent models, there are many similarities between canine colorectal cancer
and the human disease. One of the benefits to canine intestinal cancer models is the onset
of tumors is more commonly found in the large intestine rather than the small intestine.
This more closely mimics the descending colon/rectal cancers that are most frequently
seen in human cases of colorectal cancer.4 Evaluation of clinical cases of canine
colorectal carcinomas have revelated cytoplasmic and nuclear accumulations of βcatenin, which further suggests a dysregulation of the WNT signaling pathway as an
important driver in the onset of colorectal cancer in the canine species.5 Despite the
similarities between canine and human colorectal cancer, the prevalence in canines is less
than 1% and therefore severely limits the effectiveness of using this model.4,5
Sheep are also an effective comparative pathological model of studying colorectal
cancer due to the similarities of lesions and metastatic behavior with the human disease.
Despite these similarities, it has been documented that 100% of intestinal
adenocarcinomas developed in sheep are found in the small intestines. Along with this
limitation, the unique physiological characteristics of the sheep ruminant fore-stomachs
has been shown as a significant weakness of this model.4,6
Orthotopic Tumors
The transition from in-vitro experiments to in-vivo typically involves implanting a
tumor in the flank of rodents. The most common models for colorectal cancer are the CT11

26 cell line, which are native to the BALB/c mouse strain, and the MC38 cell line which
are native to the C57BL/6 moue strain. Palpable tumors typically develop within 14 days
and the mice begin to show physiological perturbations associated with cancer. Tumors
can grow to be large and can account for more than 15% of the animal’s total body
weight. These models typically mimic the symptoms of tumor burden which include
increased circulating IL-6 and insulin resistance. These models are primarily used for
rapid studies and are often incorporated into preliminary understandings of novel
compounds. The accelerated development of tumors makes the tumor burden less like the
human disease; but is still accepted as a model of studying colorectal cancer.7 Further, in
the development of colorectal cancer, it is important to understand that a colorectal tumor
implanted in the flank of an animal is not in its native hypoxic environment and may
develop and respond differently to treatments since the tumor is more available to the
systemic circulation.8,9
Diet-Induced Rodent Neoplasia Models
Epidemiological evidence has shown diet as a key modulator to the incidence of
colorectal cancer in humans.10-12 Several rodent studies have been conducted to examine
the influence of poor diet on the incidence of colorectal cancer. This diet typically is
designed to mimic the poor “Western diet” that has become problematic to the current
health of Americans. In rodent studies, the “Western diet” is designed to increase caloric
fat intake from 5% to as much as 60%, decrease calcium intake from 0.5% to 0.05%, and
decrease vitamin D intake to 100 IU/kg from 1,000 IU/kg.4,13
Feeding of the Western diet for as little as 12 weeks has been shown to induce
hyperplasia of the colonic crypts in rats and mice.13 Longevity studies have also shown
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that after 2 years of being fed the Western diet, 70% of mice developed dysplastic crypts
and small polypoid lesions, most of which were found in the distal colon.14 Another study
has also shown that a 2-year feeding of a Western diet low in fiber, choline, folate, and
methionine lead to 25% of C57BL/6 mice to develop intestinal tumors and
adenocarcinomas. Feeding the Western diet to mice has also been shown to induce a
transcript profile in normal colonic mucosa that was similar to the pattern loss of the Apc
allele in Apc138N/+ mice.15 The Western diet model of spontaneous colorectal cancer is an
attractive model to study the etiology of colorectal cancer, however, the severity of the
dietary fat intake combined with the time necessary for tumor development do not reflect
the etiology of human colorectal cancer.
Chemically Induced Models
A large variety of chemicals have been shown to have mutagenic properties and
have been used to controllably induce cancer. 1,2-dimethylhydrazine (DMH) and its
metabolite azoxymethane (AOM), are the two most commonly use carcinogens to induce
colorectal cancer in rodents.16 DMH and AOM are alkylating agents that are typically
injected intraperitoneally or subcutaneously over several weeks to induce tumorigenesis.
AOM is typically used to produce colorectal polyps and can cause mutations in the K-ras,
Src/PI3K/Akt, β-catenin, TGF-β, and p53 signaling pathways to drive tumor
development.17,18 The AOM model can be used on its own or be paired with dietary DSS
supplementation. DSS is used to induce colitis and systemic inflammation which further
drives tumor development. This model is useful for studying the gene-gene and geneenvironment interactions that influence the pathophysiology of colorectal cancer.
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However, it is suggested that this model is not viable due to the little evidence supporting
the etiology of human colorectal cancer resulting from exposure to alkylating agents.4
Apcmin/+
The Apcmin/+ mouse has been one of the leading models for preclinical colorectal
and intestinal cancer research over the past 25 years. The phenotype of these mutant mice
showed severe clinical symptoms of intestinal cancer from the onset of a usually fatal
case of regenerative anemia attributed to multiple intestinal neoplasms, or “min.” The
min mouse has a naturally occurring T-to-A nonsense mutation at nucleotide 2,549 of the
Adenomatous polyposis coli (Apc) gene that pares the Apc protein at the codon 850, this
predisposes the mice to develop multiple intestinal adenomas.19 The min mutation is
autosomal dominant, and homozygosity for the mutant allele is embryonic lethal.
Heterozygous Apcmin/+ typically become anemic by 60 days of age and progress through
worsening clinical symptoms of intestinal cancer and usually die by 120 days of age.4,19
The use of the Apcmin/+ mouse model has been widely used to study
carcinogenesis or to test novel treatments and delivery methods. The Apcmin/+ mouse has
also been used to study genetic modifications of colorectal cancer risk or Modifiers of
Min (MoM).4,20 This model, however, leads to the development of polyps primarily in the
small intestine with few polyps found in the colon. Therefore, it is commonly used as a
model of cancer cachexia but is also effective as a preclinical model for drug
development.
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2.3 Treatments for Colorectal Cancer and Non-Specific Toxicities
The last 60 years has seen great strides for medical technology and has led to an
improved ability to treat multiple cancers. Since the discovery of DNA replication
blocking mechanisms of Aminopterin, the predecessor to current treatment methotrexate,
research into blockading functions of cell growth have been the major focus for the
development of anti-cancer therapies. As the incidence of different types of cancer
evolved in the medical community, there was an increased demand of treatment methods.
Present therapies have seen improved targetability of tumor subtypes and increased early
detection. As various mechanisms of cancer development and treatment are discovered,
so paralleled the evolution of chemotherapy treatments. This evolution of treatments has
further led to treatments focused on drug combinations, delivery techniques, tissue
specificity, and overcoming drug resistance by carcinomas.21,22
Common Treatment Regimes
Chemotherapy is the most widely used treatment of colorectal cancer.
Specifically, 5 Fluorouracil has been the first-choice chemotherapy drug for CRC for
many years. 5FU functions as a thymidylate synthase inhibitor and is typically injected
intravenously (IV). The most common regimen used in clinical settings involves 4
consecutive days of 5FU treatment with daily monitoring of behavior and phenotypic
changes in the patient. If the patient is described as well adapted and responsive to the
treatment on day 5 another single injection will be delivered every other day for 6 days or
until the patient starts to show symptoms of non-specific toxicity. This regimen is given
at the discretion of the attending physician and can be prescribed either as an adjuvant
therapy to a colon resection or as a sole method of treatment.23,24
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The use of high energy radiation (such as x-rays) or particles to destroy cancer
cells is more often used in rectal cancer than colon cancers. The use of radiation is
commonly adjuvant to chemotherapy or surgical resection. When used with surgery,
radiation is used to kill cancer cells that may have invaded through the colon, posing a
risk for metastasis after surgery. Because of the risk for causing gut barrier dysfunction,
radiation is seldomly used in cases where it can be avoided.
Immunotherapy
The introduction of immunotherapy has recently revolutionized the understanding
of biology and medical science and has led to a vast array of targeted therapeutics.25
Unfortunately, the realm of colorectal cancer has seen little benefits from the
immunotherapy revolution. In a recent clinical trial, patients treated with Pembrolizumab
(Keytruda) reported 0% response rate in primary CRC. However, Pembrolizumab did
gain approval from the FDA in May 2017 for use in patients with unresectable or
metastatic colon cancer that has tested positive for microsatellite instability-high (MSI-H)
or deficient mismatch repair (dMMR) and have previously undergone chemotherapy.
Currently, the use of immunotherapy in metastatic colorectal cancer has proven to be the
most promising avenue. However, as stated above, the current technology has shown
little to no promise in the treatment of primary colorectal cancers.26
Non-Specific Toxicities
Non-specific toxicities are the major burden associated with current treatments for
colorectal cancer. As described above, 5FU is the most commonly used chemotherapeutic
used in the treatment of colorectal cancer. However, its clinical utility remains hampered
by acquired resistance and hematopoietic and gastrointestinal toxicities. Being the most
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commonly prescribed chemotherapeutic for colorectal cancer, the majority of literature
has focused on elucidating the non-specific toxicities associated with 5FU. 5FU functions
as a thymidylate synthase inhibitor with a half-life of approximately 15 min when
injected intravenously. When used in the treatment of CRC, it is estimated that
approximately 1% of the injected compound will reach the colon to induce an anti-tumor
effect. This translates to a 10-15% success rate in the clinic.27
As such, many side effects are associated with 5FU treatment, the most common
including fatigue, loss of appetite, and diarrhea, all of which can lead to a reduced quality
of life.28 Furthermore, 7.5% of cancer patients treated with chemotherapy die as a result
of non-selective chemotherapy toxicity rather than the cancer itself.29 One of the most
potent side effects of 5FU treatment is intestinal mucositis. Mucositis usually appears
along the entire gastrointestinal tract from mouth to anus and causes general debility.23,3032

Mucositis of the intestine is characterized by increased crypt apoptosis and villus

atrophy, leaving the mucosal tissue open to infection and ulceration.33,34 Several factors
or genes contributing to the 5FU-induced mucositis have been previously studied; the
formation of reactive oxygen species (ROS) and the production of pro-inflammatory
cytokines, such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNFα) have
been implicated in this process.31,33,35 Furthermore, histological evaluation of the small
intestine indicates obvious villus destruction and inflammation of the crypts.35,36
Another well-documented side-effect of 5FU is the incidence of cytopenia and
anemia. Most patients present with severe cytopenia and anemia after treatment with
5FU. This directly translates to patients becoming immunocompromised and developing
nosocomial infections which can worsen their condition. Further, anemia results in severe
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fatigue and weakness which lowers quality of life and the ability to maintain tissue
homeostasis during treatment periods.
Finally, many patients present with increased sensitivity to touch and complaints
of pain. Where this mechanism of toxicity has remained elusive to medical research,
recent efforts have utilized complementary and alternative therapeutics to blunt these
responses to provide relief during intense bouts of pain.
The Future of Treatments in Colorectal Cancer
Recent advances in medical technology have improved the clinical efficacy of
diagnosis and early-stage treatment of CRC. However, more needs to be done in the
respect to treating and preventing colorectal cancer. The future of cancer treatment
involves a bimodal approach through 1) prevention and 2) physiological
engineering.12,34,37-43 As our understanding of nature and biomolecular engineering
improves, so will the ability to design personal therapies to prevent the onset and improve
current therapeutic interventions. As with the focus of this dissertation, it is important to
consider multiple aspects of physiology when designing experimental interventions and
in clinical medicine.
Phases of Drug Development
The progression of drug testing requires many pre-clinical and clinical steps that
are highly regulated by the FDA. The first step in drug development involves the use of
pre-clinical animal and in-vitro based experiments that show effective and safe delivery
methods of the proposed compound. After this extensive bout of investigations, the FDA
can decide whether the drug is reasonably safe for progression to human trials, or to take
the drug back to formulation. Once in clinical trials the drug is considered an
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investigational new drug and must pass three phases of clinical testing. These phases are
overseen by both medical research teams and non-research-based scientists and
physicians.
Phase 1 testing is usually conducted in healthy volunteers in an effort to
determine side effects and to perform necessary human pharmacokinetic analyses. The
number of participants for this phase is typically between 20 and 80. Phase 2 studies
begin once the drug has been determined safe for healthy humans. This phase tests a
variety of patients with certain diseases or conditions and is compared in a controlled
study against a placebo drug or current form of treatment. In Phase 2, the number of
participants can be expanded to at most 300 and is usually determined based on the range
of conditions being investigated. At the end of Phase 2, if a drug has shown evidence of
effectiveness in a certain population, Phase 3 can begin. Phase 3 is typically aimed at a
more targeted population and can be initiated as a follow-up study with larger participant
populations. The number of participants in Phase 3 can be anywhere from a few hundred
to three thousand. Phase 3 can also be expanded to multiple centers.
After passing all three phases of human clinical trials, post-market and
commitment studies are required by a sponsor and are monitored by the FDA. This
typically allows the drug to enter longevity studies in human participants to determine
any long-term side effects that may arise from continuous use of the drug. Once passed
by the FDA, the drug can be submitted as a new compound and within six months can be
passed and distributed for use in clinical medicine.44
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Many times, it has been necessary for a drug to undergo a Phase 4 trial. This
involves recruiting greater numbers of participants to confirm certain findings that might
have been contradictory or abnormal to previous investigation. Recently, companies such
as Merk, have initiated Phase 0 studies of new drugs. This involves utilizing a small
participant pool and performing microdosing of the drug. Microdosing allows for the
drug to be delivered at a concentration 100X lower than the proposed therapeutic dose.
Phase 0 also confirm bench-to-bedside translation of compounds to confirm mechanistic
actions and deem the drug safe for use in greater populations of human participants.
2.4 Hallmarks of Immunology in Cancer and Cancer Treatments
The immune niche of a tumor
With the emergence of immune-based therapies, the immune microenvironment
has become of significant interest as a primary regulatory mechanism that can determine
the outcome of anti-cancer treatments. Tumor immune evasion and immune promoting
factors are two primary hallmarks of cancer contributing to the maintenance of a tumor
microenvironment.45 Recently, the difference between a “Hot” and “Cold” tumor has
been highlighted as significant to the prognosis and therapeutic outcome of anti-cancer
treatments. “Hot” tumors are described as those that contain large amounts of immune
cells and “cold” tumors are the opposite and do not contain large amounts of immune
cells.
The “hot vs. cold” status has been shown to play a significant role in the outcome
of therapies. A recent article by Newman et. al. 2020 injected unadjuvanted seasonal
influenza vaccines into melanoma and breast cancer orthotopic tumors effectively
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changing them into “hot” tumors43. This reduced tumor size by increasing CD8+ T-cells
and decreasing regulatory B-cells within the tumor. This finding demonstrates that
turning a tumor from “cold” to “hot” can promote anti-tumor effects and can be utilized
to improve upon current therapies that may be ineffective.
Tumor associated macrophages
A major focus of this dissertation, specifically in Aim 3, will be on tumor
associated macrophages or TAMs. The presence of TAMs has been shown to play a vital
role in the outcome and prognosis of many cancers.46 Macrophages are derived from
monocyte precursors circulating in the blood and are recruited to the tumor by
chemokines such as MCP-1 and TGFβ.46 Once recruited to the tissue, monocytes will
mature into macrophages. It is generally understood that the recruitment of macrophages
to the tumor contribute to the maintenance of the tumor microenvironment and exert protumoral functions. Pro-tumoral macrophages are characterized as M2-type macrophages,
which are polarized from exposure to cytokines such as TGFβ and IL-10.47,48 The
presence of M2-type macrophages in the tumor microenvironment have been shown to
promote proliferation, invasion and metastasis, angiogenesis, and tissue remodeling.49,50
There is some evidence suggesting that recruitment of M1-type macrophages through
increased TNFα, IL1β, and IFNγ might reverse this pro-tumoral environment and cause
tumor remission. Therefore, therapeutic interventions targeting TAMs and reducing the
M2-type phenotype within the tumor microenvironment might contribute to improved
survival and subsequent success of further therapeutic outcome.46,47,50,51
It is important to establish that there is conflicting literature on macrophage
phenotype, as defined by expression of cell-surface markers. This conflicting body of
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literature is primarily derived from the discrepancy in what is defined as a ‘mature
macrophage’ and the differences in these markers seen from tissue to tissue. For example,
a review by Bain and Schridde 2018 describes mature macrophages as
CD64+MHCIIhiCD206+CD163+ cells.52 In addition, they define lamina propria
macrophages as highly expressing CD11b, CD11c, CD14, and CX3CR1 cells. CD11b is
widely accepted as a monocyte marker, but where Bain and Schridde do not follow some
bodies of literature is with addressing the expression of F4/80 and CD68. F4/80 and
CD68 are two of the most widely cited markers of macrophage expression and are
commonly used to identify total mature macrophage populations.53-55 Further, we and
others have previously defined M1-type macrophages as CD11c-expressing cells and
M2-type macrophages as CD206-expressing cells. CD80, CD86, TLR2, and TLR4 have
also been suggested to be expressed on M1-type macrophages. Additionally, CD204 and
CD163 have been suggested to be expressed on M2-type macrophages.
Whereas there is discrepancy in the expression of markers between tissues, there
is a common consensus that macrophages are highly plastic cell types that exist on a
transitionary spectrum that varies from tissue to tissue. In this dissertation, where we
examine macrophages, we define total macrophages by flow cytometry as
CD45+CD11b+Ly6C+F4/80+ cells which are then further gated against CD11c and
CD206. From here where we define CD11c as M1-type and CD206 as M2-type
macrophages. Where we use tissue gene analysis, we utilize expression of EMR1 (F4/80)
to describe total macrophage populations and ITGAX (CD11c) and MRC1 (CD206) as
M1-type and M2-type macrophages, respectively.
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T-cells
T-cells function in both a direct and indirect manner in the response to cancer.
Killer T-cells will attack and kill cancer cells directly and are identified as CD8 positive
cells. Killer T-cells have been shown to first find cancer cells and can also be stimulated
to kill cancer cells. Helper T-cells fight cancer indirectly and are identified as CD4
positive cells. Helper T-cells are known to assist in the communication between the Tcell receptor (TCR) and with antigen-presenting cells (APCs). The TCR complex and
CD4 bind to distinct regions of the antigen-presenting MHC Class II molecule. T-Cells
play a major role in what is known as the cancer-immunity cycle. As cancer cells are
killed, tumor specific antigens are released and are taken up and presented by APCs. In
the lymph, these APCs now activate CD4+ T-cells which allows them to specifically
attack the tumor cells. CAR-T cells are engineered similarly to this process to specifically
target cancer cells.56-59
In humans, the count of CD4+ and CD8+ cells have been shown to be directly
related to clinical outcome and survival. In colon cancer patients, longer disease-free
survival is correlated with higher CD8+ counts, lower CD4+/CD8+ ratio, and higher
CD8+/FoxP3+ ratio. Immunoscoring (IS) is an index-based density of CD3+ and CD8+
tumor infiltrating lymphocytes (TILs). IS has been shown as a reproducible method from
predicting survival of patients with advanced CRC. These values indicate that the
presence of CD8+ cells, measured in the circulation or directly from tumors, is correlated
to increased survival and anti-tumor responses.58,60
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B-cells
Whereas T-cells physically attach to and attack cancer cells, B-cells target them
indirectly through the production of antibodies. B-cells can play a critical role in cancer
protection and anti-cancer response. B-cells present in the tumor microenvironment
secrete antibodies that can directly inflame the tumor parenchyma and cytokines that can
activate angiogenesis in the vasculature. These responses are capable of inhibiting
effector cells such as CD8+ T-cells and NK cells. These B-cells are termed B-regulatory
cells (B-regs) and exists as a heterogenous population that can directly or indirectly
influence cancer outcome. The specific cytokine release can cause significant influence
on the tumor microenvironment. For example, IL-10 producing B-regs can exacerbate
inflammation and support cancer growth by promoting a pro-tumorigenic niche within
and surrounding the tumor microenvironment.61
Solid tumors in humans often contain significant B-cell populations. The number
of tumor-infiltrating B-cells were identified as the second-best predictor of positive
disease outcome51. Antibodies directed against intracellular can be directly produced by
B-cells. A study by Mizukami et. al. 2006 showed regression of human lung cancer tissue
xenotransplanted into SCID mice was associated with higher levels of tumor-resident Bcell derived IgG in the serum of recipients62. Furthermore, B-cell derived antibodies have
been shown to bind mouse tumors in an antigen-specific manner and mediate
complement-dependent lysis59.
Natural Killer (NK) cells
Natural Killer cells are lymphocytes that were first identified for their ability to
attack tumor cells without deliberate immunization of activation. Furthermore, NK cells
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have also been shown to kill cells that are infected with certain viruses and attack cells
that lack expression of MHC class I antigens. Recently, the discovery of NK receptors
and their ligands has uncovered the molecular mechanisms that regulate NK activation
and function. One of the most documented mechanisms is through IL-12 dependent
activation of NK cells. IL-12 release is part of a cytokine axis in which myeloid cellderived IL-12 triggers lymphoid cell-derived IFNγ production and contributes to
cytotoxic activation63,64. IL-23 and IL-27 are part of the IL-12 family of cytokines. As
with IL-12, macrophages and DCs can produce IL-23 and IL-27 upon sensing pathogens
or their products64,65.
One of the original models of immunotherapy involved allogenic adoptive
transfer of NK cells. Unlike T-cells, which can induce autoimmune reactions, NK cells
appear to be safe when obtained from another person and then injected. Certain ligands
such as NKG2D (CD314), DNAM1 (CD226), 2B4 (CD244), 4-1BB (CD137), PD1, and
CTLA4 have been implicated in the activation of NK cells towards tumors. Of these
ligands, CD314 has been shown to be removed by tumor cells which causes NK cell
evasion. The most promising therapeutic intervention against this mutation has been the
use of monoclonal antibodies against the proteolytic cleavage site on the MICA and
MICB proteins. Preventing this cleavage, in-turn, prevents the shedding of CD314 and
rendering tumors susceptible to NK attack66.
Dendritic Cells (CDs)
Dendritic cells are a heterogenous population of antigen presenting cells that have
been shown to infiltrate the tumor microenvironment. Where normally, DCs play a
critical role in the priming and maintenance of local immunity; in the presence of cancer,
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different subtypes of DCs are recruited to the tumor which can function to either enhance
or suppress the anti-tumor immune response. There are four primary phenotypes of DCs
which are associated with the tumor microenvironment: Plasmacytoid DCs (pDCs) which
function in tolerance induction, Conventional DCs type 1 (cDC1) which function in
MHC-I cross-presentation, Conventional DCs type 2 (cDC2) which function in MHC-II
presentation, and Inflammatory DCs (Inf-DCs) or Monocyte-derived DCs (moDCs)
which function in MHC-I cross-presentation and MHC-II presentation67.
Death of tumor cells, especially from chemotherapy or radiation, have been
shown to modulate tumor associated DCs and enhance anti-tumor immunity. Similarly,
anti-PD1 therapy requires DC-T cell crosstalk and the initiation of anti-tumor CD8+ T
cell responses by cross-presentation in DCs. DC modulating therapies are currently part
of a large field of immunotherapy research. Flt3-L treatment has been one of the most
promising strategies to elicit anti-tumor T-cell immunity. Flt3-L is highly expressed by
cDC1. Pre-treatment of cDC1 cells with Flt3-L and then subsequent adoptive transfer has
been shown to enhance efficacy of checkpoint therapy blockade in animal models of
melanoma and glioblastoma.68
The actual understanding of the immunoregulatory functions of the tumor
microenvironment expand past the scope of this review. However, it is well understood
that certain changes in the tumor microenvironment can promote an anti-tumor niche and
may be most efficiently achieved by directly or indirectly influencing one or more of the
above described immune cells. Therefore, therapeutic interventions showing a
mechanism directly influencing these cells is important in developing proper anti-cancer
therapeutics.
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Taken together, the immune system is well-known to regulate and directly impact
the outcome of cancer onset and therapeutic intervention. Therefore, it is imperative to 1)
understand the mechanisms of immune function during cancer and 2) to develop
interventional and preventative therapeutics that can directly ameliorate the inflammatory
consequences of cancer and the current debilitating therapeutics that are administered
clinically.
2.5 Emodin: 1,3,8-trihydroxy-6-methylanthraquinone

Fig 2.1 Emodin (1,3,8-trihydroxy-6-methylanthraquinone)
Emodin (1,3,8-tryhydroxyanthraquinone) (Fig 2.1) is a natural anthraquinone
isolated from several Chinese herbs, including Rheum palmatum, Polygonum cuspidatum,
and Polygonum multiflorum. Multiple pre-clinical investigations have demonstrated
emodin to contain a wide spectrum of pharmacological benefits, including; antiviral69,
antibacterial70, anti-allergic71, anti-osteoporotic72, anti-diabetic73, anti-inflammatory74,75,
neuroprotective76, hepatoprotective77, and anti-tumorigenic77-79 properties.
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Evidence for anti-inflammatory properties
The primary goal of this proposal is to utilize emodin as a complementary
therapeutic to attenuate the pro-inflammatory responses to 5FU chemotherapy and
cancer. Recent evidence utilizing in-vitro investigations or orthotopic tumors have shown
reduced NF-κB, STAT6, P38 signaling along with reduced IL-6, TNFα, and MCP1
secretion with emodin. In the presented investigations of this proposal, we will aim to 1)
confirm these findings in models of 5FU toxicity and colorectal cancer and 2) to discover
any further mechanisms of action that might contribute to associated benefits of Emodin
as a primary or complementary therapeutic.
We will focus primarily, but not exclusively, on the polarization of macrophages
in the gut. Iwanowycz et al 2016 showed evidence of M1 and M2 bi-directional
depolarization of macrophages in-vitro.80 A follow-up study by Iwanowycz et al 2016
confirmed this phenomenon and further showed increased cytotoxic T-cell activation
leading to reduced orthotopic tumor burden in a model of breast cancer.78 We will
directly expand on this work utilizing two models of colorectal cancer to confirm the
anti-tumor potential and build on the literature of immunoregulatory properties of
emodin.
Tissue specific effects
As described above, the benefits of emodin have been extensively demonstrated
in-vitro. However, these studies have revealed conflicting results about the mechanisms
of emodin. For example, emodin has been shown to activate P38 MAP Kinase in human
hepatoblastoma cells81,82 and in osteoblasts72 but has shown decreased activation in nonsmall cell lung carcinoma83 and in hepatic stellate cells.84 Further, activation of ERK1/2
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MAP Kinase has been shown to be increased in non-small cell lung carcinoma85 and
colorectal cancer cells86 but decreased activation in the amelioration of viral
myocarditis.69 These discrepancies overshadow the potential in-vivo benefits of emodin
and provoke further investigations of this promising dietary agent.
P2X7 Receptor as potential mechanism of action
The mechanism of action of emodin has yet to be discovered. Recent
investigations, however, show evidence in-vitro of a mechanism targeting the P2X7
receptor. The P2X7 receptor is found primarily in the central and peripheral nervous
systems but also on the surface of microglia, macrophages, and the retina. There is
evidence that has shown the P2X7 receptor as a pattern recognition receptor for the
extracellular ATP-mediated apoptotic cell death, regulation of receptor trafficking, mast
cell degranulation, and pro-inflammatory cascade. A study by Jelassi et al. 2013
demonstrated emodin was able to reduce breast and non-small cell lung carcinoma cell
invasion by antagonizing P2X7 receptor mediated ATP-current.79 Further, a study by
Zhang et al 2019 showed emodin reduced ATP-dependent pancreatic duct cell injury by
antagonizing the P2X7 receptor.87
Overall, emodin contains the potential to be used as a complementary and primary
therapeutic in multiple aspects of cancer treatment. This dissertation will attempt to
provide vital preclinical evidence in support of this hypothesis in an effort to promote the
study of emodin in clinical trials.
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CHAPTER 3
IMPACT OF 5 FLUOROURACIL CHEMOTHERAPY ON GUT INFLAMMATION,
FUNCTIONAL PARAMETERS, AND GUT MICROBIOTA1

_____________________
1

Sougiannis AT, VanderVeen BN, Enos RT, et al. Impact of 5 fluorouracil chemotherapy
on gut inflammation, functional parameters, and gut microbiota. Brain Behav Immun.
2019;80:44‐55.
Reprinted here with permission of publisher.
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3.1 Abstract
Emerging evidence suggests that gut microbiota may influence the response to
chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU)
chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC)
and to further determine whether gut microbiota can influence this response. 50 C57BL/6
were randomized into four groups; Control+Vehicle (n=10), Control+5FU (n=10),
AOM/DSS+Vehicle (n=15), and AOM/DSS+5FU (n=15). CRC was induced chemically
by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and
1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or
5FU (cycle 1: 40 mg/kg, cycle 2+3: 20 mg/kg). Functional tests (grip strength and run-tofatigue) were performed prior to 5FU treatment (baseline) and at the completion of the
second cycle of 5FU. Following the third 5FU cycle, mice were euthanized, and the colon
was evaluated for expression of inflammatory genes using RT-qPCR and stool samples
were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota
transplantation from 5FU treated mice to control mice (n=10–15/group) to determine
whether 5FU associated changes in the microbiota could influence functional measures
and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending
decrease in run-to-fatigue performance in cancer mice (p=0.06). Select intestinal
inflammatory genes were significantly elevated with 5FU treatment and this was further
exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity
and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05).
Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and
altered select colon inflammatory markers (p < 0.05). This study provides evidence of an
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effect of 5FU on inflammatory responses and functional measures in a mouse model of
CRC and suggests that gut microbes may play a role in some, but not all, 5FU related
perturbations.
3.2 Introduction
5 Fluorouracil (5FU) chemotherapy is widely used in the treatment of colorectal
cancer (CRC), and has been the first-choice chemotherapy drug for CRC for many
years39,88. However, its clinical utility remains hampered by acquired resistance and
hematopoietic and gastrointestinal toxicities resulting from its non-selectivity30,32. 5FU
functions as a thymidylate synthase inhibitor with a half-life of approximately 15 min
when injected intravenously (I.V.)30,89. When used in the treatment of CRC, it is
estimated that approximately 1% of the injected compound reaches the colon to induce a
potential anti-tumor effect. This translates to a 10–15% success rate in the clinic27.
Currently, the common regimen of 5FU therapy involves 4 consecutive days of 5FU
treatment with daily monitoring of behavior and phenotypic changes in the patient. If the
patient is described as well adapted and responsive to the treatment on day 5 another
single injection will be delivered every other day for 6 days or until the patient starts to
show symptoms of non-specific toxicity23,24. As such, many side effects are associated
with 5FU treatment, the most common including fatigue, loss of appetite, and diarrhea,
all of which can lead to a reduced quality of life28. Furthermore, 7.5% of cancer patients
treated with chemotherapy die as a result of non-selective chemotherapy toxicity rather
than the cancer itself29. Therefore, identifying methods to better evaluate the associated
toxicity related to chemotherapy and the mechanisms involved is of great public health
importance.
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One of the most potent side effects of 5FU treatment is intestinal mucositis.
Mucositis usually appears along the entire gastrointestinal tract from mouth to anus and
causes general debility23,30-32. Mucositis of the intestine is characterized by increased
crypt apoptosis and villus atrophy, leaving the mucosal tissue open to infection and
ulceration33,34. Several factors or genes contributing to the 5FU-induced mucositis have
been previously studied; the formation of reactive oxygen species (ROS) and the
production of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6, and
tumor necrosis factor-α (TNFα) have been implicated in this process31,33,35,90.
Furthermore, histological evaluation of the small intestine indicates obvious villus
destruction and inflammation of the crypts33,35,36. However, the majority of literature
explaining 5FU-induced intestinal mucositis fails to utilize a disease model limiting a
complete understanding of the side effects of 5FU specifically in the context of CRC.
Gut microbiota have been implicated in 5FU associated toxicity91,92. 5FU leads to
gut dysbiosis (i.e. an imbalance of gut microbes) and the ensuing inflammation leads to
exacerbated intestinal mucositis92. Several preclinical studies have reported a drastic shift
from commensal bacteria (i.e., Bifidobacterium and Lactobacillus spp.) to Escherichia,
Clostridium, and Enterococcus spp. following even a single intraperitoneal dose of 5FU92. Mechanistic support for this relationship is provided by the reduced intestinal
mucositis and decreased cytokine levels in 5FU treated mice after antibiotic induced
depletion of microbes92. Understanding the influence of gut microbes on 5FU related
toxicity may lead to the dentification of targets (i.e. bacteria themselves or pathways that
they mediate) to reduce side effects of chemotherapy.
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Using the azoxymethane/dextran sodium sulfate (AOM/DSS) model of CRC, we
sought to characterize the effects of 5FU on colon inflammation and functional measures
in CRC and to further determine whether gut microbiota can influence this response. We
detected a general anti-tumor effect of 5FU in AOM/DSS treated mice; however, side
effects including mortality, adverse physiological outcomes, mucositis, and colon
inflammation were evident. Further, we observed significant alterations in gut microbiota
in the presence of 5FU. Fecal transplantation experiments also were conducted in control
mice to investigate the potential causality between gut microbiota and 5FU toxicity. Our
findings indicate that gut microbes may play a role in some, but not all, 5FU related
perturbations.
3.3 Methods
3.3.1. Animals
Male C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor,
ME) and were cared for in the animal facility at the University of South Carolina. Mice,
randomized upon arrival to the animal facility to prevent litter biases in microbiome data,
were housed five per cage and maintained on a 12:12-h light-dark cycle in a low-stress
environment (22 °C, 50% humidity, low noise). Mice were kept in a room isolated from
all other ongoing animal experiments and were handled only by the primary
investigators. All mice were habituated to the AIN-76A diet prior to any interventions
and were given food and water ad libitum through the course of the study. All methods
were in accordance with the American Association for Laboratory Animal Science, and
the Institutional Animal Care and Usage Committee of the University of South Carolina
approved all experiments.
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3.3.2. AOM/DSS protocol and 5FU treatment experiment 1
In experiment 1 (Fig. 1A), 50 mice were randomly divided into four groups:
Control+Vehicle (n=10), Control+5FU (n=10), AOM/DSS+Vehicle (n=15), and
AOM/DSS+5FU (n=15). At 12 wk of age (baseline week 0) mice received either an
intraperitoneal injection of the carcinogen93, AOM (10 mg/kg) (Sigma, St. Louis, MO),
diluted in phosphate buffered saline (PBS) (AOM/DSS) or PBS alone (Control). Mice
receiving the AOM injection were subjected to two cycles of DSS (36–50 kDa) (MP
Biomedical, Solon, OH)-supplemented water at final concentrations of 2 and 1% at
weeks 1 and 4, respectively. Each DSS cycle lasted for a 1-wk period. Body weights and
symptom scores were determined semi-weekly along with food and water measurements.
Calculation of symptom score was performed as previously described94

, taking into

account percent body weight loss, stool consistency, and rectal bleeding. Briefly, fresh
colonic evacuates were smeared onto “Hemoccult” tape to assess severity of diarrhea and
were tested with developer (Beckman Coulter, Brea, CA) to assess rectal bleeding.
Bleeding was scored; no positive detection of blood (0), detection of blood but not
grossly visible (2), and gross visibility of blood (4). Diarrhea was scored; solid cylinder
(0), soft cylinder and easily spreadable (2), and non-cylindrical or runny (4). Body weight
was calculated as percent body weight loss; 0–5% (0), 6–10% (1), 11–15% (2), 15–20%
(3), 20–25% (4), and>25% (5). Scores of all three categories were summed to obtain an
overall symptom score for each mouse.
5FU (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile PBS, pH7.4
and then sterile filtered through a 0.2 μm syringe filter. 5FU was administered in 3
cycles; cycle 1: 40 mg/kg, cycle 2 and 3: 20 mg/kg via intraperitoneal injection. 5FU was

35

prepared fresh at the beginning of each cycle. Sterile filtered PBS alone was used as the
vehicle control. Each cycle consisted of 5 consecutive days of injections followed by 9
days of recovery. The treatment period lasted for 5 weeks and mice were sacrificed 24 hr
after the final injection of the third cycle.
3.3.3. Fecal transplantation experiment 2
For the fecal transplantation experiment (Fig. 1B), 35 mice were randomly
divided into four groups: Donor Vehicle, Donor 5FU, Recipient Vehicle (Vehicle FMT),
Recipient 5FU (5FU FMT) (n=5 per Donor group and n=10–15 per Recipient group).
The Donor 5FU group was injected with 40 mg/kg 5FU for 5 consecutive days as
described earlier. All Donor mice were sacrificed 9 days after initial injection and a
mucosal scrape was performed of the distal enteric tract (cecum to anus) to harvest the
microbiota for fecal transplantation. Fecal materials were suspended in sterile 10%
glycerol/PBS, allowed to settle by gravity for 10 min, and aliquoted into daily
requirements for Recipient groups. To perform the FMT study we adopted a protocol by
Reikvam et al. 201195. Recipient mice were pretreated with the following antibiotic
cocktail every 12 h for 10 days prior to FMT: Vancomycin (50 mg/kg), Neomycin (100
mg/kg), Metronidazole (100 mg/kg), and Amphotericin-B (1 mg/kg) via oral gavage
supplemented with Ampicillin (1 mg/ml) in the drinking water given ad libitum. All
antibiotics were purchased from ACROS Organics, New Jersey. FMT was administered
via oral gavage for 14 days with 150 μl respective fecal suspension from PBS or 5FU
injected mice.
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3.3.4. Grip strength assessment
All experimental mice were utilized to evaluate the effects of 5FU treatment on
grip strength. Grip strength was measured prior to 5FU administration (week 8) and
during the recovery period of the second cycle (week 11) in experiment 1 and following
antibiotic treatment (week 0) and fecal transplantation (week 2) in experiment 2. Briefly,
holding the mice by the tail, the front and back feet were allowed to grip the grate. Mice
were then pulled from the grate, generating a force that was measured by the force
transducer (Aurora Scientific, Ontario, Canada). Five measurements were taken
consecutively, with 2 min rest between sets until a total of 15 measurements were taken
for each mouse. The averages of the 15 measurements were used in the data analysis.
Measurements were performed by the same investigator through the entirety of the study.
3.3.5. Run-to-fatigue assessment
To determine the effect of 5FU on fatigability, mice were subjected to a run-tofatigue test prior to 5FU administration (week 8) and during the recovery period of the
second cycle (week 11) in experiment 1 and following antibiotic treatment (week 0) and
fecal transplantation (week 2) in experiment 2. After 3 consecutive days of habituation
during the night cycle, mice were subjected to the following run-to fatigue protocol: 15min warm-up, 20 m/min for 30 min, and 25 m/min thereafter until fatigue was reached.
Fatigue was defined as the time at which mice were no longer able or willing to keep up
with the treadmill despite hand prodding for at least 1 min. All treadmill tests were
performed during the night cycle by the same two investigators (ATS, BNV) through the
entirety of the study.
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3.3.6. Tissue collection
Mice were euthanized by isoflurane overdose 24 h post final injection (cycle 3,
day 6) in experiment 1 and on day 15 in experiment 2 (Fig. 1A, B). Blood was collected
from the inferior vena cava and tissues were removed, weighed, and immediately snapfrozen in liquid nitrogen and stored at −80 °C or fixed in 10% formalin until further
analysis. Briefly, the colon was carefully dissected distal to the cecum and proximal to
the anus. Mesentery adipose tissue was removed with forceps. Colons were then flushed
with PBS, opened longitudinally, and flattened with a cotton swab. In experiment 1,
colonic polyps were counted under a dissecting microscope and were categorized
according to size (> 2, 2-1, and<1). For both experiment 1 and 2, a 5-mm piece of the
distal colon was cut and fixed in 10% buffered formalin (Fisher Scientific, Pittsburg, PA)
for 24 h for immunohistochemical and morphological analysis. The remaining colon was
cut in half and snap frozen for RNA analysis. The distal portion of the ileum also was cut
and fixed in 10% buffered formalin for 24 h for morphological analysis. The liver was
dissected, and a small portion was fixed in 10% buffered formalin for 24 h, for
morphological analysis.
3.3.7. Blood profile
In both experiment 1 and 2, a complete blood count was performed using the
VetScan HMT (Abaxis, Union City, CA) for determination of white blood cells (WBCs),
lymphocytes (LYM), monocytes (MON), neutrophils (NEU), red blood cells (RBCs),
Hemoglobin (HGB), Hematocrit (HCT), and platelets (PLT). Neutrophil/lymphocyte
ratio (NLR) was calculated from obtained values. Briefly, whole blood removed from the
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inferior vena cava was placed in an EDTA microtube and analyzed on the VetScan HMT
according to the manufacturer’s instructions.
3.3.8. Hematoxylin and eosin staining & histopathology
Hematoxylin and eosin staining of the colons, small intestines, and liver were
performed as previously described96. Colon specimens were characterized according to
the presence of epithelial neoplasia to: no adenomas/dysplasia (ND), adenomas with low
grade dysplasia (LGD) adenomas with high-grade dysplasia (HGD) and
adenocarcinomas. The presence of non-specific colitis also was evaluated in the small
intestine and the colon (data not shown). Liver specimens were assessed and
characterized according to the severity of hepatocellular injury: normal, early steatosis
without inflammation, and acute hepatitis (AHI). All histological analyses were
performed blindly by a certified pathologist (I.C.). All tissue morphological
measurements were performed in triplicate and the coefficient of variance was
determined to be less than 5%. Monocytes/macrophages were observed by positive
staining of CD68+ (Abcam, ab125212) cells in the colon tissue.
3.3.9. Gene expression
Quantification of colonic expression of TNFα, MCP-1, NOS2, IL-6, IL-10, IL-1β,
IL-4, EMR-1, Ly6G, IFN-γ, and FOXP3, were performed as previously described96.
Briefly, RNA was extracted using TRIzol reagent (Life Technologies, GIBCO-BRL,
Carlsbad, CA) and chloroform procedures. Because DSS has been shown to inhibit
polymerase and reverse transcriptase activity, lithium chloride was used to purify the
RNA as described in detail by Viennois et al. 201397. RNA sample quality and quantities
were verified using an Agilent Bioanalyzer and determined to be of good quality based
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on A260/A280 values (> 1.8) prior to cDNA synthesis using QuantiTect Reverse
Transcription kit (Qiagen 205313). Quantitative RT-PCR analysis was carried out as per
the manufacturer’s instructions (Applied Biosystems) using Taq-Man Gene Expression
Assays. Data were normalized to vehicle treated controls and compared to two reference
targets (TBP and H2AFV), which were evaluated for expression stability using
GeNorm98,99.
3.3.10. Microbiome analysis
All Microbiome analysis and sequencing was performed by the University of
North Carolina Microbiome Core. Fecal evacuates were collected from each mouse at the
conclusion of the study and were chosen at random for 16S rRNA sequencing, at least
one sample from each cage was used to prevent a cage effect in the data. A final
n=5/group was obtained and used for 16S rRNA sequencing. DNA was isolated from
fecal evacuates homogenized with bead-beating using the Qiagen Qiamp Fast DNA Stool
Mini Kit (Qiagen #51604) and was used for 16S rRNA gene targeted sequencing using
the V4 region on an Illumina MiSeq sequencer100,101. Amplification of the 16S rRNA V4
hypervariable region was carried out using the 16S V4 515F forward (5′ TCGTCGGCAG
CGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA 3′) and V4
806R reverse primer (5′ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGAC
TACHVGGGTWTCTAAT 3′) with added Illumina adapter overhang nucleotide
sequences. The PCR conditions used were initial denaturing step at 95 °C for 3 min,
followed by a cycling of denaturing of 95 °C for 30 s, annealing at 55 °C for 30 s and a
30 s extension at 72 °C (25 cycles), a 5 min extension at 72 °C and a final hold at 4 °C.
Each 16S amplicon was purified using the AMPure XP reagent (Beckman Coulter,
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Indianapolis, IN). In the next step each sample was amplified using a limited cycle PCR
program, adding Illumina sequencing adapters and dual index barcodes (index 1(i7) and
index 2(i5)) (Illumina, San Diego, CA) to the amplicon target. The thermal profile for the
amplification of each sample had an initial denaturing step at 95 °C for 3 min, followed
by a denaturing cycle of 95 °C for 30 s, annealing at 55 °C for 30 s and a 30 s extension
at 72 °C (8 cycles), a 5 min extension at 72 °C and a final hold at 4 °C. The final libraries
were again purified using the AMPure XP reagent (Beckman Coulter), quantified and
normalized prior to pooling. The DNA library pool was then denatured with NaOH,
diluted with hybridization buffer and heat denatured before loading on the MiSeq reagent
cartridge (Illumina) and on the MiSeq instrument (Illumina).
Automated cluster generation and paired–end sequencing with dual reads were
performed according to the manufacturer’s instructions. Multiplexed paired-end fastq
files were produced from the sequencing results of the Illumina MiSeq using the Illumina
software configure BclToFastq. The paired-end fastq files were joined into a single
multiplexed, single-end fastq using the software tool fastq-join. Demultiplexing and
quality filtering was performed on the joined results. Quality analysis reports were
produced using the FastQC software. Bioinformatics analysis of bacterial 16S amplicon
sequencing data was conducted using the Quantitative Insights Into Microbial Ecology
(QIIME) software102. Operational taxonomic units (OTUs), an operational definition used
to classify groups of closely related individuals103, were picked from the quality filtered
results using pick_de_novo_otus.py. Chimeric sequences were detected and removed
using ChimeraSlayer. Alpha diversity and beta diversity analysis were performed on the
data set using the QIIME routines: alpha_rarefaction.py and beta_diversity_-
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through_plots.py, respectively. Summary reports of taxonomic assignment by sample and
all categories were produced using QIIME summarize_taxa_through_plots.py and
summarize_otu_by_cat.py103. Samples were rarefied at 10,000 reads/sample. FastTree2
(Price MN, Dehal PS, Arkin AP FastTree 2- approximately maximum-likelihood tress for
large alignments) to build the phylogenetic tree. Finally, we used an open reference
method for OTU picking. Phylogenetic Investigation of Communities by Reconstruction
of Unobserved States (PICRUSt) was used to predict the functional gene content in the
fecal microbiota based on taxonomy obtained from the Greengenes reference database.
PICRUSt and LefSe were performed online in the Galaxy workflow framework.
3.3.11. Statistical analyses
All data were analyzed using commercial software (SigmaStat, SPSS, Chicago,
IL). All outcomes were analyzed using a two-way ANOVA (disease×treatment), threeway ANOVA (disease×treatment×time) or by a Two-Tailed Student’s T-Test where only
two groups were compared. A Student-Newman-Keuls test was used for all post-hoc
analyses. Survival curve analysis was conducted by Log-rank (Mantel-Cox) test. Pearson
correlations were used to test the relationship between microbiota and colonic gene
expression. Any data that were not normally distributed or did not display equal variance
were logarithmically transformed so that those criteria were met. Statistical significance
was set with an alpha value of p < 0.05. Data are presented as mean ± SEM.
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3.4 Results
3.4.1. Experiment 1: 5FU causes adverse physiological effects, increases colon
inflammation, and alters gut microbiome profile
3.4.1.1. 5FU reduces tumor burden but decreases survival in AOM/DSS mice
As expected, there was a main effect of AOM/DSS on body weight loss during
the DSS administration (weeks 0–8) (p < 0.05) but not during the 5FU treatment period
(weeks 8–13). Three cycles of 5FU (weeks 8–13) caused noticeable weight loss in both
control and AOM/DSS mice but this did not reach statistical significance. However, there
was a significant interaction detected beginning at week 9; within AOM/DSS, 5FU
treated mice experienced greater weight loss than AOM/DSS alone (2A, B, p < 0.05).
Consistent with this, a Mentel-Cox test indicated significant survival risk in
AOM/DSS+5FU mice compared to all other groups (Fig. 2C, p < 0.05). As expected, a
main effect of AOM/DSS on severity of symptoms was detected during DSS
administration as well as during the duration of the 5FU treatment (Fig. 2D, p < 0.05).
Similarly, at weeks 9–13 (beginning 1 week after 5FU treatment) a main effect of 5FU
was detected for symptom score (Fig. 2D, p < 0.05). Further, there was a significant
interaction at weeks 10–11; AOM/DSS+5FU exhibited greater symptom scores than
AOM/DSS alone. At necropsy, there was no main effect of AOM/DSS or 5FU in liver
weight; however, a significant interaction was detected within AOM/DSS mice where
5FU significantly increased liver weight compared to AOM/DSS alone (Fig. 2E, p <
0.05). As expected, a main effect of AOM/DSS was detected for spleen weight with
AOM/DSS groups having significantly greater weight (Fig. 2F, p < 0.05) but there was
no effect of 5FU and no interaction. Both AOM/DSS and 5FU reduced the total weight of
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the epididymal fat pad (Fig. 2G, p < 0.05) but there was no significant interaction.
Similarly, a main effect of 5FU was detected in mesenteric fat pad mass with 5FU
resulting in overall lower weight (Fig. 2H, p < 0.05). A trending decrease in total polyp
number (Fig. 2I, p=0.18) and a significant decrease in large polyp number (Fig. 2J) (p <
0.05) was recorded in AOM/DSS+5FU mice compared to AOM/DSS alone. Consistent
with this, histological analysis of the colonic polyps in AOM/DSS mice treated with 5FU,
revealed less adenomas with adenocarcinoma and more low-grade dysplasia (Fig. 2K,L)
compared to AOM/DSS alone.
3.4.1.2. Nonspecific toxicity of 5FU destroys intestinal tissue morphology and induces
hepatotoxicity

To observe some of the most commonly associated side effects of chemotherapy,
we analyzed the small intestine and liver tissue. Histological analysis revealed a main
effect of 5FU in shortening of the length/atrophy of the villi in small intestine (Fig. 3A,
B, p < 0.05). Histology of the livers revealed acute hepatitis in 80% of the AOM/DSS
mice treated with 5FU and in 90% of the cases the presence of necrosis accompanied by
the formation of abscesses (Fig. 3C, D); findings compatible with liver toxicity.
3.4.1.3. 5FU alters blood profile differently in the presence of tumor burden
A main effect of both 5FU and AOM/DSS was detected in LYM, RBC, HGB,
HCT, and PLT counts (Table 1, p < 0.05); 5FU treatment decreased LYM, RBC, HGB,
HCT but increased PLT whereas AOM/DSS treated mice exhibited increased LYM but
decreased RBC, HGB, HCT and PLT (Table 1, p < 0.05). Further, there was a significant
interaction detected within AOM/DSS; 5FU treated mice presented with greater WBC,
MON, NEU counts, and NLR (Table 1, p < 0.05) compared to AOM/DSS alone.
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3.4.1.4. 5FU alters the immune profile of the colon.
There was a significant main effect of both 5FU and AOM/DSS in mRNA
expression of inflammatory cytokines TNFα and NOS2 (Fig. 4, p < 0.05). Further, a main
effect of AOM/DSS was detected in mRNA expression of inflammatory cytokine IFNγ
and macrophage marker EMR1. Interestingly, a significant interaction was detected
within AOM/DSS where AOM/DSS mice treated with 5FU showed increased mRNA
expression of inflammatory cytokines and chemokines MCP-1, IL6, IL1β, IL10 and the
regulatory T-cell marker FOXP3 (Fig. 4, p < 0.05) compared to AOM/DSS alone. There
was no significant difference in IL4 expression between any groups (Fig. 4).
3.4.1.5. 5FU affects functional measures of fatigue
To evaluate the effects of 5FU on peripheral muscle fatigue we utilized grip
strength testing (measured as absolute strength in N and relative N/Kg body weight). No
significant differences between groups were detected in relative grip strength (N/Kg);
however, analysis of absolute strength indicates a significant interaction within
AOM/DSS treatment in which AOM/DSS mice treated with 5FU exhibited a significant
decrease in strength (Fig. 5A, B, p < 0.05) compared to AOM/DSS alone. To measure the
effect of 5FU on fatigability, mice were challenged with a run-to-fatigue test. Given that
there were no differences in absolute values at baseline between any of the groups, the
data is presented as percent performance change (Fig. 5C). No significant main effects
were detected; however, AOM/DSS mice treated with 5FU showed a strong trend for a
decreased overall performance compared to AOM/DSS alone with a majority (7/9) of
mice recording negative changes in performance (Fig. 5C, p=0.06).
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3.4.1.6. 5FU treatment alters gut microbiota and correlates with colonic gene expression
Recent investigations have indicated that 5FU significantly alters the gut
microbiota in both the colon and small intestine. Further, alterations in gut microbiota
composition may have detrimental effects on immune function in the gut. To focus our
investigation on the colon microenvironment we performed 16S rRNA sequencing on
fecal pellets collected during euthanasia (the full analysis will be available upon request
to the corresponding author). A Shannon plot and total sequences per sample figures were
generated to demonstrate differences in community richness and evenness to estimate
within-community diversity (alpha-diversity) (Fig. 6A, B). Results of the alpha-diversity
plots indicate that three cycles of 5FU did not necessarily alter microbiota diversity in
control mice but did alter the richness and evenness in AOM/DSS mice (Fig. 6A, B).
Unweighted UniFrac PCoA analysis demonstrated that there is a difference in betadiversity across groups at the OTU level (Fig. 6C). A two-way ANOVA was performed
to determine main effects and interactions among phyla and class. AOM/DSS increased
the relative abundance of OTUs in Proteobacteria and Verrucomicrobia (Fig. 6D, p <
0.05) but decreased it in Actinobacteria, Bacteroidetes, and Tenericutes (Fig. 6D, p <
0.05) whereas 5FU increased the relative abundance of OTUs in the Actinobacteria and
Verrucomicrobia phyla (Fig. 6D, p < 0.05). Surprisingly, there were no main effects in
the relative abundance of OTUs of the Firmicutes phylum. Interactions were evident
within AOM/DSS and 5FU; within AOM/DSS, 5FU decreased the relative abundance of
OTUs in the Firmicutes phylum compared to AOM/DSS alone (Fig. 6D, p < 0.05) and
within 5FU, AOM/DSS had significantly less relative abundance of OTUs of
Actinobacteria compared to 5FU alone (Fig. 6D, p < 0.05). Interestingly, the
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aforementioned differences were seen in a similar fashion at the class level. A main effect
of AOM/DSS was detected for decreased relative abundance of Actinobacteria,
Bacteroidia, Erysipelotrichi, Deltaproteobacteria, and Mollicutes and increased
abundance of Betaproteobacteria and Verrucomicrobia classes (Fig. 6E, p < 0.05).
Further, a main effect of 5FU was detected in which the relative abundance of OTUs
were decreased in the classes Coriobacteria and Deltaproteobacteria and increased in the
Actinobacteria, Bacilli, Betaproteobacteria, and Verrucomicrobia classes (Fig. 6E, p <
0.05). There was no significance differences detected in the class Clostridia. A significant
interaction was found within 5FU in which AOM/DSS mice had significantly greater
abundance of OTUs of Actinobacteria compared to 5FU alone whereas 5FU resulted in a
decrease in Bacteroidia in the absence of AOM/DSS (Fig. 6E, p < 0.05).
To observe the potential relationship between gut microbiota changes and colon
gene expression we performed Pearson correlations on three of the most influenced
microbial phyla that relate to inflammation and cancer outcome; Bacteroidetes,
Proteobacteria, and Verrucomicrobia. Six genes; TNFα (r=0.788, p < 0.01), MCP-1
(r=0.588, p < 0.01), NOS2 (r=0.679, p < 0.001), IL6 (r=0.671, p < 0.01), IL1b (r=0.516p
< 0.05), and FOXP3 (r=0.535, p < 0.05) were positively correlated with Verrucomicrobia
abundance (Fig. S1A–F). Similarly, eight genes; TNFα (r=0.528, p < 0.05), MCP-1
(r=0.717, p < 0.01), IL6 (r=0.685, p < 0.01), IFNγ (r=0.582, p < 0.01), IL1β (r=0.742, p <
0.01), IL10 (r=0.647, p < 0.01), FOXP3 (r=0.717, p < 0.01), and NOS2 (r=0.624, p <
0.01) were positively correlated with Proteobacteria abundance (Fig. S1G–N). Lastly,
three genes; IL10 (r=−0.616p < 0.01), IL6 (r=−0.476, p < 0.05), and FOXP3 (r=−0.680, p
< 0.01) were negatively correlated with Bacteroidetes abundance (Fig. S1O–Q).
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3.4.1.7. Metagenomic PICRUSt analysis indicates functional consequences of altered
microbiota.

To investigate the functional consequences of the taxonomic changes in gut
microbial composition, we performed PICRUSt metagenomic analysis to generate a
functional profile of the microbial communities investigated. The full analysis will be
available upon request to the corresponding author. We present here the most interesting
of the findings (Fig. S2A–D). We detected a main effect of 5FU and AOM/DSS in
predicted expression of nitrate reductase subunits (alpha, beta, gamma, and delta), [citrate
(pro-3S)-lyase] ligase and [protein-PII] uridylyltransferase (Fig. S2A, p < 0.05), and
acylphosphatase (Fig. S2C, p < 0.05). Similarly, there is a main effect of AOM/DSS in
predicted expression of 5′nucleotidase (Fig. S2A, p < 0.05) and a main effect of 5FU on
fumarate hydratase expression (Fig. S2D, p < 0.05). There were no significant
interactions for the aforementioned outcomes. However, a significant interaction was
detected for beta-mannosidase within 5FU; 5FU alone increased beta-mannosidase but it
was significantly decreased in AOM/DSS mice treated with 5FU (Fig. S2B, p < 0.05).
3.4.2. Experiment 2: fecal transplantation of 5FU-disturbed microbiota alters host
physiology

3.4.2.1. Fecal transplantation affects functional measures of fatigue
To elucidate the role of the gut microbiota on the adverse side-effects associated
with 5FU treatment we performed fecal transplantation studies in control mice (Fig. 1B).
No body weight or organ weight difference was detected between the two groups
(Vehicle FMT and 5FU FMT) (Fig. 7A–F). All mice were challenged to the same fatigue
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tests used in experiment 1. A significant decrease in absolute grip strength (Fig. 7G, p <
0.05) and a trending decrease in relative grip strength (Fig. 7H, p=0.06) was detected in
mice treated with 5FU FMT compared to vehicle control. In the run-to-fatigue test, a
trending decrease (Fig. 7 I, p=0.07) in performance was recorded in 5FU mice compared
to control. Similar to Experiment 1, we noticed a large number (6/15) of mice with
negative performance changes following 5FU FMT.
3.4.2.2. Fecal transplantation manifests a unique blood profile
Upon analysis of the blood profile, we noticed a significant increase in WBC,
MON, and LYM counts in 5FU FMT mice vs Vehicle FMT controls (Table 2, p < 0.05).
However, no differences in NEU and RBC counts were detected (Table 2). The increase
in lymphocyte count contributed to a trending decrease in NLR in 5FU FMT mice
compared to Vehicle FMT controls (Table 2, p=0.07).
3.4.2.3. 5FU fecal microbial transplantation reduces macrophage populations in the
colon

To further understand the potential contribution of gut microbiota on
inflammatory responses following 5FU treatment, we performed gene expression analysis
on the colon tissue. Contrary to our hypothesis, we found a decreased expression of
MCP-1, IL10, and EMR1 in 5FU FMT mice compared to Vehicle FMT controls (Fig.
8A, p < 0.05). A trending decrease in IL1β (p=0.08) also was detected with no
differences in TNFα, NOS2, IL4, and Ly6G expression (Fig. 8A). Investigating the
morphology of the colon tissue, we did not notice any histological differences between
Vehicle FMT and 5FU FMT mice (Fig. 8B). The gene expression data explained above
indicate a decreased macrophage population in 5FU FMT mice relative to Vehicle FMT
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controls. To confirm this finding, we performed immunohistochemical analysis of
CD68+ cells present in the colons (Fig. 8C). Although we did not directly quantify,
observation suggests fewer CD68+ positive cells in the lamina propria and epithelial
layers in 5FU FMT mice.
3.5 Discussion
5FU chemotherapy is widely used in the treatment of CRC. However, side effects
including fatigue, loss of appetite, and diarrhea, all of which can lead to a reduced quality
of life, are common. Emerging evidence suggests that the gut microbiota may play a role
in this response. In the current study, we sought to characterize the effects of 5FU on
colon inflammation and functional measures in CRC and to further determine whether
gut microbiota can influence this response. Despite a general anti-tumor effect of 5FU,
we document findings of non-selective toxicity in intestinal and liver tissue that which
are associated with reduced functional performance and decreased survival. Select
intestinal inflammatory genes were significantly elevated with 5FU treatment and this
was further exacerbated with cancer. Both 5FU and AOM/DSS treatment result in
significant alterations in gut microbiota and predicted functional parameters. Finally,
using fecal transplantation we demonstrate that a 5FU altered microbiome influences the
systemic and colonic immune environment and can impact functional parameters.
Our findings indicate that a clinically relevant chemotherapy regimen has general
anti-tumor effects in the AOM/DSS model of CRC. This is consistent with previous
reports of a beneficial effect of 5FU in intestinal tumorigenesis in the Apcmin/+ mice
model where a 60–80% reduction in polyps was reported104. Despite these benefits
however, our data indicates that 5FU reduces body weight, exacerbates symptom severity
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score, increases liver weight, and decreases epididymal fat mass, consistent with a
decrease in survival. These results are not surprising given the well documented toxicities
resulting from 5FU non-selectivity30,32. The manifestations of 5FU induced toxicity have
been mainly attributed to ‘mucositis’ or the disruption of the mucosal barrier35,105. We
confirm this damaging mechanism as we report a main effect of 5FU treatment on
reducing villus length in the distal ilium. Further complications of chemotherapy in CRC
include progressive liver failure leading to premature death36,105,106. Our results are
consistent with this as the majority of AOM/DSS mic treated with 5FU presented with
acute necrotizing inflammation with abscesses in the liver. These histological findings are
indicative of an immune response against a bacterial infection107,108, evidence that can be
associated with the presence of leaky gut syndrome; however, further investigation would
be needed to confirm this finding. Other studies have reported similar results using short,
high-dosage treatment regimens (Chang et al., 2012; Li et al., 2017) but have utilized
non-diseased mouse models33,91. Our findings suggest that the chemotherapy regimen
administered in this experiment, using a mouse model of CRC, is effective in replicating
the clinical outcome of 5FU treatment.
Given 5FU’s well documented effects on blood parameters, we used a diverse
blood panel analysis to specifically investigate its effects on circulating immune cells and
factors contributing to chronic anemia in the context of CRC. Consistent with clinical and
experimental literature, we observe decreased circulating immune cells and indications of
severe anemia with 5FU treatment and in the presence of cancer.35,37 As expected, the
combined treatment of 5FU and AOM/DSS had worsening effects on anemia including
RBCs, HCT and HGB. Interestingly, however, where 5FU seemingly causes significant
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immune cell death in a healthy physiological state, it appears that the already altered
physiology caused by the AOM/DSS model of tumor burden increased the systemic
immune response when combined with 5FU. This specifically caused an increase in
neutrophils and monocytes, but not lymphocytes. The mechanism for this increase in
circulating innate immune cells is unclear and warrants further investigation.
ROS produced following initiation of 5FU-related mucositis induces tissue injury
and triggers a cascade of inflammatory pathways including nuclear factor kappa-B (NFκB) activation. Once activated by 5FU, NF-κB induces gene expression and production
of pro-inflammatory cytokines, which, in turn, lead to tissue injury and apoptosis.109 In
addition, CRC itself leads to significant colon inflammation as we have previously
reported.110 Therefore, it is possible that colon-specific inflammation may be exacerbated
following treatment of 5FU in CRC leading to worsening symptoms and poor prognosis.
Thus, we next examined the effects of 5FU on colon inflammation in the context of CRC.
As hypothesized, both 5FU and AOM/DSS lead to an increase in select inflammatory
mediators with a greater degree of inflammation noted in AOM/DSS mice treated with
5FU. As such, it is possible that this ‘inflammatory cytokine storm’ may explain, at least
in part, the increased mortality in AOM/DSS mice treated with 5FU.
To establish the functional deficits associated with chronic 5FU treatment, we
performed a grip strength and run-to-fatigue test. AOM/DSS mice treated with three
cycles of 5FU significantly reduced absolute grip strength and there was a strong trend
towards a decreased run-to-fatigue time. This was consistent with findings of a previous
study by our group that characterized the chronic fatigue of 5FU treatment.111 The
mechanisms responsible for 5FU-related fatigue in cancer patients have not yet been fully
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elucidated. However, several hypotheses have been postulated and include: central
serotonin dysregulation, hypothalamus-pituitary-adrenal axis dysfunction, circadian
disruption, depression, anemia, and central and peripheral inflammation.112,113 Arguably,
the strongest of these are inflammation and anemia. Our data supports these hypotheses
given the increase in anemia related outcomes and inflammation in AOM/DSS mice
treated with 5FU – mice with the greatest performance deficits.
Recent investigations have implicated a direct role of gut microbiota in the
development and treatment of CRC. Therefore, we next examined the effects of 5FU on
the gut microbiota profile. Others have reported differences in gut microbiota following
5FU treatment in non-cancer mice.91 However, to our knowledge this is the first report of
a change in microbiota profile when 5FU is administered in the presence of CRC in an
experimental mouse model; specifically, we note a decrease in alpha diversity. We focus
our discussion on the most important and novel findings of the post-hoc analysis of
bacterial phyla. We saw a decrease in abundance of Firmicutes phylum in AOM/DSS
mice treated with 5FU but not in AOM/DSS alone. The Firmicutes represent one of the
most abundant phyla of the gut microbiota and are important for short-chain fatty acid
production and maintenance of gut homeostasis.91,114 In-fact decreases in Firmicutes have
previously been associated with inflammatory bowel disease and CRC.114,115 This
suggests a possible role of chemotherapeutics in altering the gut microbiota in the
presence of CRC in a manner that exacerbates gut dysbiosis and may contribute to a
worse prognosis following chemotherapy treatments. Further, both 5FU treatment and
AOM/DSS treatment increased relative abundance of Verrucomicrobia. This is not
surprising given that the Verrucomicrobia phylum is suggested to be directly related to
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inflammation in the colon.40,116,117 The increase in Proteobacteria phylum with
AOM/DSS appeared to result from increased Betaproteobacteria. This is consistent with
findings in human fecal samples in which Betaproteobacteria were found to be increased
in patients with CRC.118 Our findings of a decrease in Bacteroidetes in AOM/DSS treated
mice are consistent with some reports of lower levels of Bacteroidetes being linked to
increased cancer risk.115 The strong correlations detected between the above-mentioned
phyla and colon inflammatory mediators suggest a potential link between gut microbes
and the exacerbated inflammation in AOM/DSS mice treated with 5FU. If
Verrucomicrobia and Proteobacteria are indeed playing a role in the creation of an
‘inflammatory cytokine storm,’ selected targeting of these phyla may help lower the
adverse toxicities common to 5FU treatment. Further, PICRUSt analysis of OTUs
indicates significant changes in predicted genes involved in environmental processing
and cellular processes. From these predicted changes it can be suggested that alterations
in the gut microbiota may affect key processes outside the gut that may be contributing to
the exacerbated disease state in AOM/DSS mice treated with 5FU.
While our gut microbiota findings are consistent with some of the previously
reported literature for both 5FU and CRC, it is important to note that inconsistencies also
exist. For example, a recent study by Li et al. (2017), reported decreased Firmicutes and
Proteobacteria, increased Bacteroidetes, and no significant change in Verrucomicrobia
following 5FU treatment in a cancer-free model91, whereas we saw increases in
Verrucomicrobia and Actinobacteria with no changes in the other phyla. However, only 3
consecutive injections of 5FU (50 mg/kg) were used by Li et al. (2017), whereas we
employed a cycled regime with the aim of investigating chronic effects of 5FU treatment.
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These differences in treatment regime likely contributed to the disparities in findings
across studies. Further, some of these differences may stem from our utilization of the
AIN-76A purified diet instead of standard chow and randomization of the mice upon
arrival to the facility to prevent maternal bias in fecal analysis.116 Similarly, while we
report here a decrease in Bacteroidetes with AOM/DSS, it should be noted that reports of
increases also have been reported in CRC119 indicating inconsistencies in the literature.
Culminating from the differences in the gut microenvironment of 5FU treated
mice, we next sought to determine whether gut microbes may be responsible for some of
the side effects associated with 5FU. Thus, we designed an experiment utilizing gut
microbiota depletion followed by subsequent engraftment by either Vehicle FMT or 5FU
FMT (Fig. 1B).95 An absence of body weight and organ weight changes from fecal
transplantation was contrary to our hypothesis and the findings of Li et al. (2017), which
showed a significant decrease in body weight following transplantation of feces from
5FU treated mice.91 As noted above, differences in the study design may have contributed
to the disparities among findings. Interestingly, however, we did find a decrease in
muscle strength and run-to-fatigue times following engraftment of 5FU FMT that is
consistent with the findings in Experiment 1. To our knowledge this is the first report of a
direct relationship between 5FU, gut microbes, and performance deficits and probes the
determination of the exact microbes that may be contributing to this response.
We next examined the effects of engraftment by either Vehicle FMT or 5FU FMT
on circulating and colonic immune responses. Performing the same diverse blood panel
as Experiment 1, we observe an increased number of circulating immune cells (WBC,
LYM, MON) in 5FU FMT mice engrafted with 5FU treated feces, a finding contrary to
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the results of direct 5FU treatment in Experiment 1. Others have reported effects of gut
bacteria on circulating immune cells.57 However, to our knowledge this is the first report
of a 5FU influenced gut microbiome on circulating immune cells. Fecal Microbial
Transplantation of microbes from mice treated with 5FU (5FU FMT) to non-diseased
(Control) mice specifically reduced the MCP-1 and EMR1 gene expression in the colon
but Ly6G was unaltered. This indicates that the engrafted microbiome may be causing a
reduction specifically in the macrophage population in the colon but not in neutrophils.
This was consistent with a notable reduction in CD68+ cells in the colon. This finding
was further supported by a decreased expression of IL-10 and a trending decrease in IL1β, cytokines that are known to be released from macrophages.111 This suggests that the
altered microbial composition resulting from 5FU treatment may, in-itself, be eliciting an
anti-inflammatory response independent of 5FU, where cellular damage from 5FU is
most likely contributing to the proinflammatory response reported in Experiment 1.
Although requiring further investigation, this would explain the correlations of certain
bacteria to both pro- and anti-inflammatory markers in the colon tissue in Experiment 1.
Taken together, these data suggest that transfer of 5FU treated feces leads to an increased
production of circulating immune cells including monocytes; yet appears to reduce
macrophages in the colon. However, the exact microbes that are driving this response
cannot be determined from the current study.
The novel findings from this study implicate that 1) the immune response to
cancer therapy may be regulated by gut microbiota and 2) gut microbiota may influence
functional outcomes following cancer therapy. This suggests that gut microbiota may
serve as a potential therapeutic target for manipulating immune responses and improving
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quality of life outcomes during cancer therapy. It is certainly possible, and even likely,
that some microbes may confer beneficial effects in this model whereas others may have
detrimental effects. Thus, future preclinical studies should determine the exact microbes
that are responsible for the aforementioned effects so that therapeutics can be developed.
Administration of antibiotics and FMT are viable options for manipulating gut microbiota
during cancer therapy and could be implemented in the clinic.
In summary, this study examined the functional and physiological effects of 5FU
in the context of CRC. Despite a general anti-tumor effect of 5FU, we report findings of
non-selective toxicity in intestinal and liver tissue that are associated with reduced
functional performance and decreased survival. The side effects of 5FU in CRC were
associated with alterations in gut bacteria and functional pathways. Finally, using fecal
transplantation we demonstrate that a 5FU altered microbiome can influence the systemic
and colonic immune environment and can impact functional parameters. However,
further studies are necessary to determine the exact bacterial populations that are
responsible for these effects and whether gut bacteria can be targeted for reducing side
effects associated with chemotherapy.
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3.7 Figures & Legends

Figure 3.1. Study Design for experiment 1 and experiment 2. A. Experiment 1 design
and 5FU treatment regimen. B. Experiment 2 design, antibiotics treatment regimen and
fecal transplantation.
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Figure 3.2. 5FU reduces tumor burden but decreases survival in AOM/DSS mice. A.
Gross body weight. B. Percent body weight change. C. Survival curve. D. Symptom
score. * Indicates statistical significance (p < 0.05) for AOM/DSS+5FU group vs. all
groups, # indicates statistical significance (p < 0.05) for Control+5FU vs.
Control+Vehicle from 3-way ANOVA. E-H. Liver, spleen, epididymal fat, and
mesenteric fat, weights at euthanization. Groups not containing the same letters (a, b, ab)
indicate statistical significance between groups (p < 0.05) from two-way ANOVA, n=9–
13/group. I. Total Polyp count. J. Polyp size. K. Dysplasia characterization. L.
Representative H&E staining of distal colon specimens at 4X, insets are 20X. * Indicates
statistical significance (p < 0.05) from students t-test, n=9–13/group.
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Figure 3.3. Nonspecific toxicity of 5FU in distal ileum and liver tissue. A.
Representative H&E staining of distal ileum specimens at 4X, insets are 20X. B.
Measurement of villus length in small intestine. Groups not containing the same letters
(a, b) indicate statistical significance between groups (p < 0.05) from two-way ANOVA.
C. Representative H&E staining of liver tissue specimens at 4X, insets are 20X. D.
Histopathological analysis of liver inflammation. n=9–13/group.
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Table 3.1. 5FU alters blood profile in AOM/DSS mice different from control. White blood cells (WBC), Lymphocytes (LYM),
Monocytes (MON), Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB), and
Hematocrit (HCT). Groups not containing the same letters (a,b,c,d) indicate statistical significance between groups (p < 0.05) from
two-way ANOVA, n=9–13/group.
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Group

WBC
(10^9/l)

LYM
(10^9/l)

MON
(10^9/l)

NEU
(10^9/l)

NLR

RBC
(10^12/l)

HGB
(g/dl)

HCT (%)

PLT
(10^9/l)

Control +
Vehicle

4.19 ±
0.39 a

2.58 ±
0.25 a

0.20 ±
0.06 a

1.40 ±
0.29 a

0.61 ±
0.12 a

9.62 ±
0.48 a

14.80 ±
0.22 a

38.65 ±
1.52 a

881.50 ±
69.44 a

Control +
5FU

2.16 ±
0.12 b

1.52 ±
0.11 b

0.06 ±
0.01 b

0.58 ±
0.05 b

0.40 ±
0.04 b

7.45 ±
0.25 b

11.28 ±
0.13 b

30.51 ±
0.98 b

1851.00 ±
115.22 b

AOM/DSS
+ Vehicle

3.65 ±
0.3 a

2.70 ±
0.27 a

0.17 ±
0.04 a

0.78 ±
0.08 a

0.33 ±
0.05 b

7.63 ±
0.48 b

11.38 ±
0.62 b

32.49 ±
1.76 b

532.69 ±
48.35 c

AOM/DSS
+ 5FU

7.21 ±
1.50 c

2.43 ±
0.26 a

0.53 ±
0.17 c

4.25 ±
1.33 c

2.04 ±
0.67 c

6.85 ±
0.21 c

8.80 ±
0.43 c

25.47 ±
1.08 c

1381.00 ±
101.99 d

Figure 3.4. 5FU alters the immune profile of the colon. A. qPCR analysis of TNFα,
MCP-1, NOS2, IL6, IFNg, IL1b, IL10, IL4, FOXP3 genes. Data were normalized to
vehicle treated controls and compared to two reference targets (TBP and H2AFV), which
were evaluated for expression stability using GeNorm. Groups not containing the
same letters (a–d) indicates statistical significance between groups (p < 0.05) from twoway ANOVA, n=9–13/group.

Figure 3.5. 5FU affects functional measures of fatigue. A. Relative grip strength
measured in newtons/kilogram (N/kg). B. Absolute grip strength measured in newtons
(N). C. Percent performance change in run-to-fatigue test from pre-5FU treatment to
post-5FU treatment. Groups not containing the same letters (a, b) indicates
statistical significance between groups (p < 0.05) from two-way ANOVA, n=9–13/group.
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Figure 3.6. 5FU alters gut microbial profile. A. Shannon plot of alpha-diversity in
microbial communities. B. Total sequences per sample by Shannon rarefaction. C.
Unweighted UniFrac Principle Coordinate Analysis (PCoA) of beta-diversity in
microbial communities. D. Percent abundance of microbial phyla. E. Percent abundance
of microbial class, n=5/group.

Figure 3.7. Fecal Transplantation of 5FU altered microbiome does not alter body
weight but does affect functional measures of fatigue. A. Gross body weight. B.
Percent body weight change. C-F. Liver, spleen, epididymal fat, and mesenteric fat,
weights at euthanization. G. Relative grip strength measured in newtons/kilogram (N/kg).
H. Absolute grip strength measured in newtons (N). I. Characterization of performance
changes in run-to-fatigue test. J. Percent performance change in run-to-fatigue test from
pre-5FU treatment to post-5FU treatment. * Indicates statistical significance between
groups (p < 0.05) from students t-test n=10–15/group.
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Table 3.2 5FU FMT manifests a unique blood profile. White blood cells (WBC), Lymphocytes (LYM), Monocytes (MON),
Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB), and Hematocrit (HCT). *
Indicates statistical significance between groups (p < 0.05) from students t-test, n=10–15/group.
WBC
LYM
MON
NEU
RBC
HGB
PLT
Group
NLR
HCT (%)
(10^9/l)
(10^9/l)
(10^9/l)
(10^9/l)
(10^12/l)
(g/dl)
(10^9/l)
Vehicle
FMT

4.84 ±
0.40

3.76 ±
0.20

0.12 ±
0.00

0.97 ±
0.20

0.25 ±
0.00

9.79 ±
0.20

14.61 ±
0.30

38.41 ±
0.80

864.11 ±
64.30

5FU FMT

6.34 ±
0.39 *

5.12 ±
0.31 *

0.34 ±
0.06 *

0.89 ±
0.10

0.18 ±
0.02

10.28 ±
0.24

14.27 ±
0.25

40.78 ±
0.83

808.23 ±
35.46

64

Figure 3.8. 5FU alters macrophage population in the colon lamina propria and is
replicated with fecal transplantation. A. qPCR analysis of TNFα, MCP-1, NOS2, IL1b,
IL10, IL4, Ly6G, and EMR1 genes in fecal transplantation mice. B, C. Representative
H&E staining and CD68+ staining, respectively, in distal colons of fecal
transplantation mice. Arrows indicate examples of positive staining. * Indicates statistical
significance between groups (p < 0.05) from students t-test, n=10–15/
group.
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3.8 Supplemental Material

Supplementary Figure S3.1. Verrucomicrobia, Proteobacteria, and Bacteroidetes
phyla correlate with key markers of inflammation in the colon. Pearson correlation
coefficients (r) are shown for Verrucomicrobia to colon gene expression of A. TNFα B.
MCP1 C. NOS2 D. IL6 E. IL1b and F. FOXP3 with the associated p-values. Pearson
correlation coefficients (r) are shown for Proteobacteria to colon gene expression of G.
TNFα H. MCP1 I. IL6 J. IFNg K. IL1b L. NOS2 M. FOXP3 and N. IL10 with the
associated p-values. Pearson correlation coefficients (r) are shown for Bacteroidetes to
colon gene expression of O. IL10 P. IL6 and Q. FOXP3 with the associted p-values.
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Supplementary Figure S3.2. Select PICRUSt analysis results indicating altered
functional consequences of 5FU treatment. A. Select markers of environmental
information processing. B. Select marker of cellular processes. C. Select marker of
xenobiotic degradation. D. Select marker involved in development of human diseases.
Different letters indicates statistical significance (p<0.05) from two-way ANOVA n=5.
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CHAPTER 4
SAFETY OF NATURAL ANTHRAQUINONE EMODIN: AN ASSESSMENT IN MICE2

_____________________
2

Sougiannis AT et. al. Submitted to BMC Pharmacology and Toxicology, 4/10/2020.
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4.1 Abstract
Background: Emodin, a natural anthraquinone, has shown potential as an effective
therapeutic agent in the treatment of many diseases including cancer. However, its
clinical development is hindered by uncertainties surrounding its potential toxicity. The
primary purpose of this study was to uncover any potential toxic properties of emodin in
mice at doses that have been shown to have efficacy in our cancer studies. In addition, we
sought to assess the time course of emodin clearance when administered both
intraperitoneally (I.P.) and orally (P.O.) in order to begin to establish effective dosing
intervals. Methods: We performed a subchronic (12 week) toxicity study using 3
different doses of emodin (~20 mg/kg, 40 mg/kg, and 80 mg/kg) infused into the AIN76A diet of male and female mice (n=5/group/sex). Body weight and composition were
assessed following the 12-week feeding regime. Tissues were harvested and assessed for
gross pathological changes and blood was collected for a complete blood count and
evaluation of ALT and creatinine. For the pharmacokinetic study, emodin was delivered
intraperitoneally I.P. or P.O. at 20 mg/kg or 40 mg/kg doses to male and female mice
(n=4/group/sex/time-point) and circulating levels of emodin were determined at 1, 4 and
12 hrs following administration via LC-MS/MS analysis. Results: We found that 12
weeks of low (20 mg/kg), medium (40 mg/kg), or high (80 mg/kg) emodin feeding did
not cause pathophysiological perturbations in major organs. We also found that
glucuronidated emodin peaks at 1hr for both I.P. and P.O. administered emodin and is
eliminated by 12 hr. Interestingly, female mice appear to metabolize emodin at a faster
rate than male mice as evidenced by greater levels of glucuronidated emodin at the 1hr
time-point (40 mg/kg for both I.P. and P.O. and 20 mg/kg I.P.) and the 4-hour time-point
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(20 mg/kg I.P.). Conclusions: In summary, our studies establish that 1) emodin is safe
for use in both male and female mice when given at 20, 40, and 80 mg/kg doses for 12
weeks and 2) sex differences should be considered when establishing dosing intervals for
emodin treatment.
4.2 Background
Emodin (1,3,8-trihydroxy-6-methylanthraquinone) (Fig 1A) is a natural
anthraquinone isolated from several Chinese herbs, including Rheum palmatum,
Polygonum cuspidatum, and Polygonum multiflorum. Pre-clinical investigations have
demonstrated emodin to contain a wide spectrum of pharmacological benefits, including;
anti-viral69, anti-bacterial70, anti-allergic71, anti-osteoporotic72, anti-diabetic73,85, antiinflammatory74,75,80,120, neuroprotective76, hepatoprotective77, and antitumorigenic78,79,86,121-123 properties (Supplemental Table 1). In fact, studies by our group
have shown that emodin is effective at reducing mammary tumorigenesis given its
actions on macrophages.78,122 Both the National Cancer Institute (NCI) and the National
Center for Complementary and Integrative Health (NCCIH) recognize the importance of
evidence-based complementary medicine modalities that may be integrated as part of
standard cancer care for all patients across the cancer continuum. However, further
development of emodin as an effective anti-cancer agent is hindered by uncertainties
surrounding its potential toxicity.
Evaluation of the safety of dietary compounds is paramount to their clinical
development. Several studies have reported side effects of emodin that may preclude its
development beyond pre-clinical studies. For instance, it has been suggested that emodin
may have mutagenic properties given the documented reports of genotoxicity and
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mutagenicity in certain strains of bacteria.124,125 There also are reports of hepatotoxic
effects of emodin depending on the dose. 126-130 Further, at very high doses (1-3 g/kg/d
for mice), emodin has been shown to have laxative effects leading to melanosis.125,131
While the number of negative reports is arguably balanced by the number of studies
reporting no side-effects, uncertainties remain and have hampered enthusiasm for further
development of this promising dietary agent.
Given the potential toxicity associated with emodin along with our efforts in the
development of emodin as a complementary cancer therapy, we performed a sub-chronic
toxicity study of emodin as a first step to clinical translation. We subjected mice to an
emodin infused diet of three different concentrations (~20 mg/kg, 40 mg/kg and 80
mg/kg) – similar doses that we have used in our efficacy studies – for 12 weeks to
monitor any potential toxic effects that emodin may have. In addition, we performed a
pharmacokinetic study to evaluate the time course of emodin clearance from the
circulation when given via two different routes of administration, intraperitoneally (I.P.)
and orally (P.O.). To ensure that we are not limiting translational relevance, both male
and female mice were used in both the toxicity and pharmacokinetic studies.
4.3 Methods
4.3.1 Animals
Male and female C57BL/6J mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and were cared for in the animal facility at the University of South Carolina
School of Medicine. Mice (n=4-5/group/sex/experiment) were randomized upon arrival
to the animal facility to prevent litter biases and were housed 4-5 per cage and maintained
on a 12:12-h light-dark cycle in a low-stress environment (220C, 50% humidity, low
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noise). Mice were handled only by the primary investigator (ATS). All mice were
habituated for 6 weeks to the AIN-76A diet prior to any interventions and were given
food and water ad libitum through the course of the study. All methods were performed
in accordance with the American Association for Laboratory Animal Science and the
Institutional Animal Care and Usage Committee at the University of South Carolina.
4.3.2 Emodin
Emodin was purchased from Nanjing Zelang Medical Technology Co., Ltd,
(Nanjing, China). Emodin was independently analyzed by the Mass Spectrometry Center
at the University of South Carolina prior to the initiation of the experimental study.
Liquid Chromatography -Ultraviolet-Mass Spectrometry (LC-UV-MS) and Nuclear
Magnetic Resonance (NMR) was performed to confirm the purity and molecular
structure of emodin (Fig 1A).
4.3.3 Emodin dosing and time course analysis for pharmacokinetic studies
Emodin was delivered intraperitoneally (I.P.) or by oral gavage (P.O.) at 20
mg/kg or 40 mg/kg doses. For the I.P. study, emodin, dissolved in DMSO was made in a
large batch, aliquoted, and stored at -200C until used for injections. It was subsequently
diluted in PBS (1% DMSO) and administered to mice I.P. at doses of 20 mg/kg (0.5
mg/mL) or 40 mg/kg (1 mg/mL). To deliver emodin P.O., we utilized a 20G 30-mm
flexible plastic tubal oral gavage needle (Instech, #FTP-20). To prevent aspiration of the
emodin bolus, mice were briefly anesthetized with 2% isoflurane prior to gavage and held
upright until consciousness was regained. Emodin was prepared fresh on the day of
administration. Briefly, emodin was mixed in pure propylene glycol (VWR, #97061) for
6-8 hours at room temperature while protected from light. The emodin solution was
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delivered to mice at 20 mg/kg (6mg/mL) and 40 mg/kg (12mg/mL) doses. We used 1%
DMSO in PBS (I.P.) or pure propylene glycol (P.O.) for vehicle controls.
Plasma emodin content was analyzed at three specific time points (t=1hr, 4hr, and
12hr) after treating male and female WT C57BL/6J mice I.P. or P.O. Emodin was given
at 20 mg/kg or 40 mg/kg; n=4 mice were used per dosage, per timepoint, and per sex.
Vehicle treated mice were used to analyze empty plasma extracts.
4.3.4 Solid Phase Extraction and LC-MS/MS Analysis
Whole blood was collected in EDTA coated tubes from the inferior vena cava and
centrifuged at 4,000 RPM for 10 min. Plasma was aliquoted and stored at -200C until
solid phase extractions. For free emodin quantification, 50 μl plasma was mixed with
equal 0.2M sodium acetate buffer with 1% ascorbic acid (pH 5.0). For emodin
glucuronide quantification, 50 μl plasma was mixed with half volume of 0.2M sodium
acetate buffer with 1% ascorbic acid and 1000 units of β-glucuronidase (Millipore Sigma
#G2174). D4-emodin (1 ng/μl) was used as an internal standard (Santa Cruz #218302).
Both tubes were then incubated at 370C for 2hr. After incubation, the mixture was
extracted with 600 μl ethyl acetate three times. The ethyl acetate layer was evaporated
under N2 gas to dryness and reconstituted in 5% ammonia water. Solid phase extraction
was performed using a vacuum manifold (Supelco #SU57250-U) with Oasis MCX
cartridges (Fisher #186000254) and was eluted with 3 mL 5% formic acid-methanol.
After elution, the eluent was evaporated under N2 gas to dryness and reconstituted in 400
μl 5% ammonia methanol.
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Emodin samples were analyzed and quantified by LC-MS/MS using electrospray
ionization in negative ion mode. Chromatorgraphic separation was performed on a
Waters Acquity UPLC system using a binary solvent gradient. Solvent A was water
containing 0.1% formic acid and solvent B was methanol. The LC column was a Waters
XBridge C18 reversed phase column (2.1mm X 100mm containing 3.5um particles)
running at a flow rate of 0.2 mL/min. The solvent gradient started at 50%B, ramped to
95%B over 10 minutes and was maintained at 95%B until 14 minutes. The gradient then
returned to initial conditions. The mass spectrometer was a Waters Premier XE triple
quadrupole instrument. Data was collected in multiple reaction monitoring (MRM) mode.
Two precursor/product ion pairs were monitored; one pair for emodin (269 daltons > 225
daltons) and one pair for the internal standard deuterium labeled emodin (273 daltons >
229 daltons). According to the standard curve of emodin in 5% ammonia methanol, the
concentration of emodin was calculated relative to the D4-emodin internal standard. Total
emodin was measured from the tube containing the β-glucuronidase, free emodin was
measured from the tube without β-glucuronidase, and glucuronidated emodin was
calculated as the difference between total emodin and free emodin.
4.3.5 Emodin diets for sub-chronic toxicity study
We analyzed the effect of emodin feeding over a 12-week period. Emodin was
infused into the AIN-76A diet at three different concentrations; 170 mg/kg, 340 mg/kg,
and 680 mg/kg (BioServ, Frenchtown, NJ). These concentrations were based on our
established average food intake of C57BL/6 mice and translate to a daily ingested dose
per body weight of ~20 mg/kg, 40 mg/kg, and 80 mg/kg, respectively. Therefore, we
separated mice into 4 groups consisting of n=5 sex/diet; Control (AIN), 20 mg/kg, 40
74

mg/kg, and 80 mg/kg. Mice were purchased at 4 weeks of age, kept on AIN-76A diet
until 10 weeks of age, and then separated into experimental groups and started on their
respective diets. Mice were maintained on their treatment diets for 12 weeks and were
given food and water ad libitum.
4.3.6 Body weights and body composition
Body weight, food, and water consumption were monitored on a weekly basis
throughout the study. Body composition was assessed after 12 weeks of emodin diet
using dual-energy X-ray absorptiometry (DEXA) (Lunar PIXImus, Madison, WI).
Briefly, mice were placed under gas anesthesia (isoflurane, 2%) and were assessed for
bone mineral density (BMD), lean mass, fat mass, and body fat percentage. Lean mass
(%) was calculated as percent lean weight and bone mineral content (BMC) of total body
weight.
4.3.7 Tissue Collection
After 12 weeks of dietary treatment, mice were euthanized by isoflurane overdose
following a 4 hour fast, blood was collected from the inferior vena cava and placed in
EDTA coated lavender top tubes for plasma collection and blood panel analysis. The
following tissues were harvested and fixed overnight in 10% neutral buffered formalin
and subsequently embedded in paraffin; spleen, liver, kidney, heart, colon, and ileum.
Colon and ileum were cleaned with PBS and swiss rolled prior to fixation. Liver,
epididymal fat, mesenteric fat, and spleen weight were determined from freshly excised
tissue prior to fixation. Colon, entire small intestine, and tibial length were also measured
using calipers during tissue collection.
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4.3.8 Blood Panel Analysis
A complete blood panel analysis was performed using the VetScan HMT (Abaxis,
Union City, CA) for determination of white blood cells (WBC), lymphocytes (LYM),
monocytes (MON), neutrophils (NEU), platelets (PLT), red blood cells (RBC),
hematocrit (HCT), and hemoglobin (Hb). Neutrophil/lymphocyte ratio (NLR) was
calculated from obtained values.
4.3.9 Plasma Markers of Toxicity
Plasma was analyzed for common markers of major organ toxicity/physiological
impairment including ALT (Cayman Chemical, 700260) and creatinine (Cayman
Chemical, 700460) and according to manufacturer’s instructions.
4.3.10 Histopathology Analysis
All tissues collected were stained with hematoxylin and eosin (H&E) as
previously described.132 To analyze the presence of fibrosis, trichrome staining was
performed in heart, liver, kidney, and spleen as previously described.133 Goblet cells
were identified in the colon and small intestine by Alcian blue staining and
counterstained by nuclear fast red as previously described.94 All histopathological
analyses were performed by a board-certified pathologist blinded to the experimental
conditions (I.C.).

76

4.4 Results
4.4.1 There is no difference in bioavailability of emodin when given I.P. vs P.O. but it
is more bioavailable in female mice.
We measured the concentrations of free emodin and glucuronidated emodin in
plasma of mice given emodin via I.P. or P.O. at 20 or 40 mg/kg doses and at t=1, 4, or 12
hrs (n=4/timepoint/sex; Fig 4.1B-E). The majority of emodin detected in each sample was
glucuronidated while free emodin was scarcely found at all time points following both
I.P. and P.O. routes of administration. The highest point of emodin detection was at the
t=1hr time point and was at approximately 50% concentration at t=4hr and was
completely eliminated at t=12hrs. Interestingly, we found that female mice had greater
concentrations of glucuronidated emodin at t=1hr in all doses and routes except for the 20
mg/kg dose given P.O. (Fig 4.1B-E, p<0.05) and at t=4hr only in mice given the 20
mg/kg dose by I.P. (Fig 4.1B, p<0.05). Overall, there was no difference between I.P. and
P.O. administration at any of the timepoints tested.
4.4.2 12-week emodin feeding does not present phenotypic toxicities in mice.
We fed male (n=5/group) and female (n=5/group) mice a purified diet (AIN-76A)
infused with three different concentrations of emodin. In statistical analysis, male and
female mice were combined. After 12 weeks of feeding, emodin dose did not affect body
weight compared to control mice (AIN-76A fed) (Fig 4.2A). Similarly, body composition
analysis did not show any differences in lean mass (%) or body fat (%) (Table 4.1) for
any of the emodin doses versus the control group. Further, there was no difference in
organ weight (liver, spleen, mesenteric fat, epididymal fat) or length (colon length, small
intestine length, or tibial length) with emodin dose (Table 4.1).
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4.4.3 Spleen and blood analyses do not indicate inflammatory responses to emodin
feeding.
To assess the sub-chronic effect of emodin on circulating immune cells we
performed a comprehensive blood panel analysis. Table 4.2 indicates that there was no
effect of emodin at any dose on circulating immune cells. To further investigate the
potential toxicity of emodin on the immune system, we performed H&E staining on
spleen biopsies. There were no histological changes of red or white pulp and there
appears to be no indication of blood flow blockage or fibrosis (Fig 4.3A).
4.4.4 Liver, Kidney, and Heart do not present with any noticeable toxicities after 12wk emodin feeding.
4.4.4.1 Emodin feeding does not cause liver toxicity
To investigate the potential toxicity of emodin to the liver we performed H&E
and trichrome staining. There were no indications of fibrosis or NASH in any of the mice
fed emodin diets (Fig 4.4A,B). To confirm our findings, we measured ALT levels in
plasma. We found that there were no elevated plasma ALT levels following any dose of
emodin (Fig 4.4C).
4.4.4.2 Emodin feeding does not cause kidney toxicity
To investigate the potential toxicity of emodin to the kidneys we performed H&E
and trichrome staining. There were very few indications (<5%) of isolated tubular ectasia
and sloughed cells in tubular lumens in addition to an absence of inflammation (Fig
4.5A). To test the function of the kidneys we measured creatinine levels in plasma.
Plasma creatinine levels were in normal range, lower that 5mg/dl in any of the mice
indicating the normal renal function (Fig 4.5B).
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4.4.4.3 Emodin feeding does not cause noticeable toxicity to the cardiovascular system.
To investigate the potential toxicity of emodin to the cardiovascular system, we
performed H&E and trichrome staining on heart muscle (Fig 4.6A,B). There was no
indication of architectural change of the tissue or fibrosis in cardiac tissue. Further, we
did not observe any indications of atrial or ventricular hypertrophy.
4.4.5 Small intestine and colon analysis do not indicate GI toxicity after 12-wks of
emodin feeding.
To assess potential gastrointestinal toxicities of sub-chronic emodin feeding, we
performed histopathological analysis on small intestine (Fig 4.7A) and colon tissue (Fig
4.7B,C). H&E staining did not indicate any significant dysplasia in either the small
intestine (Fig 4.7A) or colon (Fig 4.7B). We furthered stained colon biopsies with Alcian
blue to assess goblet cell integrity. Alcian blue staining did not show any significant
differences in goblet cell count or morphology in the colon (Fig 4.7C).
4.5 Discussion
Emodin (Fig 4.1A), a natural anthraquinone, has shown many potential health
benefits in pre-clinical models. In fact, we have reported that emodin is effective at
reducing tumorigenesis given its actions on macrophages.78,122 However, further
development of emodin as an effective anti-cancer agent is hindered by uncertainties
surrounding its potential toxicity. The primary purpose of this study was to uncover any
potential toxic properties of emodin in mice using doses that we have found to have
efficacy in our cancer studies.78,122 In addition, we sought to assess the time course of
emodin clearance when administered both I.P. and P.O. in order to begin to establish
effective dosing intervals. We found that 12 wks of low (20 mg/kg), medium (40 mg/kg),
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or high (80 mg/kg) emodin feeding does not cause pathophysiological perturbations in
major organ systems. We also found that glucuronidated emodin peaks at 1hr for both I.P.
and P.O. administered emodin and is eliminated by 12 hr.
Despite inconsistencies in the literature, previous investigations have shown that
emodin is typically cleared by 12 hr after injection/ingestion.77,122,134 We show in the
present study that emodin is rapidly metabolized to its glucuronidated form, peaking at 1
hr, and is completely cleared by 12 hr when given both I.P. and P.O. Further, we confirm
that the parent free emodin is undetectable after 1 hr, even at higher doses. Some of the
inconsistences in the literature are likely due to the varying vehicles used. It is important
to note that emodin is not soluble solely in PBS or water and must have an alcohol-based
solvent to dissolve. Several previous studies have reported using saline or PBS only as a
vehicle,70,73,121,135 which is likely to result in delivery of a non-homogenous solution, and
presumably inconsistent pharmacokinetic data. We aimed to deliver a homogenous
solution of emodin to improve our consistency of plasma analysis. Thus, emodin was
dissolved in pure DMSO for the I.P. study and in propylene glycol for the P.O. study.
Our findings are supported by previously published work.77,122,134,136 For example, a
study by Shia et al., 2010 utilized a similar solvent to propylene glycol (PEG 400) and
showed comparable results using male Sprague-Dawley rats.136 While we report peak
levels of emodin at 1 hr post administration for both the I.P. and P.O. studies, it is
important to note that our assessment was limited to 1 hr, 4 hr and 12 hr time-points.
Thus, it is certainly possible that emodin may have peaked prior to, or following, the 1 hr
time-point. Evaluation of additional time-points is necessary to fully determine the timing
of peak levels of emodin.
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Of further interest with the pharmacokinetic findings is the indication that
females have almost double the amount of glucuronidated emodin in the circulation at 1
hr following injection/gavage. When given I.P., this difference remains at the 4 hr timepoint (only significant in the 20 mg/kg dose), but not in mice given emodin via P.O. This
finding is consistent with Liu et al., (2010) that showed in an ex vivo experiment that
emodin is absorbed and metabolized at a faster rate in females vs. males.75 Although the
clearance of emodin is comparable between males and females, it is important to note this
difference in pharmacokinetics between males and females so that appropriate dosing can
be implemented during the transition to clinical investigations.
Given the potential toxicity associated with emodin along with our efforts in the
development of emodin as a complementary cancer therapy we performed a sub-chronic
toxicity study of emodin as a first-step to clinical translation. We subjected mice to an
emodin infused diet of three different concentrations (~20 mg/kg, 40 mg/kg and 80
mg/kg) – similar doses that we have used in our efficacy studies - for 12 wks to observe
any potential toxic effects that emodin may have. Emodin did not impact body weight or
body composition in the current study. Further, there was no effect of emodin on major
organs. It should be noted that others have reported beneficial effects of emodin on
metabolic disorders including a reduction in body weight; however, unlike the current
study, these effects were documented in the settings of diet-induced obesity. 137,138
There is some suggestion that emodin may have mutagenic properties given the
documented reports of genotoxicity and mutagenicity in certain strains of bacteria.124,125
However, a two-year genetic toxicology and carcinogenesis study conducted by the
National Toxicology Program (NTP) of the NCI showed no evidence of carcinogenic
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activity for emodin in female mice and equivocal evidence in male mice given a low
incidence of renal tubule adenoma and carcinoma (1 mouse in each of 35 mg/kg and 70
mg/kg groups of 10) following a two year feeding study.139 Only in doses of 170 mg/kg
and higher were significant toxicities noticed in this study.139 Together with other
assessments of emodin from carcinogenicity studies, evidence does not support a
genotoxic risk of emodin to humans.124,125,131 In fact, there are a number of recent reports
that indicate anti-tumor effects of emodin including studies by our group.78,122 This is
further supported by the current study; we show that emodin, when given at doses of 20,
40, and 80 mg/kg for 12 wks, does not appear to have mutagenic properties.
There also are some reports of hepatotoxic effects of emodin while other studies
report hepatoprotection.126-130 Based on a review of the literature it is likely that emodin
has bidirectional potential, both liver protection126,127 and hepatoxicity126-130 depending on
the dose. In our study, we found no hepatoxicity with daily emodin treatment for 12 wks
and this was supported by no elevation in plasma ALT levels. Similarly, there are some
indications that emodin, or foods containing emodin, may cause kidney toxicity140 while
other reports document that emodin may actually serve as a therapeutic for kidney
injury.141 We found no evidence of nephrotoxicity in the current study nor did we see
elevated plasma creatinine levels following emodin treatment. Further, emodin has been
shown to have laxative effects leading to melanosis, but only at very high doses, for
example, 1-3 g/kg/d for mice.125,131 Thus, it is not surprising that we did not find any
laxative effects following administration of emodin in the 20-80 mg/kg dose range. Nor
did we document any dysplasia in the small intestine or the colon. While toxic effects of
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emodin have not been documented in the spleen or heart, at least to our knowledge, we
assessed these tissues and report no toxic effects.
4.6 Conclusion
In summary, we show that the pharmacokinetics of emodin does not differ
significantly between the peritoneal and oral routes of administration. However, there are
sex differences in the pharmacokinetics of emodin with female mice having higher levels
of metabolized emodin that should be considered during the transition to clinical
investigations. Further, we confirm that emodin is a safe compound to be used in both
male and female mice when given at 20, 40, and 80 mg/kg doses for 12 wks.
4.7 Figures & Legends

Figure 4.1. Emodin is rapidly glucuronidated when given I.P. and P.O. and is more
bioavailable in females. A. Chemical structure of emodin (PubChem CID: 3220). B-E.
Total, glucuronidated, and free emdoin bioavailability in male and female mice 1hr, 4hr,
and 12hr after given I.P at B) 20 mg/kg and C) 40 mg/kg and P.O. at D) 20 mg/kg and E)
40 mg/kg. n=3-4/dose/timepoint/sex. * indicates statistical significance (p<0.05) between
sexes of total emodin. # indicates statistical significance (p<0.05) between sexes of
glucuronidated emodin.
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Figure 4.2. 12-week emodin feeding does not present phenotypic changes in male
and female mice. A. Body weight at end of 12-week feeding for male and female mice.
n=5/group.
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Table 4.1. Male and female mice fed emodin for 12-weeks do not show differences in body composition and major organ
weight. Lean mass and body fat percentage (%) were measured using DEXA scan. Liver, spleen, mesenteric fat, and epididymal fat
were measured in milligrams (mg). Tibial length was measured in millimeters (mm). Colon length and small intestine (SI) length were
measured in centimeters (cm). n=5/group.
Group
Control (AIN)
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Low Emodin
(20mg/kg)
Medium Emodin
(40 mg/kg)
High Emodin
(80 mg/kg)

Lean
Mass
(%)
72.5 ±
1.11
72.8 ±
1.19
73.7 ±
1.49
73.5 ±
1.28

Body Fat
(%)

Liver
(mg)

Spleen
(mg)

18.4 ±
1.65
19.6 ±
1.21
18.6 ±
1.77
18.3 ±
0.97

1162.0 ±
90.66
1225.4 ±
67.54
1272.9 ±
65.02
1268.7 ±
69.63

110.1 ±
9.72
110.1 ±
7.52
98.8 ±
5.78
89.4 ±
4.04

Mesenteric Epididymal
Fat (mg)
Fat (mg)
281.8 ±
41.55
333.8 ±
39.18
328 ±
57.04
332.3 ±
60.85

464 ±
118.45
6098.1 ±
86.46
569 ±
141.06
504.9 ±
102.89

Tibial
Length
(mm)
16.57 ±
0.15
16.65 ±
0.14
16.62 ±
0.17
16.67 ±
0.16

Colon
Length
(cm)
8.0 ±
0.21
7.95 ±
0.17
7.78 ±
0.14
8.03 ±
0.20

SI
Length
(cm)
32.7 ±
0.58
32.35 ±
0.50
31.33 ±
0.37
32.1 ±
0.48

Table 4.2. Male and female mice fed emodin for 12-weeks do not show changes in CBC counts. White blood cells (WBC),
lymphocytes (LYM), monocytes (MON), neutrophils (NEU), neutrophil:lymphoctye ration (NLR), red blood cells (RBC), hemoglobin
(HGB), hematocrit (HCT), and platelets (PLT) were measured using a VetScan HMT (Abaxis, Union City, CA). n=5/group.
Group
Control (AIN)
Low Emodin
(20mg/kg)
Medium Emodin
(40 mg/kg)
High Emodin
(80 mg/kg)

WBC
(10^9/l)
5.39 ±
0.63
4.99 ±
0.32
5.30 ±
0.43
5.58 ±
0.38

LYM
(10^9/l)
4.03 ±
0.38
3.97 ±
0.26
4.31 ±
0.29
4.48 ±
0.31

MON
(10^9/l)
0.21 ±
0.06
0.17 ±
0.04
0.14 ±
0.04
0.18 ±
0.04

NEU
(10^9/l)
1.15 ±
0.31
0.85 ±
0.10
0.85 ±
0.16
0.91 ±
0.12

NLR
0.27 ±
0.06
0.21 ±
0.02
0.19 ±
0.02
0.21 ±
0.03

RBC
(10^12/l)
10.41 ±
0.54
10.82 ±
0.10
10.49 ±
0.14
10.23 ±
0.17

HGB
(g/dl)
15.97 ±
0.15
16.39 ±
0.15
16.39 ±
0.25
16.03 ±
0.25

HCT
(%)
42.06 ±
1.86
42.88 ±
0.43
41.86 ±
0.59
40.32 ±
0.67

PLT
(10^9/l)
717.78 ±
62.73
716.90 ±
22.33
680.20 ±
32.56
693.60 ±
26.30
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Figure 4.3. 12-week emodin feeding does not present histological changes in spleen.
A. Representative 10X and 40X (insets) images of male and female spleens stained with
H&E. n=5/group.

Figure 4.4. 12-week emodin feeding does not cause liver toxicity. A. Representative
H&E stains of livers imaged at 10X and 40X (insets). B. Representative trichrome stains
of livers imaged at 10X and 40X (insets). C. Plasma ALT activity measured in units/mL
(U/mL) plasma. Dashed line indicates critical toxic levels (20 U/mL). n=5/group.
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Figure 4.5. 12-week emodin feeding does not cause kidney toxicity. A. Representative
H&E stains of kidneys imaged at 10X and 40X (insets). B. Plasma creatinine measured in
milligrams/deciliters (mg/dl) of plasma. Dashed line indeicates critical toxic levels
(5mg/dl). n=5/group.

Figure 4.6. 12-week emodin feeding does not cause cardiotoxicity. A. Representative
H&E stains of cardiac tissue imaged at 10X and 40X (insets). B. Representative
trichrome stains of cardiac tissue imaged at 10X and 40X (insets).
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Figure 4.7 12-week emodin feeding does not cause GI toxicity. A. Representative
H&E stains of swiss rolled small intestines imaged at 10X and 40X (insets). B.
Representative H&E stains of swiss rolled colons imaged at 10X and 40X (insets). C.
Representative alcian blue stains of swiss rolled colons imaged at 10X and 40X (insets).
n=5/group.
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4.8 Supplemental Material
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Supplementary Table 4.1. Emodin Review. Assessment of studies examining the potential therapeutic properties of emodin in
various models of pathology. Studies that examined more than one dose of emodin or time point were treated as separate experiments
when totaling each respective outcome. ↔ = No Change, ↓ = Decrease, ↑ = Increase, N/A = Not Assessed, HFD = High Fat Diet.
Outcomes
Gut
Author Pathology
Model Method Dose Route
Overall
Inflammation/ Signali
Mic
BW
PK/PD
Outcome
Pathology
ng
robi
ota
SMAD
2: ↓
SMAD
1
Inhibition
4: ↓
10 mg/kg dose
Peak:
BALB/c
mg/k Hypod
of
miRHepG2
showed no
1hr
Bai et
Liver
nu/nu
g or
ermic tumorigene
34a: ↑
Implanta
N/A
mortality and
Cleared: N/A
al. (1)
Cancer
mice
10
Injecti
sis and
VEGF
tion
reduced
12 hr
(Male)
mg/k
on
reduced
R: ↓
metastasis
t1/2: 2hr
g
mortality
AKT:
↓
ERK1/
2: ↓
HFD
50
Reduced blood
Daily
Improves
(60
mg/k
glucose with
11βHS
Oral
body
Obesity
kcal%
g or
Prednisone
D1: ↓
C57BL/
Gavag weight and
Feng et
and
fat, 20
100
Improved
PEPC
6J mice
e
reduces
↓
N/A
N/A
al. (2)
Metabolic
kcal%
mg/k
insulin
K: ↓
(Male)
(Distill metabolic
Syndrome
protein,
g or
sensitivity
G6Pase
ed
dysfunctio
20
200
Reduced
:↓
H2O)
n
kcal%
mg/k
cholesterol and

carbohy
drates)

Guo et
al.
(3)
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Höhn et
al. (4)

Iwanow
ycz et
al. (5)

Iwanow
ycz et
al. (6)

Pancreatic
Cancer

Colon
Cancer

Inflammati
on

Breast
Cancer

g

BALB/c
PANC-1
nu/nu
Implanta
mice
tion
(Male)

40
mg/k
g and
80
mg/k
g

WAG/R
jj Rats
(Male)

2.5
mg/k
g or 5
mg/k
g

In-vitro
peritone
al MΦs
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IL4,
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and
IFNγ

C57BL/
EO771
6 and
and 4T1
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tion
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ne Efficacy
itabin
e
Alone
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(Saline
) Daily
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low doses

↓

10
In vitro
mg/m (DMS
l
O)
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N/A
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(2%
DMSO
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tumor
growth

N/A
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g
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specific
inflammatory
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N/A

p-NFκB: ↓
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↓
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N/A

N/A
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routes
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N/A
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Inhibit
ed
H3K27
Suppress M1
trimeth
and M2 activity
ylation
remova
l
IRF4:
Inhibited MΦ
↓
infiltration
pIncreased TSTAT6
cell activation
:↓

)
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Breast and
non-small
cell lung
carcinomas

In vitro
carcino
ma

pC/EBP
β: ↓
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↓
CSF1:
↓
Thy-1:
↓
Breast
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ng P2X7
receptors
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μM
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tumor
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Jia et al.
(8)
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LDLR-/Mice
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)
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Diet
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g
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daily
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Jia et al.
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↔
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)
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induced
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5-40
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g
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9: ↓
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Tang et
al. (19)

Non-small
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al. (24)

Liver
Cancer

In vitro
carcino
ma

Bel7402
HCC
cell line

100
μM

In vitro
(DMS
O)

Induced
apoptosis
in cell
cultures
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Increased villus
height, crypt
number, and
goblet cell
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proximal
jejunum

p53: ↓

N/A

N/A

N/A
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cellular
infiltration to
lungs and
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levels

IL-4: ↓
IL-5: ↓
IL-13:
↓
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MMP9: ↓
HO-1:
↑
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Will kill
mosquitos
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N/A
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Bcl-2:
↓
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Tota
l
Bact
eria:
↔
Clos
tridi
um
spp.
:↓
Lact
oba
cillu
s
spp.
:↑
Bifi
dba
cteri
a
spp.
:↑
Ente
roco

ccus
spp.
:↓
C.
perf
ring
ens:
↓
E.
coli:
↓

100
Zhang et
al. (26)

Viral
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ATP
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↓
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↓

N/A

N/A
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CHAPTER 5
THE EFFECT OF ANTHRAQUINONE EMODIN ON SURVIVAL,
LYMPHOCYTOPENIA, AND GUT HEALTH DURING 5FU CHEMOTHERAPY3

_____________________
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5.1 Abstract
Emodin, a natural anthraquinone, has been shown to have anti-inflammatory properties
and may be effective to ameliorate off-target toxicities of 5FU chemotherapy. We
evaluated chronic (n=5-20/group) and acute (n=20/group/sex) interventions to 5FU.
Emodin improved run-to-fatigue time both acutely and chronically but only improved
grip strength and peripheral nociception sensitivity chronically. Acutely, emodin reduced
small intestine IL10, Mrc1, and Ly6G while reducing NOS2, TNFα, and Ly6G and
increasing Mrc1 chronically. In the colon, emodin did not cause significant alterations in
inflammatory gene expression but reduced NOS2 and Muc5ac chronically. Acutely, male
mice retained circulating lymphocytes with increased emodin dosage. Further, emodin
improved cell cycling in bone marrow increasing S and G2/M phase cells. Utilizing 16S
rRNA FISH, 5FU caused pockets of mucus disruption, gut barrier damage, and
alterations in bacterial spatial arrangement, which were mitigated with emodin. Taken
together, emodin treatment may contribute to improved hematopoietic integrity and GI
health by reducing damaging inflammation, which may improve overall quality of life.
5.2 Introduction
Synthetic chemotherapeutics such as antimetabolites, anthracyclines, and taxanes
have improved the overall efficacy of cancer treatment regimens but present significant
risk to the patient both during and after treatment29,88,142. Chemotherapy treatment has
approximately a 12% success rate clinically. However, nearly 10% of patients receiving
chemotherapy die during the first 30 days of treatment. Further, it is estimated that 70%
of surviving patients will develop non-specific toxicities as a result of chemotherapy
treatment29. Therefore, it is of great importance to develop safe and effective
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complementary treatments to attenuate the toxicity of chemotherapeutics giving the
patient a better quality of life during treatment. We, and others, have previously
characterized hallmark characteristics of 5FU toxicity32,35,111,132,142. Most notably the
presence of intestinal mucositis and lymphocytopenia contributes to the reduced survival
and quality of life associated with 5FU23,33,91,142. These characteristics are closely
monitored clinically and can be limiting to the success of interventional therapies39,143.
Therefore, amelioration of these symptoms might improve 5FU outcome.
There has been a recent upsurge in the clinical utilization of herb-derived
compounds due to evidence of multiple health benefits attributed to continual use with
these compounds. A compound that could attenuate the multiple non-selective toxicities
associated with chemotherapy could have great clinical potential. Emodin is a trihydroxyanthraquinone found in several Chinese herbs, including Rheum palmatum and
Polygonum multiflorum144,145. Emodin has been shown to attenuate the severity of
multiple experimental disease models including arthritis, liver damage, atherosclerosis,
myocardial ischemia, and cancer by reducing the inflammatory cascades associated with
these conditions73,77,79,80,121,134,144,146,147. Recent investigations have indicated emodin can
reduce activation of pro-inflammatory signaling NF-κB, STAT6, Erk1/2, and
P3872,77,122,148. However, the direct mechanism of action of emodin has yet to be
discovered. Emodin may have a potential target in the P2X7 receptor75,79,87,145,149. The
P2X7 receptor is found the central and peripheral nervous systems, in microglia,
macrophages, and the retina75,149. The P2X7 receptor has also been shown to serve as a
pattern recognition receptor for extracellular ATP-mediated apoptotic cell death,
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regulation of receptor trafficking, mast cell degranulation, and inflammation145,149 and is
therefore of interest as a therapeutic target.
In the present study, we aimed to establish the efficacy of emodin as a
complementary therapeutic to attenuate the non-selective toxicity of 5FU chemotherapy.
We utilized a previously established protocol of 5FU treatment which was paired with
complementary emodin treatment given three-times per week. We performed chronic and
acute studies of 5FU toxicity investigating the benefits of complementary emodin.
Investigating the chronic effects, we observed a 100% survival rate in mice treated with
5FU + Emodin. This was complemented by reduced pain sensitivity, improved grip
strength, and reduced fatigability. We observed increased M2-type macrophages (MRC1)
and reduced neutrophils (Ly6g) in the small intestine but not in the colon. However, we
did report a decrease in dysplasia inducing Muc5ac in the colon. Acutely, we observed
improved body weight in 5FU + Emodin treated mice and a maintained peripheral
lymphocyte count. Utilizing 16S rRNA FISH we observed a dose dependent response of
maintained structural integrity of the proximal and distal colon in emodin treated mice.
We saw increased macrophages in the bone marrow and expression of the
proinflammatory markers which was paralleled by drastic cell death and cell cycle arrest
with 5FU. Interestingly, we observed increased cells inG2/M phase in the bone marrow
and decreased CD11c expression of Emodin treated mice. Overall, we believe that
emodin may be protecting the hematopoietic system during 5FU treatment, leading to a
more regulated inflammatory response and protection of the gastrointestinal system.

107

5.3 Methods
5.3.1 Animals
Male and female C57BL/6 mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and were cared for in the animal facility at the University of South Carolina.
Mice were randomized upon arrival to the animal facility to prevent litter biases in
microbiome data and were housed five per cage, maintained on a 12:12-h light-dark cycle
in a low-stress environment (220C, 50% humidity, low noise). Mice were kept in a room
isolated from all other ongoing animal experiments and were only handled by the primary
investigators. All mice were habituated to the AIN-76A diet prior to any interventions
and were given food and water ad libitum through the course of the study. All methods
were in accordance with the American Association for Laboratory Animal Science, and
the Institutional Animal Care and Usage Committee of the University of South Carolina
approved all experiments.
5.3.2 Experimental Design
Mice were acclimated to the animal facility at the University of South Carolina
for 6 weeks prior to the start of experiments. In the chronic study (Fig 5.1A), N=50 mice
were randomly assigned into 4 groups: Control (n=5), Emodin (n=5), 5FU + Vehicle
(n=20), and 5FU + 40 mg/kg Emodin (n=20). In the acute study (Fig 5.4A): N=80/sex
mice were randomly assigned into 4 groups; 5FU + Vehicle (n=20/sex), 5FU + 20 mg/kg
Emodin (n=20/sex), 5FU + 40 mg/kg Emodin (n=20/sex), and 5FU + 80 mg/kg Emodin
(n=20/sex).
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5.3.3 Emodin Preparation
Emodin was purchased from Nanjing Zelang Medical Technology Co., Ltd,
(Nanjing, China). Emodin was independently analyzed by the Mass Spectrometry Center
at the University of South Carolina prior to the initiation of the experimental study. LCUV-MS and NMR was performed to confirm the purity of Emodin and the molecular
structure (Fig S1A). Emodin was delivered via oral gavage to mice using 20ga 30mm
flexible plastic tubing oral gavage needles (Instech, #FTP-20). Emodin was prepared
fresh, daily, in a 24mg/mL stock solution using pure propylene glycol (VWR) and mixed
for 6-8 hours at room temperature protected from light prior to gavage. The 24mg/mL
solution was used for 80 mg/kg dosing; 12mg/mL and 6mg/mL dilutions were also
prepared for 40 mg/kg and 20 mg/kg doses, respectively. Pure propylene glycol was used
as a vehicle control in all experiments.
5.3.4 5FU and Emodin treatment regime
5FU (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile phosphate
buffered saline (PBS), pH7.4 and then sterile filtered through a 0.2μm syringe filter. 5FU
was administered in 3 (chronic, Fig 5.1A) or 1 (acute, Fig 5.4A) cycles of a 35 mg/kg
dosage and was administered via intraperitoneal injection. Each cycle consisted of 5
consecutive days of injections followed by 9 days of recovery. 5FU was prepared fresh at
the beginning of each cycle. Sterile filtered PBS alone was used as the vehicle control. To
avoid potential drug interactions Emodin and 5FU were administered separately. 5FU
was given in the AM time slot of the light cycle and Emodin was given in the PM time
slot of the light cycle. The t1/2 of 5FU is 15 minutes and we have previously determined
that emodin is cleared from the circulation 12 hr after oral gavage.
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5.3.5 Peripheral Neuropathic Nociception
All experimental mice were utilized to evaluate the effects of 5FU treatment on
peripheral neuropathic nociception. After a brief habituation to the testing apparatus,
right hind-paws were tested for neuropathic nociception by a single experimenter blinded
to experimental conditions using Von Frey filaments (North Coast Medical, Morgan Hill,
CA). Each Von Frey filament was tested for 5 consecutive measurements, data was
calculated as the paw withdrawal threshold in grams of force. Threshold was determined
by 3 consecutive reactions to the stimulus. Measurements were performed by the same
investigators through the entirety of the study (ATS). Total stimuli were also summed to
interpret total sensitivity to the touch test.
5.3.6 Grip strength assessment
All experimental mice were utilized to evaluate the effects of 5FU treatment on
grip strength. Grip strength was measured prior to 5FU administration and during the
recovery period of the second cycle. Briefly, holding the mice by the tail, the front and
back feet were allowed to grip the grate. Mice were then pulled from the grate, generating
a force that was measured by the force transducer. Five measurements were taken
consecutively, with 2 min rest between sets until a total of 15 measurements were taken
for each mouse. The averages of the 15 measurements were used in the data analysis.
Measurements were performed by the same investigator through the entirety of the study
(ATS).
5.3.7 Run-to-fatigue assessment
To determine the effect of 5FU on fatigability, all experimental mice were
subjected to a run-to-fatigue test prior to 5FU administration and during the recovery
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period of the second cycle (chronic) or in the night cycle after the final 5FU
administration (acute). After 3 consecutive days of habituation during the night cycle,
mice were subjected to the following run-to fatigue protocol: 20 m/min for 30 min and 25
m/min following a 15-min warm-up. Fatigue was defined as the time at which mice were
no longer able or willing to keep up with the treadmill despite hand prodding for at least
1 minute. All treadmill performances were performed during the night cycle by the same
investigators through the entirety of the study (ATS and BNV). Data were analyzed as
percent performance change from baseline (week -1) to post treatment (week 1 – acute,
week 4 – chronic).
5.3.8 Tissue collection
Mice were euthanized by isoflurane overdose and blood was collected from the
inferior vena cava. Tissues were removed, weighted and immediately snap-frozen in
liquid nitrogen and stored at -800C or fixed in 10% formalin until further analysis. The
colon was carefully dissected distal to the cecum and proximal to the anus. Mesentery
adipose tissue was removed with forceps. The colon was flushed with PBS, opened
longitudinally, and flattened with a cotton swab. Colon length was measured using
calipers. A 5-mm piece of the distal portion of the colon was cut and fixed in 10%
buffered formalin (Fisher Scientific, Pittsburg, PA) for morphological analysis. The
remaining colon was hemi-sectioned longitudinally and snap-frozen for further analysis.
The distal portion of the ileum was cut and fixed in 10% buffered formalin for
immunohistochemical and morphological analysis, the remining distal-middle portion of
the small intestine was cut in half and snap-frozen for further analysis.
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5.3.9 Anemia markers
A complete blood panel analysis was performed using the VetScan HMT (Abaxis,
Union City, CA) for determination of WBCs, LYM, MON, NEU, PLT, RBCs, Hct, and
Hb. Neutrophil/Lymphocyte ratio (NLR) was calculated from obtained values.
5.3.10 Histopathology
Hematoxylin and eosin (H&E) staining of the colon and small intestines were
performed as previously described132. All images were obtained using a Nikon E600.
Intestinal mucositis was assessed via measurement of the epithelial architecture of the
villi (small intestine) using ImageJ. Goblet cells were identified by Alcian blue staining
and counterstained with nuclear fast red as previously described94. All histopathological
analyses were performed by a board-certified pathologist blinded to the experimental
conditions (I.C.). All tissue morphological measurements were performed in triplicate
and the coefficient of variance was determined to be less than 5%.
5.3.11 Gene expression
Quantification of colonic expression of EMR-1, MRC1, ITGAX, Ly6G, IL10,
NOS2, TNFα, MCP1, OCLN, MUC2, and MUC5ac were performed as previously
described132. Briefly, RNA was extracted using TRIzol reagent (Life Technologies,
GIBCO-BRL, Carlsbad, CA) and chloroform procedures. RNA sample quality and
quantities were verified using an Agilent Bioanalyzer and determined to be of good
quality based on A260/A280 values (>1. 8) prior to cDNA synthesis using QuantiTect
Reverse Transcription kit (Qiagen 205313). Quantitative RT-PCR analysis was carried
out as per the manufacturer’s instructions (Applied Biosystems) using Taq-Man Gene
Expression Assays. Data were normalized to vehicle treated controls and compared to
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five reference targets (B2M, TBP, HPRT, HMBS, and H2AFV), which were evaluated
for expression stability using GeNorm algorithm.98,99
5.3.12 Bone Marrow Flow Cytometry and Cell Cycle Analysis
Bone marrow was taken from both femoral shafts by flushing with saline and
passing the resulting extracts through a 70μm filter. Red blood cell lysis was performed
with 20 second hypotonic solution (0.2% NaCl) treatment followed by hypertonic (1.6%
NaCl) cessation. Bone marrow isolates were blocked with FC block and stained with
CD11b – APC, F4/80 – FITC, and CD45 – PE/Cy7 (Biolegend, San Diego, CA)
antibodies for 1hr at 40C. Lymphocytes were identified by gating for CD45+ cells.
Macrophages were determined to be CD11b+F4/80+ cells. Aliquots of bone marrow
isolates were also fixed in 70% ethanol for 24h at -200C before staining with Ki67 – APC
and propidium iodide – PE-Texas Red (Biolegend San Diego, CA) according to standard
protocols. Data were acquired using a BD FACS Aria II cell sorter and analyzed by
FlowJo v10.6.2.
5.3.13 Western Blotting
Briefly, bone marrow extracts were homogenized in Mueller Buffer containing
protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO). Total protein concentrations
were determined by the Bradford method. Equal amounts of crude protein homogenates
(10ug) were separated on hand-casted SDS-polyacrylamide gels and electrophoretically
transferred to a PVDF membrane using a Royal Genie Blotter (IDEA Scientific,
Minneapolis, MN). Membranes were blocked for 1hr at room temperature with 5% nonfat milk in tris-buffered saline with 0.1% tween (TBST). Western blots were performed
using primary antibodies P2X7 (Alomone Labs #APR-004), TNFα (Proteintech #60291113

1-Ig), and CD11c (Cell Signaling #97585). An anti-rabbit (Cell signaling: #7047) IgG
horseradish peroxidase conjugated secondary antibody was diluted 1:2000 in 5% milkTBST and incubated for one hour at room temperature. An enhanced chemiluminescent
substrate for detection of horseradish peroxidase (Thermo Scientific, Watham, MA) was
used to visualize the antibody-antigen interaction. Autoradiography films were scanned,
and blots were quantified using scientific imaging software ImageJ (NIH Bethesda, MD).
After completion of the western blot, all membranes were stained with Amido black
(VWR #AAJ66798-14) and the densitometry of each lane was calculated using ImageJ
allowing for total protein normalization as previously described150.
5.3.14 16S rRNA FISH
A subset of mice (n=3) were used to observe the bacterial spatial organization
present in the colon. Briefly, colons were excised whole from the rectum to the anus,
opened longitudinally without disturbing opened tissue, and fixed for 24hrs in Carnoy’s
solution (6:6:1 – Ethanol:Acetic Acid:Chloroform) then processed and embedded into
paraffin blocks by standard techniques. 5μm section were placed on SuperFrost slides for
FISH studies. The oligonucleotide probe (EUB338: 5’-GCTGCCTCCCGTAGGAGT-3’)
was purchased from EuroFins synthesized with carbocyanite dye (Cy3) added to the 5’end. In-Situ Hybridizations were performed according to previously published
protocols117,151,152. Fluorescent images were taken using a Leica DM2500 fluorescent
microscope.
5.3.15 Statistical analyses
All data were analyzed using commercial software (SigmaStat V3.5, SPSS,
Chicago, IL). All outcomes were analyzed using a two-way ANOVA (disease x
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treatment) for the chronic treatment investigation and a one-way ANOVA for the acute
investigation. A Student-Newman-Keuls test was used for all post-hoc analyses. A
student’s t-test was used to analyze Ly6G expression during the chronic study due to only
two groups (of four total) have detectable levels of expression. Survival curve analysis
was conducted by Log-rank (Mantel-Cox) test. Any data that were not normally
distributed or did not display equal variance were logarithmically transformed so that
those criteria were met. Statistical significance was set with an alpha value of p<0.05.
Data are presented as mean ± SEM.
5.4 Results
5.4.1 Complementary emodin delays weight loss and improves survival and quality of life
during chronic 5FU.
A 3-cycle 5FU regimen caused significant body weight loss through the entire
duration of the treatment period (Fig 5.1A,B; p<0.05). A main effect of 5FU and emodin
therapy exists at various points through the course of treatment (Day 2, 4, 6, 8, 10, 28, 30,
32, and 34); within control mice there was no effect of emodin therapy throughout the
treatment period. However, there was a significant interaction detected within 5FU, in
which emodin treated mice had significantly greater body weight at days 7, 8, 10, 11, 12,
13, and 14 (Fig 5.1B; p<0.05). n=3/20 mice in the 5FU+Vehicle group did not survive the
first cycle of 5FU chemotherapy, a Mantel-Cox test indicated that there was no
significant risk for this group; regardless, no other experimental groups had decreased
survival (Fig 5.1C). At necropsy, there were no significant differences detected for liver
and spleen weight (Table 1). A main effect of 5FU was detected for decreasing
epididymal and mesenteric fat pads; but no significant interaction of emodin treatment
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was found. Interestingly, a main effect of emodin treatment was detected in increasing
colon length; however, there was no interaction detected with 5FU (Table 5.1).
5.4.2 Complementary emodin improves functional measures of fatigue associated with
chronic 5FU.
We have previously established a battery of functional tests that can detect
differences in performance associated with 5FU toxicity132. We find a main effect of 5FU
on increasing touch sensitivity (p<0.05), a trending effect of emodin treatment (p=0.051),
and a trending interaction (p=0.051) between 5FU and emodin treatment (Fig 5.1D).
Despite these results, two-way ANOVA indicated a difference between treatment groups
within 5FU in which emodin treated mice showed reduced pain sensitivity (p<0.05). This
result is likely from the ceiling effect inherent of this assay which does not allow for main
effects to be elucidated from the data collection. To further our analysis of peripheral
neuropathy, we summed the total responses of each mouse throughout the peripheral
neuropathy assay (see methods). Two-way ANOVA of these summed responses
indicated a main effect of both 5FU and emodin treatment (Fig 1E; p<0.05). Again, we
report a trending interaction (p=0.058) between emodin and vehicle treated groups within
5FU mice. Despite this, emodin treated 5FU mice showed significantly reduced total
responses during the peripheral neuropathy assay compared to 5FU alone (Fig 5.1E;
p<0.05).
A grip strength test was used to measure absolute (N) and relative (N/kg) front
limb strength. We found no main effects of 5FU or emodin treatment in absolute grip
strength (Fig 5.1F); however, vehicle treated 5FU mice showed significantly lower
absolute force production compared to control mice (Fig 5.1F; p<0.05). Further, there
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was a significant interaction (Fig 5.1F; p<0.05) within 5FU in which emodin treated mice
showed increased absolute grip strength compared to 5FU alone, however, were still
lower than control mice. Relative grip strength showed no significant main effects of
either 5FU or emodin treatment; further, there was no significant interaction detected (Fig
5.1G).
To investigate the fatiguability induced by 5FU treatment we analyzed run-tofatigue data as a percent performance change from baseline (see methods). We report a
main effect of both 5FU and emodin treatment on percent performance change (Fig 5.1H;
p<0.05). 5FU mice treated with vehicle had significantly lower performance compared to
control mice. Interestingly, 5FU mice treated with emodin showed significantly less
performance deficits compared to 5FU alone, however, were still lower than control mice
(Fig 5.1H; p<0.05).
5.4.3 Complementary emodin does not rescue 5FU-induced anemia and
lymphocytopenia.
We have previously reported that 5FU treatment causes significant cytopenia.132
As expected, we observe a main effect of 5FU on decreasing WBC, LYM, NEU, RBC,
HGB, and HCT; however, we do not detect an interaction of 5FU with emodin treatment
(Table 5.2; p<0.05). Further, we find a main effect of 5FU for increasing PLT counts;
however, we also do not find a significant interaction of 5FU with emodin treatment
(Table 5.2; p<0.05). Interestingly we do not report any significant effects of 5FU or
emodin treatment on MON counts and the NLR (Table 5.2).
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5.4.4 Complementary emodin reduces inflammation and protects small intestine tissue
during chronic 5FU treatment.
One of the most significant effects of 5FU is non-selective toxicity targeted
towards the small intestine tissue. Measuring the villus length of small intestine tissue,
we find a significant main effect of 5FU treatment in decreasing villus length (Fig
5.2A,B; p<0.05); further, we find a significant interaction with emodin treatment within
the 5FU group which had greater villus length compared to 5FU treatment alone, but
lower length compared to control mice (Fig 5.2A,B; p<0.05). We performed gene
expression analysis to observe any differences select pro-inflammatory cytokines in
addition to macrophage (F4/80) and neutrophil (Ly6g) populations. Interestingly, mice
treated with 5FU had decreased NOS2 expression in the small intestine but increased
TNFα and MCP-1 (Fig 5.2C; p<0.05). Emodin treatment only seemed to interact
significantly with TNFα leading to reduced levels compared to mice treated with 5FU
alone (Fig 5.2C; p<0.05). We further report no difference in total macrophages (EMR1)
or M1-like macrophages (Itgax) but increased M2-like macrophages (Mrc1) in mice
treated with 5FU+Emodin compared to 5FU alone (Fig 5.2D; p<0.05). Neutrophils are
minimally expressed in the small intestine and are not usually detected with conventional
qPCR. Within 5FU treated mice, however, we detect Ly6g expression in the small
intestine which was trending (p=0.12) decrease in emodin treated mice when normalized
back to 5FU+Vehicle treated mice and analyzed via a student’s t-test (Fig 5.2E).
5.4.5 Emodin improves colon health during chronic 5FU treatment.
We performed a similar analysis in the colon as reported above. Interestingly, we
find a significant increase in NOS2, TNFα, and MCP1 in mice treated with 5FU alone
compared to vehicle treated controls (Fig 5.3A; p<0.05). Further, however, we find a
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significant interaction with emodin only in NOS2 expression (p<0.05) but not in TNFα or
MCP1 (Fig 5.3A) We assessed macrophage markers EMR1, Itgax, and Mrc1 but found
no changes across all groups (Fig 3B). We found a main effect of neutrophil marker Ly6g
in 5FU treated mice but no interaction between 5FU and emodin (Fig 5.3C). To assess
gut health, we measured OCLN expression and report a main effect of 5FU to decrease
OCLN expression but there was no significant interaction with emodin (Fig 5.3D).
Interestingly, we show an increase in Muc5ac expression in 5FU treated mice with a
trending decrease (p=0.05) in 5FU+Emodin mice. Despite this, we report no difference in
Muc2 expression across all groups. We stained distal colon biopsies with hematoxylin
and eosin and Alcian blue but found no significant histopathological differences between
all groups (Fig 5.3E).
5.4.6 Complementary emodin delays weight loss during an acute bout of 5FU in male
and female mice and reduces fatigability.
To study the acute benefits of emodin on reducing 5FU toxicity, we investigated
male and female mice treated with 5 consecutive days of 5FU and complementary
emodin given at 20 mg/kg, 40 mg/kg, or 80 mg/kg (Fig 5.4A). All three dosing groups of
emodin lost significantly less weight compared to mice treated with 5FU alone (Fig
5.4B,C; p<0.05). Specifically, male mice treated with 20 mg/kg, 40 mg/kg, and 80 mg/kg
had significantly lower weight loss compared to vehicle treated controls on days 3, 4, 5,
6, and 7 (Fig 5.4B; p<0.05). Female mice treated with 20 mg/kg had significantly lower
weight loss compared to vehicle treated controls on days 5, 6, and 7, female mice treated
with 40 mg/kg had significantly lower weight loss compared to vehicle treated controls
on day 7 only, and female mice treated with 80 mg/kg had significantly lower weight loss
compared to vehicle treated controls on days 5 and 7 only (Fig 5.4C; p<0.05).
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A subset of mice (n=10) were utilized to assess the same functional tests used in
the chronic phase of the study. Male and female mice functional test performances were
pooled for analysis. We saw no noticeable differences between or within all groups in
peripheral nociception (Fig 5.4D,E) or grip strength (Fig 5.4F,G) tests. Interestingly, we
found a dose dependent response to improvement in run-to-fatigue performance change
(Fig 5.4G; p<0.05), with the benefits beginning to show in the 40mg/kg dose and
improving in the 80 mg/kg dose.
Weighing the major organs, we found no significant differences between groups
(Table 5.3). Interestingly, male mice treated with 5FU + 20 mg/kg emodin had a
significantly greater (Table 5.3; p<0.05) spleen weights compared to all other groups.
However, this weight was not indicative of significant pathology and is expected to be a
type I error.
5.4.7 Increasing dosage of emodin rescues peripheral blood lymphocytopenia associated
with acute 5FU treatment in males only.
In both male and female mice, 5FU decreases total WBC count, of which is
mostly attributed to loss in circulating LYM. In male mice only, we found a dose
dependent increase in total WBC with increasing emodin dosage which was attributed
primarily to increased total LYM counts (Table 5.4; p<0.05). There was no difference in
MON, NEU, RBC, HGB, HCT, or PLT measures between sex or treatment dosage.
Interestingly, we found a significant decrease in NLR in male mice treated with 80 mg/kg
emodin. This was also seen in female mice treated with both 40 mg/kg and 80 mg/kg
emodin (Table 5.4; p<0.05).
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5.4.8 Emodin reduces inflammation to small intestines and benefits gut architecture.
To investigate the acute benefits of emodin on small intestine health, we
performed villus measurements on male mice as described in our chronic experiment.
Interestingly, each treatment group had significantly different measurements compared to
all other groups with mice treated with 80mg/kg emodin recording the greatest relative
villus length compared to mice treated with 5FU alone (Fig 5.5 A,B; p<0.05). Gene
expression analysis indicates no significant differences in pro-inflammatory cytokines
NOS2, TNFα, or MCP1 (Fig 5.5C). However, we do show a significant decrease in IL10
expression in mice treated with 40 mg/kg and 80 mg/kg emodin compared to mice treated
with 5FU alone (Fig 5.5C; p<0.05). This trend was paralleled by a significant decrease in
M2-like macrophages (MRC1) (p<0.05) but no decrease in total macrophages (EMR1)
and M1-like macrophages (Itgax) (Fig 5.5D). Interestingly, we also show a decrease in
neutrophil marker Ly6G expression in mice treated with 40 mg/kg and 80 mg/kg emodin
compared to mice treated with 5FU alone (Fig 5.5E; p<0.05).
5.4.9 Emodin does not alter immune status of the colon acutely but, may benefit bacterial
spatial arrangement and gut integrity.
We performed an immune cell panel analysis on the colon tissue of male mice
treated acutely with 5FU + emodin. Analyzing NOS2, TNFα, MCP1, and IL10
expression we only report a significant increase in NOS2 in mice treated with 40 mg/kg
(Fig 5.6A;p<0.05), however we believe this to be a type-I error and not attributed to
pathology associated with emodin treatment at 40 mg/kg. We analyzed macrophage
markers EMR1, MRC1, and ITGAX in addition to neutrophil marker Ly6g, however, we
found no significant differences between groups (Fig 5.6B,C). Interestingly, upon
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performing markers for gut integrity, as in out chronic investigation, we did not notice
any difference in OCLN, Muc5ac, and Muc2 between groups (Fig 5.6D).
To further our analysis of the colon, we used a subset of male mice to assess gut
bacterial spatial arrangement using 16S rRNA FISH. Because of the landscape
differences between the distal and proximal portions of the colon we separated our
analysis to include each region. Within the proximal colon, we notice a thin mucous layer
separating the bacteria (yellow) and epithelial cells (blue). When assessing 5FU treated
mice, we noticed significant disposition of the mucosal layer and bacterial organization
(arrow). We also observed invasion of bacteria within the crypts (arrow). We saw
reduction of this phenotype when emodin is introduced into the treatment regime. In the
20mg/kg emodin treated mice we observed a reduced incidence of crypt invading bacteria
and a complete elimination of this phenotype in the 40 mg/kg and 80 mg/kg doses (Fig
6A). Interestingly, we see that mice treated with 5FU + Vehicle also have significant
bacterial invasion in the distal portion of the colon. As seen in the proximal portion of the
colon, the 20 mg/kg emodin treated mice have a slight reduction of this characteristic and
a complete elimination of this exists in the 40 mg/kg and 80 mg/kg emodin treated mice
(Fig 5.6B).
5.4.10 Emodin reduces bone marrow inflammation and may work to maintain actively
cycling cells.
In a separate cohort of male mice, we performed an acute analysis of 5FU + 40
mg/kg emodin treatment to analyze bone marrow health. We isolated bone marrow and
assessed the macrophage content using flow cytometry. Interestingly, we found a
significant increase in percentage of CD11b+ F4/80+ cells in 5FU treated mice (p<0.05),
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however this was not decreased with emodin treatment (Fig 5.7A,B). The severity of
cytopenia caused discrepancies on whether more inflammation was present in 5FU mice.
Therefore, we isolated protein content of bone marrow and assessed protein expression of
the CD11c, P2X7 receptor, and TNFα. Paralleling the trends seen in macrophage content,
we see that 5FU treated mice had a significantly increased CD11c (p<0.05), P2X7
receptor (p<0.05), and TNFα (p<0.05) expression but only CD11c was significantly
lower (p<0.05) in emodin treated mice compared to 5FU alone (Fig 5.7C-E).
Interestingly, when normalizing to total protein content using amido black staining, we
observed a significant banding difference between control and 5FU treated mice.
Although total protein content was the same according to Bradford assay, this finding
indicates that there are substantial perturbations to the cellular environment of the bone
marrow in 5FU treated mice.
We performed a cell cycle analysis of the bone marrow content and observed that
5FU treated mice have fewer total cells compared to controls (Fig 5.8A). Further, we
found that emodin treated mice have a lower percentage of cells in G1/G0 phase
compared to control and 5FU+Vehicle treated mice. Interestingly, there was a greater
percentage of cells in S phase in emodin treated mice compared to 5FU alone (Fig
5.8A,B; p<0.05). Following this pattern, emodin treated mice had a trending increase in
G2/M phase cells (Fig 5.8A,B; p=0.07). Although total cell content is lower in 5FU
treated mice compared to controls, this finding indicates more cells are proliferating in
mice receiving complementary emodin compared to 5FU alone.
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5.5 Discussion
5FU chemotherapy is widely used in the treatment of CRC. However, common
side effects including fatigue, peripheral neuropathy, and diarrhea can lead to a reduced
quality of life24,31,153. Emerging evidence has shown that natural anthraquinone emodin
can be used as a safe and effective anti-inflammatory compound to reduce such
physiological perturbations77,78,121. Therefore, in the current study, we aimed to
investigate the ability for emodin to reduce the common side effects and inflammation
associated with 5FU treatment. Despite significant weight loss, complementary emodin
treatment improved survival in cancer-free mice and reduced severity of sensitive
peripheral nociception, muscular weakness, and fatigability. Select intestinal markers of
inflammatory cells indicate cite specific benefits of emodin and a reduction of
pathological perturbations to the small intestine and colon barrier. Further, bone marrow
analysis indicated a mitigation of the toxic effects of 5FU to the bone marrow and an
attenuation of associated lymphocytopenia.
We report here an important first step in establishing emodin as a safe and
effective complementary therapeutic in clinical oncology. In the chronic study, we
observe 100% survival in mice treated with emodin compared to 84% survival in mice
treated with 5FU alone during a 3-cycle regimen. Previous investigations by our lab have
shown that 5FU can cause significant toxicities in the presence of cancer132. However,
this previous investigation utilized a different dosing regimen (40, 20, 20 mg/kg)
compared to the present study. In the present study, we utilized a consistent 35 mg/kg
dosing regimen which caused significant physiological perturbations in a cancer-free
model. Our data indicate that emodin can effectively reduce the functional deficits
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associated with chronic 5FU treatment. We report here that chronic 5FU given at 35
mg/kg can increase peripheral nociception sensitivity, reduce muscular strength, and
cause significant fatiguability; each of which can be rescued with complementary emodin
treatment. The mechanisms of these 5FU-associated perturbations have not yet been fully
elucidated. However, several hypotheses have been proposed including serotonin
dysregulations, HPA dysfunction, circadian disruptions, depression, anemia/cytopenia,
and central/local inflammation.27,88,154 Arguably, the strongest of these are inflammation
and anemia. In our acute phase investigation, in male mice only, we observe significant
increases in WBC and LYM counts with complementary emodin compared to 5FU alone.
In our chronic phase investigation, however, we do not see significant recovery of
systemic anemia and cytopenia with complementary emodin. However, we do report
increased hemoglobin and reduced platelet count in mice treated with emodin compared
to 5FU alone. This indicating that preventing the drastic lymphocytopenic effects early in
5FU treatment might be sufficient to prolong survival and improve quality of life.
Incidentally, where these mitigated effects may contribute to performance and quality of
life improvements, it does not explain the full benefits of emodin.
One of the most documented 5FU-induced toxicities involves inflammatory
damage to the gastrointestinal barrier or ‘mucositis.’ We report here that the
characteristic shortening of the villi in the small intestine typically seen with 5FU can be
ameliorated with complementary emodin treatment both acutely and chronically. Where
the mechanisms of mucositis remain elusive, our findings here indicate that 5FU causes
an increase in neutrophil marker Ly6g which is attenuated with complementary emodin.
Further, we report that there is no increase in total macrophages, according to EMR1
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(F4/80) expression with 5FU but an increase in M2-type macrophage marker MRC1
(CD206) in mice receiving complementary emodin. M2-type macrophages are more antiinflammatory type macrophages and are characterized as resident ‘repair’ cells53.
Interestingly, we see that M2-type macrophages are reduced acutely with complementary
emodin. It is likely that this response is indicative of gut resilience during 5FU. Acutely,
emodin may be working to reduce tissue damaging neutrophil infiltration to the gut and,
in result, reduces the severity of mucositis leading to less activation of M2-type
macrophages. Chronically, however, emodin may be benefiting the homeostatic balance
that exists in the gut leading to an improved immune response through activation of M2type macrophages. This, in turn, would lead to maintained turnover of tissue and repair of
5FU-induced damage to the intestinal villi. Interestingly, when we assay the colon for the
same markers, we do not find increased MRC1 expression or reduced Ly6g expression
with complementary emodin treatment. This indicates that despite an overall benefit to
gastrointestinal physiology, it appears that emodin might be playing a site-specific role in
the small intestine leading to the observed overall benefits to quality of life.
The degree of mucositis varies through the GI system, we have previously shown
that low dose 5FU can disrupt immune homeostasis and cause severe small intestine and
colon inflammation132. In the present study, we show that there is no increase in colon
macrophages with both acute and chronic 5FU treatment, but there is a pathological
response causing increased Muc5ac expression. Muc5ac is transiently expressed in the
colon and is increased in situations of dysplasia and colon dysfunction155. Here we show
that chronic 5FU increases Muc5ac expression 7-fold and that emodin can reduce this
expression of Muc5ac despite not rescuing the increased Ly6g or reduced OCLN
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expression. Interestingly, we did not see any increased inflammation or alterations in
Muc5ac or OCLN in our acute phase analysis but a decrease in NOS2 expression when
mice are treated chronically with 5FU and emodin. To our knowledge, there is no body of
literature linking NOS2 expression with Muc5ac perturbations. However, we believe that
5FU-induced overexpression of Muc5ac may be increasing tissue/location dependent
increases in NOS2 which would cause gut barrier dysfunction and reduced gut integrity
during 5FU treatment. This further suggests that initial exposure to 5FU might not
elucidate these toxic mechanisms and that repeated 5FU exposure might be contributing
to the chronic toxicities associated with chemotherapy. Where these findings require
further investigation, we believe we have uncovered a significant mechanism of intestinal
mucositis in the colon which can be attenuated with complementary emodin at a dose of
40 mg/kg.
The role of the microbiome has been implicated in many pathologies40,94,116-118,150.
We have previously shown that 5FU can cause significant perturbations to the gut
microbiota which might be exacerbating associated non-specific toxicities132. In the
present study, we aimed to investigate the spatial arrangement and homeostatic
environment of the colon. Swidsinski et. al. 2016152, describes the colon as a bacterial
bioreactor that has evolutionarily been developed to house the commensal relationship
between bacteria and humans. In taking with these ideals, we examined the spatial
arrangement of bacteria within the colon using 16S rRNA FISH. We observe that 5FU,
when given acutely, can cause significant perturbations to the bacterial environment. We
observe pockets of significant invasion of bacteria to the mucous layer and the epithelia
in the distal colon and disruption of gut morphology in 5FU treated mice. Interestingly,
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we observe a dose dependent reduction of this phenotype with emodin and a reestablished mucous barrier. Where emodin may not be altering the immune environment
of the colon, we show here that significant alteration in bacterial spatial arrangement may
have implications on the gut-immune system axis and may be contributing to the overall
benefit to quality of life seen with our functional testing.
We further aimed to investigate the hematopoietic benefits of emodin when given
acutely. As a thymidylate synthase inhibitor, 5FU will target any actively proliferating
tissue. It has been well established that 5FU causes significant lymphocytopenia and
anemia when given acutely and chronically27,30,36. We investigated the inflammatory
status of the bone marrow via flow cytometry and found that despite systemic cytopenia,
there was an increase in total macrophages counts in the bone marrow. This indicating
that local inflammation might be present in the bone marrow leading to exacerbated
effects of 5FU toxicity. Interestingly, we show that a 40 mg/kg dose of emodin does not
ameliorate the total macrophage count in the bone marrow but may reduce CD11c
expressing M1-type macrophages. This reduction in M1-type macrophages may signify
the mechanism of emodin in ameliorating the toxicities associated with 5FU. Previous
investigations have shown macrophages specific ‘depolarizing’ effects of emodin invitro80, a mechanism that may be occurring in the bone marrow with 5FU treatment invivo. To further investigate the mechanism of emodin, we assayed the expression of the
P2X7 receptor in the bone marrow. Interestingly, we did not find similar trends to CD11c
expression. However, it is important to note that despite no difference in protein
expression, emodin might be reducing activity of this Ca2+ ATPase receptor. Further
experimentation would be needed to confirm this mechanism, however. Complementary
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to these findings, we also show that 40 mg/kg emodin is sufficient to cause increased
percentage of S phase and G2/M phase cells according to Ki67/PI staining. This provides
further evidence that emodin may be acting directly on the hematopoietic system to
ameliorate 5FU-induced cytopenia. Further investigations on specific types of myeloid
precursor cells would be needed to find specific mechanisms associated with the benefits
of complementary emodin.
In summary, we show here that natural anthraquinone emodin is a safe and
effective complementary therapeutic which can be used to ameliorate the toxic sideeffects of 5FU both acutely and chronically. We report improved quality of life measures
through reduced pain sensitivity, improved grip strength, and reduced fatigability. We
show improved gut resilience to 5FU-induced mucositis through reduced Ly6g
expression and a M2-type macrophage dependent maintenance of gut homeostasis. This
was complemented by a reduction of perturbations to gut bacterial spatial arrangement
and bacterial invasion to crypts within the proximal and distal colon. Finally, we report a
potential mechanism of emodin which might reduce bone marrow inflammation and
reduce systemic lymphocytopenia. Despite the benefits described here, further studies are
necessary to determine the exact mechanisms of emodin before moving to clinically
based investigations.
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5.6 Figures & Legends

Figure 5.1. Complementary emodin improves survival and quality of life during a 3cycle regimen of 5FU. A. Study design. B. Relative change in body weight measured as
percent (%) from baseline. * indicates statistical significance at indicated time point from
two-way ANOVA between 5FU + Emodin and 5FU alone. C. Percent survival. D. Pain
threshold measured in grams (gr). 1 gr was maximal pressure tested using VonFrey
Filaments. E. Pain threshold measured as a sum of scores during VonFrey filament test.
F. Absolute grip strength measured in Newtons (N). G. Relative grip strength measured
as Newtons per kilogram (N/Kg) H. Percent (%) performance change in run-to-fatigue
test from pre-5FU treatment to post-5FU treatment. Groups not containing the same
letters (a-c) indicates statistical significance between groups (p < 0.05) from two-way
ANOVA, n = 5–20/group.
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Table 5.1. The effect of chronic 5FU and emodin on major organs. Liver, spleen, epididymal fat, mesenteric fat, and colon length
weights at euthanization. Groups not containing the same letters (a, b, ab) indicate statistical significance between groups (p < 0.05)
from two-way ANOVA, n = 5–20/group.
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Group

Liver (mg)

Spleen (mg)

Mesenteric
Fat (mg)

Epididymal
Fat (mg)

Colon
Length (mm)

Control +
Vehicle

1143 ± 87.47

91.80 ± 13.86

165.0 ± 11.70 a

672.0 ± 99.77 a

72.75 ± 4.15

Control +
Emodin

1166 ± 39.86

74.80 ± 7.42

146.2 ± 33.61 a

619.6 ± 86.16 a

79.20 ± 3.33

5FU +
Vehicle

1216 ± 29.04

81.41 ± 5.94

123.1 ± 10.88 b

398.6 ± 17.77 b

78.12 ± 1.34

5FU +
Emodin

1207 ± 23.77

80.05 ± 2.826

120.1 ± 9.75 b

465.6 ± 25.16 b

81.21 ± 1.41

Table 5.2. The effect of chronic 5FU and emodin on blood profile in mice. White blood cells (WBC), Lymphocytes (LYM),
Monocytes (MON), Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB),
Hematocrit (HCT), and Platelets (PLT). Groups not containing the same letters (a-c) indicate statistical significance between groups
(p<0.05) from two-way ANOVA, n=5-20/group.
Group
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Control +
Vehicle
Control +
Emodin
5FU +
Vehicle
5FU +
Emodin

WBC
(10^9/l)
4.37 ±
0.21a
5.24 ±
0.38 a
2.55 ±
0.16 b
2.93 ±
0.17 b

LYM
(10^9/l)
3.31 ±
0.21 a
3.95 ±
0.32 a
1.80 ±
0.15 b
2.16 ±
0.17 b

MON
(10^9/l)
0.186 ±
0.10
0.13 ±
0.02
0.11 ±
0.02
0.13 ±
0.02

NEU
(10^9/l)
0.88 ±
0.10 ab
1.14 ±
0.05 a
0.64 ±
0.04 ab
0.63 ±
0.05 b

NLR
(A.U.)
0.27 ±
0.05
0.29 ±
0.01
0.88 ±
0.55
0.35 ±
0.05

RBC
(10^12/l)
10.22 ± 0.14 a
9.9 ± 0.25 a
6.23 ± 0.19 b
6.37 ± 0.14 b

HGB
(g/dl)
15.07 ±
0.40 a
14.70 ±
0.32 a
9.28 ±
0.26 b
9.99 ±
0.09 c

HCT (%)
40.37 ±
0.57 a
38.98 ±
1.21 a
25.25 ±
0.74 b
26.16 ±
0.61 b

PLT
(10^9/l)
734.0 ±
21.59 a
728.3 ±
38.36 a
2350.0 ±
159.6 b
1856.0 ±
109.2 c

Figure 5.2. Emodin improves small intestine morphology and promotes M2macrphage polarization during 5FU treatment. A. Representative H&E images of
small intestine biopsies at 4X. B. Measurement of villus length in small intestine,
measurements are normalized to vehicle treated controls and represented as arbitrary
units (A.U.). C. qPCR analysis of NOS2, TNFα, and MCP1 inflammatory cytokines. D.
qPCR analysis of macrophage markers EMR1, MRC1, and ITGAX. E. qPCR analysis of
neutrophil marker Ly6G. Data were normalized to vehicle treated controls and compared
to five reference targets (B2M, TBP, HPRT, HMBS, and H2AFV), which were evaluated
for expression stability using GeNorm. Groups not containing the same letters (a-c)
indicates statistical significance between groups (p<0.05) from two-way ANOVA, n=520/group.
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Figure 5.3. Emodin does not reduce colon inflammation but may improve gut
resilience during 5FU treatment. A. qPCR analysis of NOS2, TNFα, and MCP1
inflammatory cytokines. B. qPCR analysis of macrophage markers EMR1, MRC1, and
ITGAX. C. qPCR analysis of neutrophil marker Ly6G. D. qPCR analysis of gut health
markers OCLN, Muc5ac, and Muc2. E. Representative H&E and Alcian Blue images of
colon biopsies at 4X, insets are 20X. Data were normalized to vehicle treated controls
and compared to five reference targets (B2M, TBP, HPRT, HMBS, and H2AFV), which
were evaluated for expression stability using GeNorm. Groups not containing the same
letters (a-c) indicates statistical significance between groups (p<0.05) from two-way
ANOVA, n=5-20/group.
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Figure 5.4. Emodin benefits quality of life during a single cycle 5FU treatment. A.
Study design. B. Relative change in body weight measured as percent (%) from baseline
in male mice. C. Relative change in body weight measured as percent (%) from baseline
in male mice. *,#, and $ indicate statistical significance (p<0.05) between 20 mg/kg, 40
mg/kg, and 80 mg/kg groups, respectively, compared to vehicle treated controls from
one-way ANOVA at each time point, n=25/group. D. Pain threshold measured in grams
(gr). 1 gr was maximal pressure tested using VonFrey Filaments. E. Pain threshold
measured as a sum of scores during VonFrey filament test. F. Absolute grip strength
measured in Newtons (N). G. Relative grip strength measured as Newtons per kilogram
(N/Kg) H. Percent (%) performance change in run-to-fatigue test from pre-5FU treatment
to post-5FU treatment. * indicates statistical significance between groups (p < 0.05) from
one-way ANOVA, n = 10/group.
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Table 5.3. The effect of acute 5FU and emodin on major organs. Liver, spleen, epididymal fat, mesenteric fat, and colon length
weights at euthanization. Groups not containing the same letters (a, b, ab) indicate statistical significance between groups (p < 0.05)
from one-way ANOVA, n = 5–20/group.
Group

136

Male
5FU+Vehicle
Male
5FU+20mg/kg
Male
5FU+40mg/kg
Male
5FU+80mg/kg
Female
5FU+Vehicle
Female
5FU+20mg/kg
Female
5FU+40mg/kg
Female
5FU+80mg/kg

Liver (mg)

Spleen (mg)

Mesenteric Fat
(mg)

Epididymal Fat
(mg)

Colon Length
(cm)

1148 ± 29.30

59.5 ± 1.34 a

229 ± 17.20

396 ± 27.80

7.50 ± 0.10

1140 ± 47.20

66.2 ± 1.64 b

201 ± 12.20

368 ± 21.10

7.75 ± 0.10

1253 ± 32.00

62.6 ± 1.36 a

235 ± 19.40

403 ± 27.00

7.94 ± 0.09

1177 ± 46.40

62.3 ± 1.75 a

202 ± 11.80

355 ± 20.90

7.79 ± 0.11

1105 ± 39.50

60.6 ± 1.49

202 ± 21.60

221 ± 26.20

7.63 ± 0.12

1101 ± 39.90

60.9 ± 1.24

180 ± 17.60

266 ± 28.8

7.59 ± 0.13

1147 ± 50.60

63.1 ± 2.54

200 ± 22.00

234 ± 21.40

7.66 ± 0.10

1058 ± 45.50

61.1 ± 1.98

178 ± 15.80

225 ± 21.90

7.49 ± 0.12

Table 5.4. The effect of acute 5FU and emodin on blood profile in male and female mice. White blood cells (WBC), Lymphocytes
(LYM), Monocytes (MON), Neutrophils (NEU), Neutrophil:Lymphocyte Ratio (NLR), Red Blood Cells (RBC), Hemoglobin (HGB),
Hematocrit (HCT), and Platelets (PLT). Groups not containing the same letters (a-c) indicate statistical significance between groups
(p<0.05) from one-way ANOVA, n=20/group.
Group
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Male
5FU+Vehicle
Male
5FU+20mg/kg
Male
5FU+40mg/kg
Male
5FU+80mg/kg
Female
5FU+Vehicle
Female
5FU+20mg/kg
Female
5FU+40mg/kg
Female
5FU+80mg/kg

WBC
(10^9/l)
1.87 ±
0.11 a
2.52 ±
0.12 b
2.63 ±
0.13 b
3.14 ±
0.18 c
2.50 ±
0.41
2.33 ±
0.15
2.91 ±
0.28
2.41 ±
0.10

LYM
(10^9/l)
1.61 ±
0.12 a
2.23 ±
0.11 b
2.36 ±
0.13 b
2.86 ±
0.18 c
2.05 ±
0.35
1.87 ±
0.16
2.59 ±
0.28
2.07 ±
0.10

MON
(10^9/l)
0.10 ±
0.01
0.12 ±
0.01
0.10 ±
0.01
0.14 ±
0.02
0.13 ±
0.04
0.12 ±
0.02
0.11 ±
0.02
0.11 ±
0.01

NEU
(10^9/l)
0.15 ±
0.02
0.17 ±
0.02
0.17 ±
0.02
0.14 ±
0.03
0.33 ±
0.06
0.34 ±
0.04
0.21 ±
0.03
0.22 ±
0.02

NLR
0.12 ±
0.02 a
0.08 ±
0.01 a
0.08 ±
0.01 a
0.05 ±
0.01 b
0.20 ±
0.03 a
0.20 ±
0.02 a
0.09 ±
0.01 b
0.11 ±
0.01 b

RBC
(10^12/l)
8.40 ±
0.11
8.48 ±
0.14
8.31 ±
0.14
8.59 ±
0.17
8.03 ±
0.22
8.26 ±
0.21
8.48 ±
0.22
8.12 ±
0.21

HGB
(g/dl)
11.84 ±
0.16
12.01 ±
0.15
12.08 ±
0.13
11.92 ±
0.16
11.80 ±
0.19
12.20 ±
0.23
12.2 ±
0.28
12.1 ±
0.24

HCT (%)
33.25 ±
0.46
33.56 ±
0.48
33.22 ±
0.58
34.09 ±
0.60
32.90 ±
0.82
33.40 ±
0.90
34.20 ±
0.86
32.80 ±
0.82

PLT
(10^9/l)
280.00 ±
18.19
285.40 ±
21.14
308.4 ±
14.04
283.30 ±
20.13
332.00 ±
32.90
340.00 ±
25.70
293.00 ±
33.50
320.00 ±
24.30

Figure 5.5. Emodin protects small intestine morphology and reduces neutrophil and
M2-macrphage expression during 5FU treatment. A. Representative H&E images of
small intestine biopsies at 4X. B. Measurement of villus length in small intestine,
measurements are normalized to vehicle treated controls and represented as arbitrary
units (A.U.). C. qPCR analysis of NOS2, TNFα, MCP1, and IL10 inflammatory
cytokines. D. qPCR analysis of macrophage markers EMR1, MRC1, and ITGAX. E.
qPCR analysis of neutrophil marker Ly6G. Data were normalized to vehicle treated
controls and compared to five reference targets (B2M, TBP, HPRT, HMBS, and
H2AFV), which were evaluated for expression stability using GeNorm. Groups not
containing the same letters (a-c) indicates statistical significance between groups
(p<0.05) from one-way ANOVA, n=15/group.
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Figure 5.6. Emodin does not reduce colon inflammation acutely but may improve
gut microbial spatial arrangement during 5FU treatment. A. qPCR analysis of NOS2,
TNFα, MCP1, and IL10 inflammatory cytokines. B. qPCR analysis of macrophage
markers EMR1, MRC1, and ITGAX. C. qPCR analysis of neutrophil marker Ly6G. D.
qPCR analysis of gut health markers OCLN, Muc5ac, and Muc2. E. Representative 16S
rRNA FISH images hybridized with EUB338 probe in proximal and distal colons.
Images are at 20X. Arrows indicate invasion of bacteria to crypts and mucus layer. Data
were normalized to vehicle treated controls and compared to five reference targets (B2M,
TBP, HPRT, HMBS, and H2AFV), which were evaluated for expression stability using
GeNorm. Groups not containing the same letters (a-c) indicates statistical significance
between groups (p<0.05) from one-way ANOVA, n=15/group.
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Figure 5.7. 5FU causes local bone marrow inflammation which may be ameliorated
acutely with emodin. A. Representative flow plots of bone marrow isolates indicating
relative macrophage content (CD11b+F4/80+). B. Counted events of total macrophages
per 10000 events collected. C. Representative western blots of CD11c, P2X7, and TNFα
and amido black staining of bone marrow protein extracts. 10 μg of protein was added to
each well. Healthy whole mouse brain was used to identify P2X7+ control. D-F.
Quantification of western blots for (D) CD11c, (E) P2X7 Receptor, and (F) TNFα. Data
were normalized to vehicle treated controls. All western blots were normalized to amido
black (total protein) content. Groups not containing the same letter (a-c) indicates
statistical significance between groups (p<0.05) from one-way ANOVA, n=4-6/group.
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Figure 5.8. Emodin increases S phase cells during 5FU treatment. A. Representative
flow plots of bone marrow isolates stained with Ki67 and Propidium Iodide. B.
Quantification of G1/G0, S, and G2/M phase cells as percent of 100,000 cells collected.
Groups not containing the same letter (a-c) indicates statistical significance between
groups (p<0.05) from one-way ANOVA, n=4-6/group.
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CHAPTER 6
ANTHRAQUINONE EMODIN REDUCES TUMOR BURDEN AND DECREASES PROTUMORIGENIC M2-TYPE MACROPHAGES IN THE AOM/DSS MODEL OF CRC4

_____________________
4

Sougiannis AT et. al. To be submitted to Journal of Experimental Medicine.
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6.1 Abstract
Emodin, a natural anthraquinone, has shown potential as an effective therapeutic agent in
the treatment of many diseases including cancer. We sought to investigate the utility of
emodin as a dietary agent used in the prevention of intestinal/colorectal cancer using the
Apcmin/+ and AOM/DSS mouse models. Emodin was given 3x/week orally in both studies
dissolved in pure propylene glycol. 16 Apcmin/+ mice were randomized into two groups;
Apcmin/+ + Vehicle and Apcmin/+ + 80 mg/kg emodin. 60 C57BL/6 were randomized into
three groups; Control (n=5), AOM/DSS+Vehicle (n=20), AOM/DSS+40 mg/kg (n=20),
AOM/DSS+80 mg/kg (n=20). CRC was induced chemically by a single 10 mg/kg
injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran
sodium sulfate (DSS). Oral emodin treatment began at the initiation of DSS (Week 2). At
the conclusion of both studies, emodin reduced total polyp count in Apcmin/+ mice treated
with 80 mg/kg (p<0.05) and in both 40 mg/kg (p<0.05) and 80 mg/kg (p<0.05)
AOM/DSS mice. We found that emodin reduces M2-type macrophages in the colonic
lamina propria of AOM/DSS mice at both 40 mg/kg (p<0.05) and 80mg/kg (p<0.05)
doses. Further we see that emodin reduces the pro-inflammatory environment of the bone
marrow in AOM/DSS mice by reducing the number of M1-type macrophages (p<0.05).
In evaluating bone protein expression; we observe that emodin reduces the expression of
the P2X7 Receptor and the phosphorylation of STAT3 at Y705 with both 40 mg/kg and
80 mg/kg doses. Taken together, we provide vital evidence of anti-tumorigenic and antiinflammatory potential for emodin to be used as an effective therapeutic in the prevention
of intestinal/colorectal cancer.
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6.2 Introduction
Colorectal cancer (CRC) is the third most common malignancy for men or
women. Preventative interventions, such as exercise and improving dietary patterns
has been shown to improve outcome. However, as CRC progresses, treatment options
become more limited and some patients select a no treatment option. Therefore, there is a
critical need to develop new preventative strategies that improve outcome and can be
administered safely.
There has been a recent increase in the clinical utility of herb-derived compounds
due to evidence of the anti-inflammatory properties of many of these compounds.
Emodin is a trihydroxy-anthraquinone that is found in several Chinese herbs, including
Rheum palmatum and Polygonum multiflorum. Emodin has been shown to attenuate the
severity of multiple experimental disease models including arthritis, liver damage,
atherosclerosis, myocardial ischemia, and cancer by reducing the inflammatory cascades
associated with these conditions. The mechanism of action of emodin has yet to be
discovered. However, an investigation by Jelassi et al 2013 suggested the P2X7 receptor
as a potential target of emodin79. The P2X7 receptor is a Ca2+ channel receptor that it is
found the central and peripheral nervous systems, in microglia, macrophages, and the
retina.75 The P2X7 receptor has also been shown to serve as a pattern recognition
receptor for extracellular ATP-mediated apoptotic cell death, regulation of receptor
trafficking, mast cell degranulation, and inflammation.145,149
Macrophages have been demonstrated to represent the majority of immune cells
in the tumor microenvironment. They are derived from monocyte precursors circulating
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in the blood and are recruited to the tumor by chemokines such as MCP-1 and TGFβ.
Once recruited to the tissue, monocytes will mature into macrophages. It is generally
understood that the recruitment of macrophages to the tumor contribute to the
maintenance of the tumor microenvironment and exert pro-tumoral functions. Protumoral macrophages are characterized as M2-type macrophages, which are polarized
from exposure to cytokines such as TGFβ and IL-10. The presence of M2-type
macrophages in the tumor microenvironment have been shown to promote proliferation,
invasion and metastasis, angiogenesis, and tissue remodeling. Further, high counts of
tumor associated macrophages (TAMs) have been associated with poor prognosis and
therapeutic outcome in CRC. Therefore, therapeutic interventions targeting TAMs and
reducing the M2-type/M1-type ratio within the tumor microenvironment might contribute
to improved survival and subsequent success of further therapeutic outcome.
In the present study, we aimed to establish the efficacy of emodin as a
preventative therapeutic in two models of colorectal/intestinal cancer. Giving emodin as a
preventative therapeutic to at-risk patients might contribute to prolonged survival and
improved immune-based therapeutic outcome. We utilized a chemically induced model
of CRC (AOM/DSS) and a genetic model of intestinal cancer (Apcmin/+). In both models,
mice develop tumors and present with chronic inflammation and anemia with increasing
tumor burden. We utilized oral emodin administration at a dose of 40 mg/kg and 80
mg/kg given orally 3x/week to observe the preventative effects in both these models. Our
data indicate that emodin is able to reduce total polyp count and size in both models.
Within the polyps of AOM/DSS mice, emodin reduced the presence of M2-type
macrophages and increase the production of NOS2.
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6.3 Methods
6.3.1 Animals
Male WT C57BL/6 and male Apcmin/+ mice were purchased from Jackson
Laboratories (Bar Harbor, ME) and were cared for in the animal facility at the University
of South Carolina. Mice were randomized upon arrival to the animal facility to prevent
litter biases in microbiome data and were housed four-five per cage, maintained on a
12:12-h light-dark cycle in a low-stress environment (220C, 50% humidity, low noise).
Mice were kept in a room isolated from all other ongoing animal experiments and were
only handled by the primary investigators. All mice were habituated to the AIN-76A diet
prior to any interventions and were given food and water ad libitum through the course of
the study. All methods were in accordance with the American Association for Laboratory
Animal Science, and the Institutional Animal Care and Usage Committee of the
University of South Carolina approved all experiments.
6.3.2 Apcmin/+ protocol
Fig 1A illustrates the protocol used to treat Apcmin/+ mice with emodin. Briefly, 16
male Apcmin/+ mice randomly divided into 2 groups: Apcmin/+ + Vehicle (n=8) and
Apcmin/+ + 80 mg/kg emodin (n=8). Mice arrived at the animal facility at the University of
South Carolina at 4 weeks of age and were immediately placed n=4/cage and given AIN76A diet and drinking water ad libitum. After one week of habituation, mice were started
on either Vehicle or emodin intervention.
6.3.3 AOM/DSS protocol
Fig 2A illustrates the protocol used to chemically induce colorectal cancer with
the AOM/DSS protocol and concurrent treatment with emodin. Briefly, 65 mice were
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randomly divided into four groups: Control + Vehicle (n=5), AOM/DSS + Vehicle
(n=20), AOM/DSS + 40 mg/kg emodin (n=20), and AOM/DSS + 80 mg/kg emodin
(n=20). At 12 wk of age (baseline week 0) mice received either an intraperitoneal
injection of the carcinogen156, AOM (10 mg/kg) (Sigma, St. Louis, MO), diluted in PBS
(AOM/DSS) or PBS alone (Control). Mice receiving the AOM injection were subjected
to two cycles of DSS (36-50 kDa) (MP Biomedical, Solon, OH)-supplemented water at
final concentrations of 2% and 1% at weeks 1 and 4, respectively. Each DSS cycle lasted
for a 1-wk period.
6.3.4 Symptom monitoring and score calculation
Both Apcmin/+ and AOM/DSS mice underwent the same symptom monitoring and
score calculation. Body weights and symptom scores were determined semi-weekly along
with food and water measurements. Calculation of symptom score was performed as
previously described94, taking into account percent body weight loss, stool consistency,
and rectal bleeding. Briefly, fresh colonic evacuates were smeared onto “Hemoccult”
tape to assess severity of diarrhea and were tested with developer (Beckman Coulter,
Brea, CA) to assess rectal bleeding. Bleeding was scored; no positive detection of blood
(0), detection of blood but not grossly visible (2), and gross visibility of blood (4).
Diarrhea was scored; solid cylinder (0), soft cylinder and easily spreadable (2), and noncylindrical or runny (4). Body weight was calculated as percent body weight loss; 0-5%
(0), 6-10% (1), 11-15% (2), 15-20% (3), 20-25% (4), and >25% (5). Scores of all three
categories were summed to obtain an overall symptom score for each mouse.
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6.3.5 Emodin Preparation
Emodin was purchased from Nanjing Zelang Medical Technology Co., Ltd,
(Nanjing, China). Emodin was independently analyzed by the Mass Spectrometry Center
at the University of South Carolina prior to the initiation of the experimental study. LCUV-MS and NMR was performed to confirm the purity of Emodin and the molecular
structure. Emodin was delivered via oral gavage to mice using flexible plastic tubing oral
gavage needles (Instech, #FTP-20). Emodin was prepared fresh in a 24mg/mL stock
solution using pure propylene glycol (VWR) and mixed for 6-8 hours at room
temperature protected from light prior to gavage. The 24mg/mL solution was used for 80
mg/kg dosing and was used to prepare a 12mg/mL dilution for delivering the 40 mg/kg
dose. Pure propylene glycol was used as a vehicle control in all experiments.
6.3.6 Tissue collection
Mice were euthanized 24 hr post final treatment with emodin and blood was
collected from the inferior vena cava. Tissues were removed, weighted and immediately
snap-frozen in liquid nitrogen and stored at -800C or fixed in 10% formalin until further
analysis. The colon was carefully dissected distal to the cecum and proximal to the anus.
Mesentery adipose tissue was removed with forceps. The colon was opened
longitudinally, and polyps were counted and measured using a dissecting microscope.
Colon length was measured using calipers. A subset of mice (n=4) was used for flow
cytometry analysis in which the colon was placed in ice cold PBS until digestion. The
remaining mice were used for qPCR analysis, polyps were removed from normal
appearing tissue and both were snap frozen until further analysis. In a subset of mice,
femurs were decalcified for 48 hr and then fixed in 10% formalin for 24 hr before being
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embedded in paraffin blocks. Within the same subset of mice, contralateral femurs and
both tibias and fibulas were snap frozen in liquid nitrogen and stored at -800C until
further analysis.
6.3.7 Polyp counting and measurements
At the conclusion of each study polyps were counted and measured using a
dissecting microscope. For Apcmin/+ mice, whole colons and small intestines were opened
longitudinally, laid flat on filter paper, and fixed in 10% formalin overnight. Tissues were
then stained in 0.1% methylene blue to visualize polyps. Polyps were counted by the
same investigator who was blinded to the treatments. Polyps were counted under a
dissecting microscope, using forceps to pick through the intestinal villi and identify
polyps. Polyps were categorized as small (< 1 mm), medium (1-2 mm), or large (> 2
mm). After polyps were counted, intestinal sections were washed with 70% ethanol and
embedded in paraffin for further analysis.
For AOM/DSS mice, freshly dissected colons were opened longitudinally, and
polyps were counted and measured under a dissecting microscope. Polyps were counted
to obtain total numbers and were also categorized as small (< 1 mm), medium (1-2 mm),
or large (> 2 mm) as in Apcmin/+ mice. Further, colons were segmented into proximal,
middle, and distal regions to record location of polyps. After polyps were counted, mice
that were not used for flow cytometry had polyps removed from healthy appearing tissue
and flash frozen in liquid nitrogen and stored at -80oC until further analysis.
6.3.8 Blood Panel Analysis
A complete blood panel analysis was performed using the VetScan HMT (Abaxis,
Union City, CA) for determination of WBCs, LYM, MON, NEU, PLT, RBCs, Hct, and
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Hb. Neutrophil/lymphocyte ratio (NLR) was calculated from obtained values. Briefly,
whole blood was placed in an EDTA coated microtube and analyzed on the VetScan
HMT according to the manufacturer’s instructions.
6.3.9 Lymphocyte Isolation and Flow Cytometry
Colons were removed and digested to obtain single cell suspensions using the
Miltenyi Biotech Lamina Propria Dissociation Kit (#130-097-410). Bone marrow was
taken from both femoral shafts by flushing with saline. Red blood cell lysis was
performed with 20 second hypotonic solution (0.2% NaCl) treatment followed by
hypertonic (1.6% NaCl) cessation. All isolates were passed through a 70 μm filter prior to
antibody staining. Bone marrow and lamina propria isolates were stained with
macrophage panel (CD11b – FITC, F4/80 – PE, CD206 - APC, CD11c – APC/Cy7, Ly6c
– PerCP/Cy5.5, and CD45 – PE/Cy7). All antibodies were purchased from Biolegend
(San Diego, CA). Cell suspensions were blocked with CD16/32 FC Block and staining
was performed for 1hr at 40C. Lymphocytes were identified by gating for CD45+ cells.
Active monocytes were identified as Ly6C+ cells. Data were acquired using a BD FACS
Aria II cell sorter and analyzed by FlowJo v10.6.2.
6.3.10 Gene expression
Quantification of colonic expression of IFN-γ, TNFα, MCP-1, IL4, IL-6, IL-10,
IL-1β, and P2RX7 were performed as previously described132. Briefly, RNA was
extracted using TRIzol reagent (Life Technologies, GIBCO-BRL, Carlsbad, CA) and
chloroform procedures. Because DSS has been shown to inhibit polymerase and reverse
transcriptase activity, lithium chloride was used to purify the RNA as described in detail
by Viennois et al. 2013.97 RNA sample quality and quantities were verified using an
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Agilent Bioanalyzer and determined to be of good quality based on A260/A280 values
(>1. 8) prior to cDNA synthesis using QuantiTect Reverse Transcription kit (Qiagen
205313). Quantitative RT-PCR analysis was carried out as per the manufacturer’s
instructions (Applied Biosystems) using Taq-Man Gene Expression Assays. Data were
normalized to vehicle treated controls and compared to five reference targets (B2M, TBP,
HPRT, HMBS, and H2AFV), which were evaluated for expression stability using the
GeNorm algorithm.98,99
6.3.11 Histopathology
Hematoxylin and eosin (H&E) staining of the bone tissue was performed as
previously described132. All images were obtained using a Nikon E600. All
histopathological analyses were performed by a board-certified pathologist blinded to the
experimental conditions (I.C.).
6.3.12 Bone Protein Isolation and Western Blot
Frozen bone femurs, tibias, and fibulas were pulverized using a mortar and pestle
while kept frozen at liquid nitrogen. Protein was purified by further homogenizing
pulverized products in Mueller buffer containing protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO). Total protein concentrations were determined by the Bradford
method. Equal amounts of crude protein homogenates (20ug) were separated on handcasted SDS-polyacrylamide gels and electrophoretically transferred to a PVDF
membrane using a Royal Genie Blotter (IDEA Scientific, Minneapolis, MN). Membranes
were blocked for 1hr at room temperature with 5% non-fat milk in tris-buffered saline
with 0.1% tween (TBST). Western blots were performed using primary antibodies P2X7
(Alomone Labs #APR-004), p-P38 (Cell Signaling #9211), and t-P38 (Cell Signaling
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#8690). An anti-rabbit (Cell signaling: #7047) IgG horseradish peroxidase conjugated
secondary antibody was diluted 1:2000 in 5% milk-TBST and incubated for one hour at
room temperature. An enhanced chemiluminescent substrate for detection of horseradish
peroxidase (Thermo Scientific, Watham, MA) was used to visualize the antibody-antigen
interaction. Autoradiography films were scanned, and blots were quantified using
scientific imaging software ImageJ (NIH Bethesda, MD). After completion of the
western blot, all membranes were stained with Amido black (VWR #AAJ66798-14) and
the densitometry of each lane was calculated using ImageJ allowing for total protein
normalization as previously described150.
6.3.13 Statistical analyses
All data were analyzed using commercial software (SigmaStat V3.5, SPSS,
Chicago, IL). All outcomes were analyzed using a one-way ANOVA. A StudentNewman-Keuls test was used for all post-hoc analyses. Survival curve analysis was
conducted by Log-rank (Mantel-Cox) test. Any data that were not normally distributed or
did not display equal variance were logarithmically transformed so that those criteria
were met. Statistical significance was set with an alpha value of p<0.05. Data are
presented as mean ± SEM.
6.4 Results
6.4.1 Emodin reduces polyp load in Apcmin/+ mice.
There was no difference in body weight or calculated symptom score between
Apcmin/+ mice treated with vehicle or 80 mg/kg emodin (Fig 6.1B,C). After 11 weeks of
treatment, mice were euthanized, and the entire small intestines were stained with
methylene blue and polyps were counted. We found that 11 weeks of emodin treatment
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reduced total polyps in Apcmin/+ mice (Fig 6.1D; p<0.05). Further, emodin reduced the
number of large (>2mm) and medium (1-2mm) sized polyps in the small intestine
compared to vehicle treated controls (Fig 6.1E; p<0.05). There was no difference in small
polyp count (<1mm) with emodin treatment (Fig 6.1E).
6.4.2 Emodin does not alter organ weight but might improve immune health in Apcmin/+
mice.
Splenomegaly, anemia/cytopenia, and cachexia are hallmarks of advanced
colorectal/intestinal cancer; therefore, reduced spleen size/weight, maintenance of healthy
major organ weight, and improved circulating blood cell counts can indicate improved
prognosis and a successful therapy. At the conclusion of the study, there was no
detectable difference in liver, spleen, epididymal fat, or mesenteric fat pad weight (Table
6.1) between vehicle and emodin treated mice. However, it is important to note that
splenomegaly was achieved at this stage with both groups having average spleen weights
greater than 200mg (Splenomegaly in mice is described as spleen weight >100mg). We
also observe no difference small intestine or colon length (Table 6.1). We performed a
comprehensive blood panel analysis at the conclusion of the study. Although not
statistically significant, we detected trending increases in total WBC count (p=0.149) and
MON count (p=0.137) and a trending decrease in NLR (p=0.081) with emodin treatment
(Table 2). Supplemental to these findings, there were no differences in LYM, NEU, RBC,
HGB, HCT, or PLT counts with emodin treatment.
6.4.3 Emodin reduces polyp load in AOM/DSS mice.
All mice injected with AOM had significantly lower body weight loss compared
to control mice for the remainder of the study. Compared to AOM/DSS mice treated with
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vehicle only; 40 mg/kg of emodin yielded a smaller change in body weight at Week 4.5,
and 80 mg/kg of emodin yielded a smaller change in body weight at Week 2, Week 4.5,
and Week 5 (Fig 6.2AB; p<0.05). Within AOM/DSS mice treated with emodin there was
a significantly smaller difference in body weight change between 40m/kg treatment and
80 mg/kg treatment at Week 2 (Fig 6.2AB; p<0.05). There was a significantly lower
symptom score calculation in 40 mg/kg and 80 mg/kg mice compared to vehicle treated
mice at Week 5, Week 8, Week 9, and Week 10 (Fig 6.2AC; p<0.05). Survival was
monitored through the course of the study. No mice expired due to complications from
oral gavage treatment. Mice that were found dead in cage (FDIC) were counted as part of
survival measurements. Although not statistically significant, through the course of study
there were three deaths in the AOM/DSS + Vehicle group (17/20 survival), two deaths in
the AOM/DSS + 40 mg/kg group (18/20 survival), and no deaths in the AOM/DSS + 80
mg/kg group (20/20 survival) (Fig 6.2A,D).
At the conclusion of the study colons were excised and polyps were counted
under a dissecting microscope. There was a statistically significant difference between
vehicle treated mice and mice treated with 40 mg/kg and 80 mg/kg (Fig 6.2E; p<0.05).
Similar to our Apcmin/+ study, we categorized polyp counts by size. This revealed that
both 40 mg/kg and 80 mg/kg emodin treatment significantly reduced medium sized (12mm) (p<0.05) polyps but not small (<1mm) and large (>2mm) polyps (Fig 2F). The
location of polyps within the colon has been shown to be important in the prognosis of
colorectal cancer with more distal polyps indicating worse outcome. With this
understanding we analyzed colon polyps in distal, middle, and proximal sections of the
colon. We found that both 40 mg/kg and 80 mg/kg emodin does not change the presence
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of distal or proximal polyps but does significantly reduce the presence of polyps in the
middle portion of the colon (Fig 6.2G; p<0.05).
6.4.4 Emodin improves liver weight in AOM/DSS mice but does associate with other
organ weight changes.
As described in the Apcmin/+ section; splenomegaly, anemia/cytopenia, and
cachexia are hallmarks of advanced colorectal/intestinal cancer. We observed
splenomegaly in all AOM/DSS mice (p<0.05) but this was not changed with emodin
treatment (Table 6.3). Advanced CRC causes organ wasting which is observed
experimentally through decreased major organ weight. We observe decreased epididymal
fat and mesenteric fat weight in all AOM/DSS mice (Table 6.3; p<0.05). Interestingly we
found that mice treated with 80 mg/kg emodin had lower epididymal fat pad weight
compared to mice treated with 40 mg/kg emodin (p<0.05) but not vehicle treated controls
(Table 6.3). There was no difference in mesenteric fat pad weight with emodin treatment
(Table 6.3). Liver weight has also been shown to decrease with progressed CRC. We
show that vehicle treated AOM/DSS mice had significantly lower liver weights on
average (Table 6.3; p<0.05). Interestingly, although not statistically significant from
vehicle treated AOM/DSS mice, we found that both 40 mg/kg and 80 mg/kg had
increased liver weight compared to vehicle treated AOM/DSS mice which yielded a nonstatistically significant difference between emodin treated mice and healthy controls
(Table 6.3).
6.4.5 Emodin reduces pro-tumoral M2-macrophage count in colon lamina propria of
AOM/DSS mice.
Tumor associated macrophages are understood to play an essential role in the
prognosis and treatment outcome of colorectal cancer. Using flow cytometry, we show
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here that colon cancer increases total lamina propria macrophages (Gated from:
CD45+/CD11b+/Ly6C+/F480+ cells). Compared to healthy controls, total macrophages
were significantly greater in AOM/DSS mice treated with vehicle (Fig 6.3A,B; p<0.05).
However, both 40 mg/kg and 80 mg/kg emodin treated mice did not have different total
macrophages compared to vehicle treated AOM/DSS mice or healthy controls (Fig
6.3A,B).
We characterize CD11c expressing macrophages as M1-type macrophages and
CD206 expressing macrophages as M2-type macrophages. Double expressing CD11c and
CD206 macrophages are characterized as cells undergoing transition and not completely
polarized M1- or M2-type macrophages. Further, cells not expressing CD11c or CD206
are characterized as M0-type macrophages. As expected, we observed a significant
increase in M2-type macrophages in the lamina propria of AOM/DSS mice treated with
vehicle (Fig 6.3C,D; p<0.05). Both 40 mg/kg and 80 mg/kg emodin treatment decreased
the abundance of CD206+ M2-type macrophages in the lamina propria (Fig 6.3C,D;
p<0.05). There was a similar trend in CD11c-/CD206- M0-type macrophages (Fig
6.3C,D; p<0.05), however, emodin treated mice did not have significantly lower M0-type
macrophages compared to mice treated with vehicle (Fig 6.3C,D). There was no
significant difference between groups in the presence of M1-type or transitioning
macrophages (Fig 6.3C,D).
M1-type macrophages are described as having anti-tumor properties and M2-type
macrophages are described as having pro-tumor properties. To observe the general provs. anti-tumor niche we show the ratio of M2 vs. M1 macrophages within the lamina
propria. We confirm the presence of a more pro-tumoral niche by reporting an increase in
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the ratio of M2/M1 macrophages which is ameliorated with 40 mg/kg and 80 mg/kg
emodin treatment (Fig 6.3E; p<0.05).
6.4.6 High dose emodin increases intra-polyp NOS2 expression.
Polyps were removed from normal appearing tissue and RNA was extracted for
inflammatory cytokine analysis via RT-PCR. Interestingly, despite reduced polyp load,
mice treated with 40 mg/kg and 80 mg/kg emodin do not have differences in MCP1, IL6,
TNFα, IL1β, IFNγ, IL10, IL4, or Tgfb1 (Fig 6.4). However, there was a significant
increase in NOS2 expression of mice treated with 80 mg/kg emodin compared to vehicle
treated controls and mice treated with 40 mg/kg emodin (Fig 6.4; p<0.05).
6.4.7 Emodin does not ameliorate cancer associated anemia but does reduce bone
marrow associated inflammation.
Hematological perturbations are a significant hallmark of advanced CRC. We find
here that all AOM/DSS mice had significantly greater monocyte counts compared to
healthy controls (Table 6.4; p<0.05). Although not statistically significant, there was a
trending decrease in monocyte counts (p=0.121) in 80 mg/kg mice compared to vehicle
treated mice. Further, there was a significant decrease in RBC counts, HGB, and HCT in
all AOM/DSS mice (p<0.05), but no difference was detected in mice treated with emodin
(Table 6.4). In parallel, there was a significant decrease in PLT counts in AOM/DSS
mice treated with vehicle and 40 mg/kg emodin (Table 6.4; p<0.05). Interestingly,
AOM/DSS mice treated with 80 mg/kg emodin had increased PLT counts but was not
statistically different from AOM/DSS mice treated with vehicle and 40 mg/kg or healthy
controls (Table 6.4). There were no significant differences detected in WBC, LYM,
NEU, or NLR detected in any experimental groups (Table 6.4).
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Bone marrow macrophages were analyzed by flow cytometry from a subset of
mice (n=2-4). Interestingly, mice treated with both 40 mg/kg and 80 mg/kg had
significantly lower total macrophages (CD45+/CD11b+/Ly6C+/F480+ cells) compared to
control and AOM/DSS alone (Fig 6.5A,B; p<0.05). Upon further analysis, we found that
AOM/DSS mice had increased M1-type macrophages (CD11c+ cells) compared to
control mice (Fig 6.5C,D; p<0.05). Interestingly, 40 mg/kg and 80 mg/kg emodin
treatment reduced M1-type macrophage counts to similar values as control mice (Fig
6.5C,D; p<0.05). In all AOM/DSS groups there was a significant decrease in M2-type
(CD206+ cells) and M0 (CD11c-/CD206- cells) compared to controls (Fig 6.5C,D;
p<0.05). There was no difference in CD11c+/CD206+ cells between all groups. We
confirm this increase in M1-type macrophages by reporting a significant increase in the
M1/M2 ratio of AOM/DSS mice compared to controls (Fig 6.5E; p<0.05). Interestingly,
we show a dose response decrease in this ratio with increasing emodin treatment in which
40 mg/kg emodin is not different from control or AOM/DSS alone but 80 mg/kg emodin
is significantly lower (p<0.05) than AOM/DSS alone but not different than control (Fig
6.5E).
6.4.8 Emodin reduces expression of P2X7 and STAT3 signaling in bone tissue of
AOM/DSS mice.
To further observe the effects of emodin on bone and bone marrow health, we
performed western blot analysis on frozen distal limb bones (femur, tibia, fibula). We
observe a significant increase in P2X7 expression in AOM/DSS mice which was reduced
with 40 mg/kg and 80 mg/kg emodin treatment (Fig 6.6A,B; p<0.05). STAT3 activation
by phosphorylation at Y705 was significantly increased in AOM/DSS mice treated with
vehicle and was decreased with both 40 mg/kg and 80 mg/kg emodin treatment (Fig
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6.6A,C; p<0.05). Interestingly, there was a significant increase in total STAT3 protein
expression in all AOM/DSS mice which was not changed with emodin treatment but
caused a significant decrease in the ratio of phospho/total STAT3 protein expression (Fig
6.6A,C; p<0.05). We found a significant increase in phospho-ERK1/2 (T202/Y204) in all
AOM/DSS mice (p<0.05) which was not changed with emodin treatment (Fig 6.6A,D;
p<0.05). Further, we found no increase in total ERK1/2 expression which caused the
phospho/total ERK1/2 ratio to have the same trends as the phospho-ERK1/2 expression
(Fig 6.6A,D; p<0.05). We also detected a significant increase in phospho-P38 in
AOM/DSS mice which trended towards a decrease in mice treated with 80mg/kg emodin
(Fig 6.6A,E; p=0.117). There was no difference in the expression of total P38 which
caused a similar trend in the phospho/total P38 ratio to have the same trends as the
phospho-P38 expression (Fig 6.6A,E; p<0.05).
6.5 Discussion
There is overwhelming evidence supporting the use of natural compounds as
preventative therapeutics in the treatment and prevention of colorectal cancer. We utilize
two models (Apcmin/+ and AOM/DSS) of intestinal/colorectal cancer to examine the
ability for dietary emodin to reduce tumor burden. In both models, we observe a
significant decrease in colon polyps. Mice treated with emodin exhibited lower protumorigenic M2-type macrophages and had reduced the ratio of M2/M1 macrophages
within the colon. Despite this decrease in M2-type macrophages, we did not observe any
change in M2 associated cytokines IL10, IL4, and Tgfb1 within excised polyps. Further,
we did not see changes in M1 associated cytokines IL6, TNFα, IL1β, and IFNγ, but we
did observe a significant increase in NOS2 expression in mice treated with 80 mg/kg
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emodin. Emodin treatment also decreased total macrophage content within the bone
marrow and reduced activation of M1-type macrophages compared to vehicle treated
controls. Further analysis showed decreased P2X7 receptor expression in whole bone
homogenates compared to vehicle treated AOM/DSS mice which presented with
increased P2X7 expression compared to healthy controls. Taken together, these data
suggest that emodin reduces pro-tumorigenic macrophages in the colon in the presence of
colon cancer and can ameliorate the pro-inflammatory consequences of colorectal cancer
by potentially targeting the P2X7 receptor.
The tumor microenvironment consists of a heterogenous population of immune
cells that can act to reduce or promote tumor growth. TAMS are conditioned by the
tumor microenvironment and exert pro-tumoral properties. Cytokines such as TGF-β, IL10, and IL-4 polarize monocytes recruited to the tumor microenvironment into M2-type
macrophages which act to promote proliferation, invasion and metastasis, angiogenesis,
and matrix deposition and remodeling. 157 TAMs have been shown to be directly
associated with poor prognosis and therapeutic outcome in CRC.46,158 Emodin has been
shown to act as a macrophage deactivator in-vitro, but has never been tested in-vivo. We
show that emodin treatment decreases polyp count and size in both Apcmin/+ and
AOM/DSS models of intestinal/colorectal cancer. This was partially explained by the
reduced M2-type macrophage (CD206+) counts within the colons of AOM/DSS mice
treated with emodin which resulted in a more balanced M2/M1 ratio of macrophages.
Interestingly, this was not elicited by reduced expression of M2-promoting cytokines
TGF-β, IL-10, and IL-4. The only change in cytokine expression detected was an increase
in NOS2 expression in mice treated with 80 mg/kg emodin only. NOS2 is known to
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promote M1-type macrophage polarization, but in the case of emodin, might be
promoting depolarization of M2-type macrophages. A study by Iwanowycz et al 2016
demonstrated that emodin promotes TNFα release from IL-4 induced M2-type
macrophages in-vitro and depolarized M2-type macrophages. Although not the same
mechanism, this suggests that emodin may be promoting M2-type macrophage
depolarization by increasing M1-promoting cytokines in a tissue dependent manner. It is
important to note that flow cytometry was performed in whole colons and not specifically
polyps; therefore, this altered macrophage phenotype may not completely represent the
tumor microenvironment.
Systemic inflammation is a hallmark characteristic of advanced colorectal cancer.
Where wo do not see alterations in the blood profile of Apcmin/+ mice, we do see a
trending decrease in circulating monocyte counts of AOM/DSS mice treated with 80
mg/kg emodin, a value which is increased with advanced CRC as indicated by
AOM/DSS mice treated with vehicle. This finding was complemented by reduced total
macrophage counts and M1-type (CD11c+) macrophages in the bone marrow of mice
treated with emodin. We identified that there were no gross histological indications of
metastasis to the bone in AOM/DSS mice (Fig 6.7), and therefore the increase of M1type macrophages in the bone marrow is likely attributed to extraneous factors from CRC
burden. However, this finding does not explain the complete benefits of emodin. The
physiological effects of this change in macrophage count needs to also be considered. We
observe a drastic decrease in total macrophage count in 40 mg/kg and 80 mg/kg emodin
treated mice that falls well below healthy control mice (2,490 and 2,380 cells vs. 9,031
cells, respectively). Considering our characterization of macrophage phenotyping, we see
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this loss in macrophage count solely attributed to the reduction of CD11c+ (M1-type)
macrophages. Beyond this finding, AOM/DSS mice presented with a drastic decrease in
CD206+ (M2-type) macrophages and CD11c-/CD206- (M0-type) macrophages
compared to healthy controls, which was not altered with emodin treatment. Therefore, it
is imperative to provide further investigations into the physiological consequences of this
drastic macrophage reduction in the bone marrow to understand the benefits associated
with emodin treatment.
The mechanism of action of emodin has yet to be discovered; however, it has
been suggested that emodin may inhibit the activity and expression of the P2X7 receptor.
The P2X7 receptor is found the central and peripheral nervous systems, in microglia,
macrophages, and the retina75,149. The P2X7 receptor has also been shown to serve as a
pattern recognition receptor for extracellular ATP-mediated apoptotic cell death,
regulation of receptor trafficking, mast cell degranulation, and inflammation.145,149 We
demonstrate in the present study that the expression of P2X7 receptor is increased in mice
receiving AOM/DSS mice alone and decreased with increasing emodin dosage. Previous
investigations have also showed that emodin can change the expression of P38 and
ERK1/2 MAP Kinases, however these findings have been inconsistent.72,81-84
Interestingly, although we see increased activation of P38 and ERK1/2 in the bone tissue
of AOM/DSS mice, there is no change associated with emodin treatment. Emodin has
also been shown to antagonize STAT3 signaling in-vitro. We confirm this mechanism in
the bone marrow environment where we see that AOM/DSS mice treated with vehicle
have increased STAT3 signaling, which was decreased with both 40 mg/kg and 80 mg/kg
emodin treatment. The culmination of previous investigations and the role of the P2X7
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receptor would suggest that emodin is working to antagonize the P2X7 receptor, which is
present on activated pro-inflammatory immune cells, and therefore contributes to the
decreased expression of STAT3 signaling. However, this mechanism needs further
investigation.
Overall, our findings indicate the efficacy of emodin as a primary therapeutic to
be used in the prevention of intestinal/colon-based cancers. The in-vivo mechanisms of
emodin have proven to be elusive and have not been explored in the presence of CRC.
We provide evidence that emodin can decrease pro-tumorigenic M2-type macrophages in
the colon of AOM/DSS by increasing NOS2 expression within the polyp environment.
We further demonstrate that emodin ameliorates the increased systemic monocyte counts
and bone marrow M1-type macrophages likely by inhibiting the activity of the P2X7
receptor. Although these findings do not definitively indicate the mechanism of action of
emodin, we are the first to show evidence of anti-cancer and anti-inflammatory
mechanisms of emodin in-vivo. These findings indicate that the benefit of emodin is
highly tissue specific and warrants further investigation to confirm the mechanisms
discussed here.
In conclusion, the present study confirms that emodin is an effective primary
therapeutic against the onset of genetic and chemically induced sporadic
intestinal/colorectal cancer. We established that emodin reduces the M2-type protumorigenic macrophages within the colon of AOM/DSS mice. Further, we provide
evidence that emodin may be acting to antagonize the P2X7 receptor within the bone
tissue of with advanced CRC and decrease the activation of macrophages within the bone
marrow. Our data support the continuing investigation of emodin as an effective anti163

inflammatory and anti-cancer therapeutic and provide insight into the tissue specific
mechanisms in which this novel drug might benefit longevity of patients at risk for
chronic diseases.
6.5 Figures and Legends

Figure 6.1. 80 mg/kg emodin reduces polyp count in Apcmin/+ mice. A. Experimental
design. B. Absolute body weight measurements during the experiment. C. Symptom
score calculation during the experiment. D. Total polyp count in the entire small intestine.
E. Polyp size. * Indicates statistical significance (p < 0.05) from students t-test, n=6–
7/group.
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Table 6.1. Emodin does not alter organ weight in Apcmin/+ mice. Liver, spleen, epididymal fat, mesenteric fat, small intestine, and
colon length weights at the conclusion of the study. Milligrams (mg), centimeters (cm).
Group

Liver (mg)

Apcmin +
Vehicle
Apcmin +
80mg/kg

1237.5 ±
115.1
1328.0 ±
47.1

Spleen
(mg)
233.0 ±
44.4
277.1 ±
65.6

Epididymal Fat
(mg)

Mesenteric Fat
(mg)

Small Intestine
(cm)

Colon
(cm)

625.8 ± 80.6

224.0 ± 36.9

32.4 ± 0.5

8.2 ± 0.2

613.7 ± 106.5

201.2 ± 20.7

32.9 ± 0.9

8.2 ± 0.1

Table 6.2. Emodin does not alter hematological perturbations in Apcmin/+ mice. White blood cells (WBC), lymphocytes (LYM),
monocytes (MON), neutrophils (NEU), neutrophil:lymphoctye ration (NLR), red blood cells (RBC), hemoglobin (HGB), hematocrit
(HCT), and platelets (PLT) were measured using a VetScan HMT (Abaxis, Union City, CA). n=6-7/group.
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Group
Apcmin +
Vehicle
Apcmin +
80mg/kg

WBC
(10^9)
3.83 ±
0.71
5.42 ±
0.64

LYM
(10^9)
2.27 ±
0.65
3.63 ±
0.64

MON
(10^9)
0.120 ±
0.048
0.301 ±
0.078

NEU
(10^9)
1.46 ±
0.19
1.48 ±
0.17

NLR
(A.U.)
0.779 ±
0.204
0.642 ±
0.265

RBC
(10^12)
6.32 ±
1.12
5.52 ±
0.95

HGB
(g/dl)
9.75 ±
1.59
9.00 ±
1.21

HCT
(%)
27.26 ±
4.60
24.60 ±
3.68

PLT
(10^9)
950.50 ±
41.97
957.14 ±
94.73

Figures 6.2. Emodin reduces polyp count in AOM/DSS mice. A. Experimental design.
B. Percent (%) change in body weight from start of experiment (W1). C. Symptom score
calculation. D. Survival curve. E. Total polyp count. F. Polyp size. G. Polyp location. #
indicates statistical significance (p<0.05) between 40 mg/kg and vehicle treated mice, $
indicates statistical significance (p<0.05) between 80 mg/kg and vehicle treated mice, %
indicates statistical significance (p<0.05) between 40 mg/kg and 80 mg/kg treated mice
from one-way ANOVA, n=5=20/group.
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Table 6.3. Emodin treatment does not alter organ weight in AOM/DSS mice. Liver, spleen, epididymal fat, mesenteric fat, small
intestine, and colon length weights at the conclusion of the study. Milligrams (mg), centimeters (cm), millimeters (mm).
Group
Control
Vehicle
40mg/kg
80mg/kg

Liver (mg)
1478.2 ±
43.1a
1245.2 ±
46.7bc
1336.3 ±
41.8ac
1314.6 ±
25.1ac

Spleen (mg)
82.2 ± 1.4
152.5 ± 20.0
139.7 ± 12.6
144.7 ± 13.4

Epididymal
Fat (mg)

Mesenteric
Fat (mg)

1426.0 ±
127.0a
714.8 ±
77.4bc
844.8 ±
59.4b
626.9 ±
35.0c

586.0 ±
52.3a
310.9 ±
28.5b
347.3 ±
25.0b
317.2 ±
13.8b

Tibia (mm)

Small
Intestine
(cm)

Colon (cm)

18.6 ± 0.2

32.6 ± 0.4

8.0 ± 0.2

18.3 ± 0.1

32.3 ± 0.3

7.5 ± 0.1

18.0 ± 0.1

32.6 ± 0.4

7.6 ± 0.1

18.3 ± 0.1

33.8 ± 0.6

7.6 ± 0.1
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Figure 6.3. Emodin reduces pro-tumorigenic M2-type Macrophages within the
AOM/DSS mouse colon lamina propria. A. Flow plots identifying mature macrophages
(CD45+/CD11b+/Ly6C+/F480+ cells). B. Quantification of mature macrophages. C.
Flow plots identifying M1-type (CD11c+) vs. M2-type (CD206+) macrophages.
CD11c/CD206+ cells are considered transitioning cells and CD11c-/CD206- cells are
considered M0-type macrophages. D. Quantification of M1, transition, M2, and M0
macrophages. E. Ratio of M2/M1 macrophage counts. Groups not containing the same
letter (a-c) indicates statistical significance between groups (p<0.05) from one-way
ANOVA, n=2(control)-4(AOM/DSS)/group.
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Figure 6.4. 80 mg/kg emodin increases NOS2 expression within polyps of AOM/DSS
mice. qPCR analysis of MCP-1, IL6, TNFα, IL1b, IFNg, NOS2, IL10, IL4, and Tgfb1
genes. Data were normalized to vehicle treated controls and compared to five reference
targets (B2M, TBP, HPRT, HMBS, and H2AFV), which were evaluated for expression
stability using GeNorm. Groups not containing the same letters (a,b) indicates statistical
significance between groups (p < 0.05) from one-way ANOVA, n=12–15/group.
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Table 6.4. Emodin does not significantly alter hematological parameters within AOM/DSS mice. White blood cells (WBC),
lymphocytes (LYM), monocytes (MON), neutrophils (NEU), neutrophil:lymphoctye ration (NLR), red blood cells (RBC), hemoglobin
(HGB), hematocrit (HCT), and platelets (PLT) were measured using a VetScan HMT (Abaxis, Union City, CA). n=5(control)20(AOM/DSS)/group.
Group
Control
Vehicle
40mg/kg
80mg/kg
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WBC
(10^9)
5.38 ±
0.48
4.57 ±
0.27
4.83 ±
0.43
5.73 ±
0.26

LYM
(10^9)
4.27 ±
0.40
3.22 ±
0.26
3.48 ±
0.36
4.15 ±
0.23

MON
(10^9)
0.040 ±
0.004 a
0.215 ±
0.029 b
0.194 ±
0.038 b
0.166 ±
0.031 b

NEU
(10^9)
1.04 ±
0.11
1.13 ±
0.12
1.16 ±
0.09
1.41 ±
0.11

NLR
(A.U.)
0.24 ±
0.01
0.43 ±
0.09
0.36 ±
0.02
0.36 ±
0.38

RBC
(10^12)
10.28 ±
0.27 a
8.19 ±
0.32 b
8.77 ±
0.29 b
8.38 ±
0.24 b

HGB
(g/dl)
16.00 ±
0.26 a
13.11 ±
0.46 b
13.76 ±
0.31b
21.88 ±
0.29 b

HCT (%)

PLT (10^9)

41.96 ±
1.18 a
33.86 ±
1.19 b
35.75 ±
1.00 b
34.90 ±
0.68 b

781.60 ±
62.84
481.18 ±
66.84
520.28 ±
59.99
615.25 ±
32.46

Figure 6.5. Increasing dose of emodin reduces pro-inflammatory macrophage
environment within the bone marrow of AOM/DSS mice. A. Flow plots identifying
mature macrophages (CD45+/CD11b+/Ly6C+/F480+ cells). B. Quantification of mature
macrophages. C. Flow plots identifying M1-type (CD11c+) vs. M2-type (CD206+)
macrophages. CD11c/CD206+ cells are considered transitioning cells and CD11c/CD206- cells are considered M0-type macrophages. D. Quantification of M1, transition,
M2, and M0 macrophages. E. Ratio of M1/M2 macrophage counts. Groups not
containing the same letter (a-c) indicates statistical significance between groups (p<0.05)
from one-way ANOVA, n=2(control)-4(AOM/DSS)/group.
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Figure 6.6. Increasing dose of emodin reduces P2X7 receptor expression and STAT3
phosphorylation/activation within the bone tissue of AOM/DSS mice. A.
Representative western blots of P2X7, p-STAT3 (Y705), t-STAT3, p-ERK1/2 (), tERK1/2, p-P38 (), t-P38, and amido black stain. B-E. Quantification of relative
expression of B) P2X7 receptor, C) STAT3, D) ERK1/2, E) P38. Groups not containing
the same letter (a-b) indicates statistical significance between groups (p<0.05) from oneway ANOVA, n=2(control)-4(AOM/DSS)/group.
6.6 Supplemental Material

Figure 6.7. No histological evidence of metastasis to bone in AOM/DSS mice. A.
Representative H&E images of bone tissue at 4X, insets are at 20X.

172

CHAPTER 7
SUMMARY AND CONCLUSIONS

173

When used in the treatment of colorectal cancer, it is reported that 5 Fluorouracil
has a 10-15% success rate. However, many patients present with multiple side effects
associated with 5FU treatment, the most common including fatigue, loss of appetite,
diarrhea, increased pain sensitivity, and anemia, all of which can lead to a reduced quality
of life. Furthermore, 7.5% of cancer patients treated with chemotherapy die prematurely
as a result of non-selective chemotherapy toxicity rather than the cancer itself. Natural
anthraquinone emodin, found in several Chinese herbs, has been shown to attenuate the
severity of multiple disease models including, arthritis, liver damage, atherosclerosis, and
cancer and thus presents an excellent subject for use as a complementary therapeutic
against 5FU toxicity and colorectal cancer. In the present document, I describe the proinflammatory consequences of 5FU treatment and identify the gut microbiome as a
potential target for amelioration of these symptoms. I further demonstrate the safety of
emodin and show its efficacy as a complementary therapeutic to ameliorate the toxicities
associated with 5FU. Finally, I show that emodin can be given as a preventative
therapeutic against colorectal cancer and demonstrate in-vivo evidence for a potential
mechanism of action of emodin to ameliorate inflammation and cancer cell survival.
In Chapter 3 I present my first study describing the mechanisms of 5FU toxicity.
In this study, I provide evidence showing 5FU causes significant perturbations to the
hematopoietic and gastrointestinal systems which correlate to reduced quality of life, as
demonstrated by reduced muscular strength and fatigability, all of which may be
associated with perturbations in the gut microbiota. In cancer-free mice we show that
5FU causes significant anemia and systemic lymphocytopenia and reduces the presence
of colon macrophages. I utilize fecal microbial transplantation to illustrate that this
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phenotype is likely controlled, in part, by alterations in the gut microbial
microenvironment and may be a targetable system against 5FU-induced toxicities.
Chapter 4 introduces the natural anthraquinone emodin (1,3,8-trihydroxy-6methylanthraquinone). It was imperative to establish the safety and pharmacodynamics of
emodin in mice prior to initiating any interventional investigations. In Chapter 4 I show
that emodin is poorly absorbed through the gut when given orally and when given
systemically. I further demonstrate that emodin is rapidly metabolized to its active form
(glucuronidated-emodin) within one hour of dosing and is cleared from the plasma within
12 hours; but does not differ between peritoneal and oral routes of administration.
However, I did uncover a significant difference in the bioavailability of emodin between
male and female mice, in which female mice have significantly higher plasma emodin
concentrations 1 hour after dosing. We also show that emodin does not cause any
noticeable pathological indications in major organ systems when given through the diet
continuously for 12 weeks at relative doses of 20 mg/kg, 40 mg/kg, and 80 mg/kg. This
culminated into an understanding that emodin is a safe compound to be used in both male
and female mice.
The pairing of emodin with 5FU was the major focus of the novelty of this
dissertation. In Chapter 5 I demonstrate that emodin improves survival and quality of life
in mice both after an acute and chronic regime of 5FU. This primarily involved
amelioration of pro-inflammatory cytokines TNFα and NOS2 within the gastrointestinal
system leading us to suggest that emodin, while not well absorbed, is able to improve gut
resilience during 5FU therapy. Where the cytokine profile of the colon did not mirror the
phenotypic benefits of emodin, I utilize 16S rRNA FISH to illustrate a dose dependent
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preservation of colon integrity and reduced infiltration of bacteria to the crypts. This
finding further illustrating the likelihood that the benefits of emodin are partially due to
mechanisms involving benefits to the gut microbial environment. Taken together, we
show that emodin treatment improves gut resilience during 5FU treatment. I further
demonstrate that acutely, emodin reduces the severity of lymphocytopenia caused by 5FU
and improves cell cycling in the bone marrow at a moderate dose (40 mg/kg). This
finding was also complemented with evidence showing that 5FU causes infiltration of
pro-inflammatory macrophages to the bone marrow which is partially ameliorated with a
40 mg/kg dose of emodin. Together, Chapter 4 and 5 demonstrate the safety and efficacy
of emodin as a complementary therapeutic and provide vital evidence for further
investigation of emodin in models of chemotherapy toxicity.
My final aim was to demonstrate that emodin can be used as primary therapeutic
against the onset of colorectal cancer. In Chapter 6, I utilize two models of sporadic
intestinal/colorectal cancer development (Apcmin/+ and AOM/DSS) to show that emodin
reduces tumor burden by up to 50% when given as a dietary supplement. I focused my
mechanistic investigations on the AOM/DSS mouse because it is a more translatable
model to the development of colorectal cancers in humans. I show using flow cytometry
that emodin diminishes the pro-tumorigenic niche in the colon by reducing the presence
of M2-type macrophages. This was complemented by an increase in NOS2 expression
within the polyps which is known to induce differentiation of anti-tumor M1-type
macrophages. Stemming from my findings in Chapter 5, I analyzed the bone marrow
inflammatory environment. I show that emodin significantly reduces the presence of total
macrophages primarily by reducing the presence of M1-proinflammatory macrophages.
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This was complemented by whole bone tissue reductions in the expression of the P2X7
receptor and decreased activation of STAT3, giving further evidence to a specific
mechanism of action of emodin.
Taken together, the evidence presented in this document illustrate the utility of
emodin as both a safe and effective complementary and primary therapeutic. Our data
specifically shows essential evidence for the use of emodin as a complementary
therapeutic to reduce 5FU induced toxicities. Additionally, we show evidence that
emodin is an effective preventative therapeutic which can reduce tumor associated protumorigenic macrophages. Due to the increasing prevalence of CRC and the hampered
clinical utility of 5FU chemotherapy, any potential complementary and alternative
therapeutic that shows promise is important to the field of biomedicine. Although further
studies are needed, the data presented here provide an essential first step towards bringing
emodin to clinical trials.
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The data presented in this document pave the way for the next step in the
progression of emodin to clinical trials. Where I have provided evidence on the efficacy
of emodin, there is still much to learn mechanistically before the next steps are taken.
In Chapter 3, we uncovered a significant role of the microbiome-immune axis
involved in the non-specific toxicities associated with chemotherapy treatment. I am
confident in this data but urge the expansion of these research designs into a cancer
model. Utilizing FMT from 5FU treated AOM/DSS mice to observe the direct role of the
microbiome in the presence of cancer will provide vital evidence towards the
understanding the role of the microbiome-immune axis in the treatment and progression
of colorectal cancer.
In Chapters 4 and 5 I revealed promising evidence towards the clinical utility for
emodin to be used as a complementary therapeutic to reduce the toxicities associated with
5FU. However, as stated above, now these investigations need to be performed in cancer
burdened mice in order to fully appreciate the clinical utility of emodin as a
complementary therapeutic to ameliorate 5FU-induced toxicity.
Finally, I am excited for the continuation of data gathering from the studies
presented in Chapter 6. Our results indicate emodin is a safe and effective drug that can
be used to prevent the onset of CRC in at-risk populations. I hope this in-vivo evidence
provided can be utilized to return to in-vitro mechanistic investigations to further our
understanding of the P2X7 receptor and its role in the benefits provided from emodin
treatment.
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Specific Aim #1 will evaluate the effect of 5 fluorouracil chemotherapy on
inflammation, functional parameters, and gut microbiota.
Rationale: It has been previously established that 5FU chemotherapy causes
severe adverse reactions and non-selective toxicities in cancer patients. Side effects
include fatigue, loss of appetite, and diarrhea among others, all of which can lead to a
reduced quality of life and premature death. Identifying strategies to increase efficacy and
reduce toxicity of chemotherapy are of significant public health importance. Further, 5FU
has been reported to cause disturbances in the gut microbiome, which can further
influence the outcome of cancer therapy. Thus, the goal of this aim is to perform a
comprehensive analysis of the physiological effects of 5FU therapy on inflammation,
functional parameters, and gut microbiota.
Experimental design for specific aim #1. Experiment 1 will contain two separate
animal experiments to test the effect of 5FU on inflammation, functional parameters and
gut microbiota.
Primary Outcomes
Functional Testing: Functional tests will be employed to evaluate the effect of 5FU on
quality of life measures associated with non-specific toxicities attributed to 5FU toxicity.
Inflammation: The inflammatory response to 5FU will be evaluated systemically and in
major organs.
Microbiome: The effect of 5FU on the gut microbiome and microbial ecosystem will be
evaluated by 16S rRNA sequencing.
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Secondary outcomes:
Polyp count and size: To confirm the anti-tumor response to 5FU we will evaluate colon
polyp count and size after 5FU treatment.
Specific Methodology Aim #1:
Animals: At approximately 12 weeks of age, C57BL/6J mice were randomized into four
groups: Control + Vehicle (n=10), Control + 5FU (n=10), AOM/DSS + Vehicle (n=15),
and AOM/DSS + 5FU (n=15). Control mice received a 200μl dose of sterile PBS and
AOM/DSS mice received a 10 mg/kg dose of AOM prepared in sterile PBS. After one
week, AOM/DSS mice received 2% DSS drinking water ad libitum for one week
followed by two weeks of recovery. After two weeks of recovery, AOM/DSS mice
received 1% DSS drinking water ad libitum for one week followed by 2 weeks of
recovery. After two weeks of recovery all groups were subjected to a battery of
functional tests (peripheral nociception, grip strength, and run-to-fatigue) over the course
of one week. After recovery from functional tests, all mice commenced a three-cycle
regime of PBS or 5FU treatment; cycle 1: 40 mg/kg, cycle 2 and 3: 20 mg/kg via
intraperitoneal injection. Each cycle consisted of 5 consecutive days of injection followed
by 9 days of recovery. The treatment period lasted for 5 weeks and mice were sacrificed
24 hr after the final injection of the third cycle.
The second animal study contained two phases; a donor phase and a recipient
phase. The donor phase contained two groups of C57BL/6J mice that received either
Vehicle (n=5) or 40 mg/kg 5FU (n=5). Treatments lasted for five consecutive days and
then mice were sacrifice four days after the final injection. Fecal matter was collected
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from mice via mucosal scrape and pellet collection from the anus to the cecum. Fecal
matter was suspended in sterile 10% glycerol/PBS, allowed to settle by gravity for 10
min, and aliquoted into daily requirements for delivery as fecal microbial transplants to
their respective recipient groups. Recipient mice were separated into two groups; Vehicle
FMT (n=10) and 5FU FMT (n=15). Prior to receiving fecal microbial transplantation,
recipient mice initially received an antibiotic cocktail which consisted of: Vancomycin
(50 mg/kg), Neomycin (100 mg/kg), Metronidazole (100 mg/kg), and Amphotericin-B (1
mg/kg) via oral gavage and was supplemented with Ampicillin (1 mg/kg) in the drinking
water given ad libitum. Antibiotic treatment lasted 10 days and mice were treated every
12 hours with gavage boluses. A few days prior to cessation of antibiotic treatment, all
mice were subjected to functional tests (grip strength and run-to-fatigue). 12 hours after
final antibiotic treatment all mice began a 14-day FMT protocol which involved 150 μl of
fecal aliquot every 24 hrs. All mice were sacrifice 24 hours after the final FMT.
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Table A.1 Animal treatment groups for experiment #1.
Strain

Treatment

Age (Weeks)

N

C57BL/6J

Control + Vehicle

12

10

C57BL/6J

Control + 5FU

12

10

C57BL/6J

AOM/DSS + Vehicle

12

15

C57BL/6J

AOM/DSS + 5FU

12

15

C57BL/6J

Donor Vehicle

10

5

C57BL/6J

Donor 5FU

10

5

C57BL/6J

Recipient Vehicle

12

10

C57BL/6J

Recipient 5FU

12

15

Table A.2 Animal clinical score guidelines.
Body Weight Loss

Fecal Hemoccult

Diarrhea

5% = 0

No blood = 0

Hard stool

6-10% = 1

Positive test = 2

Soft stool = 2

11-15% = 2

Visible blood = 4

Runny stool = 4

16-20% = 3
>20% = 4

Functional Testing:
Grip strength assessment
All experimental mice were utilized to evaluate the effects of 5FU treatment on
grip strength. Grip strength was measured prior to 5FU administration (week 8) and
during the recovery period of the second cycle (week 11) in experiment 1 and following
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antibiotic treatment (week 0) and fecal transplantation (week 2) in experiment 2. The
assay was performed as follows: Holding the mice by the tail, the front and back feet
were allowed to grip a grate attached to a force transducer (Aurora Scientific, Ontario,
Canada). Mice were then pulled from the grate, generating a force that was measured by
the force transducer. Five measurements were taken consecutively, with at least 2 min
rest between sets until a total of 15 measurements were taken for each mouse. The
averages of the 15 measurements were used in the data analysis. Measurements were
performed by the same investigator through the entirety of the study. Body weight was
measured immediately prior to the administration of the grip strength test and used to
calculate relative (N/kg) grip strength.
Run-to-fatigue assessment
To determine the effect of 5FU on fatigability, mice were subjected to a run-tofatigue test prior to 5FU administration (week 8) and during the recovery period of the
second cycle (week 11) in experiment 1 and following antibiotic treatment (week 0) and
fecal transplantation (week 2) in experiment 2. After 3 consecutive days of habituation
during the night cycle, mice were subjected to the following run-to fatigue protocol: 15min warm-up, 20 m/min for 30 min, and 25 m/min thereafter until fatigue was reached.
Fatigue was defined as the time at which mice were no longer able or willing to keep up
with the treadmill despite hand prodding for at least 1 min. All treadmill tests were
performed during the night cycle by the same investigators through the entirety of the
study.
Blood Panel Analysis: Blood panel analysis was performed using the VetScan HMT
(Abaxis, Union City, CA). Blood was collected in EDTA-coated lavender top tubes from
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the inferior vena cava of mice that were overdosed with isoflurane. Tubes were mixed by
inverting multiple times and stored on ice until transported to the School of Medicine for
analysis. Tubes were places in the VetScan HMT apparatus, and the following counts
were obtained: WBC, LYM, MON, NEU, PLT, RBC, Hct, and Hb.
Neutrophil/Lymphocyte ratio (NLR) was calculated from obtained values.
Polyp count: At tissue collection the colon was carefully dissected distal to the cecum and
proximal to the anus. Mesentery adipose tissue was removed with forceps. The colon was
opened longitudinally, and polyps were counted and measured using a dissecting
microscope.
RNA isolation and qPCR: Tissue samples were homogenized in 1 mL TRIzol reagent
(Life Technologies, GIBCO-BRL, Carlsbad, CA) reagent using mechanical bead beating.
After incubating for 5 min at room temperature, 200μl of ultrapure chloroform was
added, samples were mixed, and then incubated at room temperature for 5 minutes.
Samples were then centrifuged at 14,000g for 15 min at 40C and the resulting supernatant
was removed and mixed with equal volume (~500 μl) ultrapure isopropanol to precipitate
RNA. After precipitation at room temperature for 5 minutes, samples were centrifuged at
14,000g for 15 min at 40C to pellet RNA. After pellets were obtained, the supernatant
was discarded, and pellets were washed twice with 70% ultrapure ethanol. Samples were
centrifuged at 7,500g for 6 min between washes. After washes, pellets were dried and
dissolved in 100 μl ultrapure RNase free water. To further purify RNA, samples were
incubated twice with 10 μl of 8M Lithium Chloride on ice for 1 hr and centrifuged at
14,000g for 20 min between incubations. After the final incubation, pellets were
dissolved in 100 μl ultrapure RNase free water and RNA was precipitated in 10 μl 3M
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Sodium Acetate and 200 μl ultrapure ethanol. After precipitation, samples were
centrifuged at 14,000g for 20 min at 40C. After centrifugation, the supernatant was
discarded and the resulting pellet was washed with 800 μl of 75% ultrapure ethanol and
recentrifuged at 14,000g for 10 min at 40C. Pellets were then dried and dissolved in 80 μl
ultrapure RNase free water. RNA sample quality and quantities were verified using a
Nanodrop One Microvolume Spectrophotometer (Thermofisher, San Diego, CA) and
determined to be of good quality based on A260/A280 values (>1. 8) prior to cDNA
synthesis using QuantiTect Reverse Transcription kit (Qiagen 205313). Quantitative RTPCR analysis was carried out as per the manufacturer’s instructions (Applied
Biosystems) using Taq-Man Gene Expression Assays. We utilized groups of 3 color gene
expression assays consisting of FAM, VIC, and JUN fluorophores. Data were normalized
to vehicle treated controls and compared to five reference targets (B2M, TBP, HPRT,
HMBS, and H2AFV), which were evaluated for expression stability using the GeNorm
algorithm.98,99
Histopathology:
Hematoxylin & Eosin staining (H&E)
Transverse sections (~5μm) were cut from the paraffin embedded tissues on a
rotary microtome. Cut tissues will be allowed to expand on a 400C -450C water bath and
then attached to (+) charged saline coated microscope slides. Excess paraffin is removed
by placing slides in a 650C oven for 1hr and then stored at 40C until staining. Sections
were warmed to room temperature for 5-10 min. In cases of polyp analysis, tissue
morphology was analyzed by observation and comparison to healthy tissue control
sections. Sections were deparaffinized using the following washing progression; 3x5min
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xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, and 1x3min 70% EtOH.
Sections were then washed for 5min in dH2O, stained with filtered hematoxylin for 5min,
then again washed 6x5 in dH2O. Sections were washed in acid alcohol mix (160mL
100% EtOH, 1mL acetic acid, and volumed to 200mL with dH2O) for 6 dips then again
washed in dH2O for 4 dips. Sections are then washed in Ammonia H2O (0.6mL
Ammonium OH volumed to 200mL with dH2O) for 6 dips and then again washed in
dH2O for 10min. The sections were then be stained with Eosin for 2min and dehydrated
in the following alcohol progression; 1x2min 70% EtOH, 1x2min 95% EtOH, 2x3min
100% EtOH, and 2x5min xylene. Sections were allowed to air dry for 30min and then
mounted for viewing with Permount mounting media. Digital photographs will be taken
from each section at 4x, 10x, 20x and 40x with a Nikon E600 Widefield Epifluorescence
and Darkfield Microscopy System at the University of South Carolina School of
Medicine, and morphology examined. All histopathological analyses were performed by
a board-certified pathologist at the University of South Carolina School of Medicine (Dr.
Ioulia Chatzistamou, M.D. Ph.D.).
Immunohistochemistry: Transverse sections (~5μm) were cut from the paraffin
embedded tissues on a rotary microtome. Cut tissues will be allowed to expand on a 400C
-450C water bath and then attached to (+) charged saline coated microscope slides.
Excess paraffin is removed by placing slides in a 650C oven for 1hr and then stored at
40C until staining. Sections were warmed to room temperature for 5-10 min. Sections
were deparaffinized using the following washing progression; 3x5min xylene washes,
2x5min 100% EtOH, 1x3min 95% EtOH, 1x3min 70% EtOH, and finally washed for
5min in dH2O. To unmask antigens, sections were incubated in citrate unmasking
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solution (Vector Labs) for 30 min at 950C and then cooled for 20min at room
temperature. Sections were then washed in PBS for 5 min then blocked in 10% serum
from the host species of the dedicated secondary antibody (i.e. Goat serum) in a humid
chamber. After blocking, primary antibodies were diluted 1:100 in 5% goat serum and
incubated overnight at 40C. The next day, sections were washed with PBS for 5 min and
then incubated with an HRP-conjugated secondary antibody for 1 hour at room
temperature in a humid chamber and finally washed in PBS. DAB solution was used to
develop HRP-conjugated secondary antibodies. After DAB development, sections were
washed with dH2O and counterstained with acidic Harris Hematoxylin solution for 30s -1
min. After briefly washing in dH2O, sections were dehydrated quickly through 95%
EtOH and 100% EtOH. Sections were allowed to air dry for 30min and then mounted for
viewing with Permount mounting media. Immunohistochemistry stains were imaged at
4x, 10x, 20x and 40x with a Nikon E600 Widefield Epifluorescence and Darkfield
Microscopy System at the University of South Carolina School of Medicine.
Fecal transplantation: For the fecal transplantation experiment (Fig. 1B), 35 mice were
randomly divided into four groups: Donor Vehicle, Donor 5FU, Recipient Vehicle
(Vehicle FMT), Recipient 5FU (5FU FMT) (n=5 per Donor group and n=10–15 per
Recipient group). The Donor 5FU group was injected with 40 mg/kg 5FU for 5
consecutive days as described earlier. All Donor mice were sacrificed 9 days after initial
injection and a mucosal scrape was performed of the distal enteric tract (cecum to anus)
to harvest the microbiota for fecal transplantation. Fecal materials were suspended in
sterile 10% glycerol/PBS, allowed to settle by gravity for 10 min, and aliquoted into daily
requirements for Recipient groups. To perform the FMT study we adopted a protocol by
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Reikvam et al. 201195. Recipient mice were pretreated with the following antibiotic
cocktail every 12 h for 10 days prior to FMT: Vancomycin (50 mg/kg), Neomycin (100
mg/kg), Metronidazole (100 mg/kg), and Amphotericin-B (1 mg/kg) via oral gavage
supplemented with Ampicillin (1 mg/ml) in the drinking water given ad libitum. All
antibiotics were purchased from ACROS Organics, New Jersey. FMT was administered
via oral gavage for 14 days with 150 μl respective fecal suspension from PBS or 5FU
injected mice.
Microbiota sequencing and PICRUSt analysis: All Microbiome analysis and sequencing
was performed by the University of North Carolina Microbiome Core. Fecal evacuates
were collected from each mouse at the conclusion of the study and were chosen at
random for 16S rRNA sequencing, at least one sample from each cage was used to
prevent a cage effect in the data. A final n=5/group was obtained and used for 16S rRNA
sequencing. DNA was isolated from fecal evacuates homogenized with bead-beating
using the Qiagen Qiamp Fast DNA Stool Mini Kit (Qiagen #51604) and was used for
16S rRNA gene targeted sequencing using the V4 region on an Illumina MiSeq
sequencer100,101. Amplification of the 16S rRNA V4 hypervariable region was carried out
using the 16S V4 515F forward (5′ TCGTCGGCAGCGTCAGATGTGTATAAGAGAC
AGGTGCCAGCMGCCGCGGTAA 3′) and V4 806R reverse primer (5′ GTCTCGTGG
GCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT 3′) with
added Illumina adapter overhang nucleotide sequences. The PCR conditions used were
initial denaturing step at 95 °C for 3 min, followed by a cycling of denaturing of 95 °C
for 30 s, annealing at 55 °C for 30 s and a 30 s extension at 72 °C (25 cycles), a 5 min
extension at 72 °C and a final hold at 4 °C. Each 16S amplicon was purified using the
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AMPure XP reagent (Beckman Coulter, Indianapolis, IN). In the next step each sample
was amplified using a limited cycle PCR program, adding Illumina sequencing adapters
and dual index barcodes (index 1(i7) and index 2(i5)) (Illumina, San Diego, CA) to the
amplicon target. The thermal profile for the amplification of each sample had an initial
denaturing step at 95 °C for 3 min, followed by a denaturing cycle of 95 °C for 30 s,
annealing at 55 °C for 30 s and a 30 s extension at 72 °C (8 cycles), a 5 min extension at
72 °C and a final hold at 4 °C. The final libraries were again purified using the AMPure
XP reagent (Beckman Coulter), quantified and normalized prior to pooling. The DNA
library pool was then denatured with NaOH, diluted with hybridization buffer and heat
denatured before loading on the MiSeq reagent cartridge (Illumina) and on the MiSeq
instrument (Illumina).
Automated cluster generation and paired–end sequencing with dual reads were
performed according to the manufacturer’s instructions. Multiplexed paired-end fastq
files were produced from the sequencing results of the Illumina MiSeq using the Illumina
software configure BclToFastq. The paired-end fastq files were joined into a single
multiplexed, single-end fastq using the software tool fastq-join. Demultiplexing and
quality filtering was performed on the joined results. Quality analysis reports were
produced using the FastQC software. Bioinformatics analysis of bacterial 16S amplicon
sequencing data was conducted using the Quantitative Insights Into Microbial Ecology
(QIIME) software102. Operational taxonomic units (OTUs), an operational definition used
to classify groups of closely related individuals103, were picked from the quality filtered
results using pick_de_novo_otus.py. Chimeric sequences were detected and removed
using ChimeraSlayer. Alpha diversity and beta diversity analysis were performed on the
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data set using the QIIME routines: alpha_rarefaction.py and beta_diversity_through_plots.py, respectively. Summary reports of taxonomic assignment by sample and
all categories were produced using QIIME summarize_taxa_through_plots.py and
summarize_otu_by_cat.py103. Samples were rarefied at 10,000 reads/sample. FastTree2
(Price MN, Dehal PS, Arkin AP FastTree 2- approximately maximum-likelihood tress for
large alignments) to build the phylogenetic tree. Finally, we used an open reference
method for OTU picking. Phylogenetic Investigation of Communities by Reconstruction
of Unobserved States (PICRUSt) was used to predict the functional gene content in the
fecal microbiota based on taxonomy obtained from the Greengenes reference database.
PICRUSt and LefSe were performed online in the Galaxy workflow framework.
Specific Aim #2 will determine the safety and efficacy of dietary emodin on reducing
toxicity of 5 fluorouracil chemotherapy.
Rationale: Emodin is a natural anthraquinone found in various Chinese medicinal
herbs. Recent evidence has demonstrated that emodin has many health benefits, including
anti-inflammatory, anti-viral, and anti-bacterial properties, among others. In this aim, we
will first characterize the safety and pharmacodynamics of emodin and then use emodin
as a complementary therapeutic to attenuate the toxicities of 5FU.
Experimental design for specific aim #2.
Primary Outcomes
Pharmacodynamics: Emodin will be measured in the plasma of male and female mice
given a 20 mg/kg and 40 mg/kg dose at specific time points to determine the peak
concentration and rate of clearance.
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Histopathology and Toxicology: A broad tissue analysis will be performed to evaluate the
systemic toxicity of emodin after 3 months of continuous feeding.
Functional Testing: Functional tests will be employed to evaluate the effect of 5FU on
quality of life measures associated with non-specific toxicities attributed to 5FU toxicity.
Inflammation: The inflammatory response to 5FU will be evaluated systemically and in
major organs.
Secondary outcomes:
Microbiome: The effect of 5FU on the gut microbiome and microbial ecosystem will be
evaluated by 16S rRNA sequencing.
Specific Methodology Aim #2:
Animals: For experiment 1; we performed a subchronic (12 week) toxicity study using 3
different doses of emodin (~20 mg/kg, 40 mg/kg, and 80 mg/kg) infused into the AIN76A diet of male and female mice (n=5/group/sex).
For experiment 2; we evaluated chronic (n=5-20/group) and acute (n=20/group/sex)
interventions to 5FU.
Emodin Preparation: Emodin was purchased from Nanjing Zelang Medical Technology
Co., Ltd, (Nanjing, China). Emodin was independently analyzed by the Mass
Spectrometry Center at the University of South Carolina prior to the initiation of the
experimental study. LC-UV-MS and NMR was performed to confirm the purity of
Emodin and the molecular structure. Emodin was delivered intraperitoneally (I.P.) or by
oral gavage (P.O.) at 20 mg/kg or 40 mg/kg doses. For I.P., emodin, dissolved in DMSO
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was made in a large batch, aliquoted, and stored at -200C until used for injections. It was
subsequently diluted in PBS (1% DMSO) and administered to mice I.P. at doses of 20
mg/kg (0.5mg/mL) or 40 mg/kg (1mg/mL). To deliver emodin P.O., we utilized a 20G
30-mm flexible plastic tubal oral gavage needle (Instech, #FTP-20). To prevent aspiration
of the emodin bolus, mice were briefly anesthetized with 2% isoflurane prior to gavage
and held upright until consciousness was regained. Emodin was prepared fresh on the day
of administration. Briefly, emodin was mixed in pure propylene glycol (VWR, #97061)
for 6-8 hours at room temperature while protected from light. The emodin solution was
delivered to mice at 20 mg/kg (6 mg/mL) and 40 mg/kg (12 mg/mL) doses. We used 1%
DMSO in PBS (I.P.) or pure propylene glycol (P.O.) for vehicle controls.
Specific Aim #2: will determine the safety and efficacy of dietary emodin on
reducing toxicity of 5 fluorouracil chemotherapy.
Table A.3 Animal treatment groups for experiment #1.
Strain

Treatment

Age (Weeks)

N

C57BL/6J

AIN Diet

10

5/sex

C57BL/6J

Low Emodin Diet

10

5/sex

C57BL/6J

Medium Emodin Diet

10

5/sex

C57BL/6J

High Emodin Diet

10

5/sex
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Table A.4 Animal treatment groups for experiment #2.
Strain

Treatment

Age (Weeks)

N

C57BL/6J

Control + Vehicle

10

5

C57BL/6J

Control + 40 mg/kg Emodin

10

5

C57BL/6J

5FU + Vehicle

10

20

C57BL/6J

5FU + 40 mg/kg Emodin

10

20

C57BL/6J

5FU + Vehicle

10

20/sex

C57BL/6J

5FU + 20 mg/kg

10

20/sex

C57BL/6J

5FU + 40 mg/kg

10

20/sex

C57BL/6J

5FU + 80 mg/kg

10

20/sex

Solid Phase Extraction and LC-MS/MS Analysis:
Whole blood was collected in EDTA coated tubes from the inferior vena cava and
centrifuged at 4,000 RPM for 10 min. Plasma was aliquoted and stored at -200C until
solid phase extractions. For free emodin quantification, 50 μl plasma was mixed with
equal 0.2M sodium acetate buffer with 1% ascorbic acid (pH 5.0). For emodin
glucuronide quantification, 50 μl plasma was mixed with half volume of 0.2M sodium
acetate buffer with 1% ascorbic acid and 1000 units of β-glucuronidase (Millipore Sigma
#G2174). D4-emodin (1 ng/μl) was used as an internal standard (Santa Cruz #218302).
Both tubes were then incubated at 370C for 2hr. After incubation, the mixture was
extracted with 600 μl ethyl acetate three times. The ethyl acetate layer was evaporated
under N2 gas to dryness and reconstituted in 5% ammonia water. Solid phase extraction
was performed using a vacuum manifold (Supelco #SU57250-U) with Oasis MCX
cartridges (Fisher #186000254) and was eluted with 3 mL 5% formic acid-methanol.
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After elution, the eluent was evaporated under N2 gas to dryness and reconstituted in 400
μl 5% ammonia methanol.
Emodin samples were analyzed and quantified by LC-MS/MS using electrospray
ionization in negative ion mode. Chromatorgraphic separation was performed on a
Waters Acquity UPLC system using a binary solvent gradient. Solvent A was water
containing 0.1% formic acid and solvent B was methanol. The LC column was a Waters
XBridge C18 reversed phase column (2.1mm X 100mm containing 3.5um particles)
running at a flow rate of 0.2 mL/min. The solvent gradient started at 50%B, ramped to
95%B over 10 minutes and was maintained at 95%B until 14 minutes. The gradient then
returned to initial conditions. The mass spectrometer was a Waters Premier XE triple
quadrupole instrument. Data was collected in multiple reaction monitoring (MRM) mode.
Two precursor/product ion pairs were monitored; one pair for emodin (269 daltons > 225
daltons) and one pair for the internal standard deuterium labeled emodin (273 daltons >
229 daltons). According to the standard curve of emodin in 5% ammonia methanol, the
concentration of emodin was calculated relative to the D4-emodin internal standard. Total
emodin was measured from the tube containing the β-glucuronidase, free emodin was
measured from the tube without β-glucuronidase, and glucuronidated emodin was
calculated as the difference between total emodin and free emodin.
Histopathology:
Hematoxylin & Eosin staining (H&E)
H&E staining was performed as described in Aim 1.
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Alcian Blue staining
Goblet cells were observed using Alcian blue staining. Transverse sections
(~5μm) were cut from the paraffin embedded tissues on a rotary microtome. Cut tissues
will be allowed to expand on a 400C -450C water bath and then attached to (+) charged
saline coated microscope slides. Excess paraffin is removed by placing slides in a 650C
oven for 1hr and then stored at 40C until staining. Sections were warmed to room
temperature for 5-10 min. Sections were deparaffinized using the following washing
progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min 95% EtOH, 1x3min
70% EtOH, and finally washed for 5min in dH2O. Sections were then stained with Alcian
Blue solution (1% Alcian blue, 3% acetic acid) for 30 min and then washed with tap
water, then dH2O. After washing, sections were counterstained with Nuclear Fast Red
solution (0.1% nuclear fast red, 5% aluminum sulfate) for 5 minutes and then washed in
tap water. Sections were then washed with dH2O and dehydrated quickly through 95%
EtOH and 100% EtOH. Sections were allowed to air dry for 30min and then mounted for
viewing with Permount mounting media. Digital photographs will be taken from each
section at 4x, 10x, 20x and 40x with a Nikon E600 Widefield Epifluorescence and
Darkfield Microscopy System at the University of South Carolina School of Medicine.
Trichrome staining
Transverse sections (~5μm) were cut from the paraffin embedded tissues on a
rotary microtome. Cut tissues will be allowed to expand on a 400C -450C water bath and
then attached to (+) charged saline coated microscope slides. Excess paraffin is removed
by placing slides in a 650C oven for 1hr and then stored at 40C until staining. Sections
were warmed to room temperature for 5-10 min. Sections were deparaffinized using the
following washing progression; 3x5min xylene washes, 2x5min 100% EtOH, 1x3min
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95% EtOH, 1x3min 70% EtOH, and finally washed for 5min in dH2O. Sections were
then re-fixed in Bouin’s solution for 1 hr at 560C and then washed in dH2O for 10 min.
Sections were then stained in Biebrich scarlet-acid fuchsin solution for 10-15 minutes and
then washed in dH2O. Sections then were differentiated in phosphomolybdicphosphotungstic acid solution for 10-15 minutes. Sections were then placed directly
(without rinsing) into aniline blue solution for 5-10 minutes, rinsed briefly in dH2O and
differentiated in 1% acetic acid solution for 2-5 minutes. Sections were then washed with
dH2O and dehydrated quickly through 95% EtOH and 100% EtOH. Sections were
allowed to air dry for 30min and then mounted for viewing with Permount mounting
media. Digital photographs will be taken from each section at 4x, 10x, 20x and 40x with
a Nikon E600 Widefield Epifluorescence and Darkfield Microscopy System at the
University of South Carolina School of Medicine, and morphology examined. All
histopathological analyses were performed by a board-certified pathologist at the
University of South Carolina School of Medicine (Dr. Ioulia Chatzistamou, M.D. Ph.D.).
Plasma Cytokine Analysis: Plasma was analyzed for common markers of major organ
toxicity/physiological impairment including ALT (Cayman Chemical, 700260) and
creatinine (Cayman Chemical, 700460) and according to manufacturer’s instructions.
Functional Testing:
Peripheral nociception assessment
All experimental mice were utilized to evaluate the effects of 5FU treatment on
peripheral neuropathic nociception. After 3 consecutive days of habituation to the testing
apparatus, right hind-paws were tested for neuropathic nociception by a single
experimenter blinded to experimental conditions using Von Frey filaments (North Coast
Medical, Morgan Hill, CA). Each Von Frey filament was tested for 5 consecutive
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measurements, data was calculated as the paw withdrawal threshold in grams of force.
Threshold was determined by 3 consecutive reactions to the stimulus. Measurements
were performed by the same investigators through the entirety of the study (A.
Sougiannis). Total stimuli were also summed to interpret total sensitivity to the touch
test.
Grip strength assessment
Grip strength assessment was performed as described in Aim 1.
Run-to-fatigue assessment
Run-to-fatigue assessment was performed as described in Aim 1.
Blood Panel Analysis: Blood panel analysis was performed as described in Aim 1.
RNA isolation and qPCR: RNA isolation and qPCR were performed as described in Aim
1.
16S rRNA in-situ hybridization: Colons were excised whole from the rectum to the anus,
opened longitudinally without disturbing opened tissue, and fixed for 24hrs in Carnoy’s
solution (6:6:1 – Ethanol:Acetic Acid:Chloroform) then processed and embedded into
paraffin blocks by standard techniques. 5μm section were placed on SuperFrost slides for
FISH studies. The oligonucleotide probe (EUB338: 5’-GCTGCCTCCCGTAGGAGT-3’)
was purchased from EuroFins synthesized with carbocyanite dye (Cy3) added to the 5’end. Sections were deparaffinized and dehydrated with 4x3 min washes in xylene
followed by 4x3 min washes in 100% EtOH. Bacterial cell walls were opened by
washing sections in ultrapure chloroform for 15 min, air dried for 1 min, then put in a
500C oven for 30 min. Hybridization buffer was prepared with 1% formamide and
prewarmed before hybridizations. 2 mL preparations were as follows: 20μl, 1,580 μl
dH2O, 360 μl 5M NaCl, 40 μl 1M Tris HCl (pH7.4), and 10 μl 10% SDS. Samples were
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incubated with EUB338 probe diluted 1:100 in buffer for 1 hr at 500C in a humid
chamber. After incubation, samples were washed with dH2O and incubated for 5 min at
room temperature with 1 μg/mL DAPI solution and washed again. Diluted hybridization
buffer was used as a mounting media and imaged immediately using a Leica DM2500
fluorescent microscope.
Western Blotting: Whole cell protein extracts were obtained by homogenizing bone
marrow isolates in 300μl Mueller Buffer. Homogenates were centrifuged at 14,000 RPM
for 15 min and then supernatants were aliquoted to new microcentrifuge tubes. Total
protein per μl was quantified using the Bradford method. Tissue homogenates were
separated on had casted 10-12% SDS-PAGE gels and transferred to nitrocellulose
membranes. The gels are transferred to nitrocellulose membranes for 1hr at 12V in room
temperature transfer buffer. After transfer, membranes were washed with dH2O and
stained with ponceau S to ensure equal loading and proper transfer. Membranes were
then blocked with TBS with 0.1% Tween 20 and 5% non-fat milk (5% TBST) for 1 hr at
room temperature and then placed in primary antibody at dilutions of 1:600-1:1000
overnight at 40C. The next day, after 3x10 min wash with TBST, secondary anti-rabbit
IgG-conjugated secondary antibodies were incubated with the membranes at 1:2000 for 1
hr in 5% TBST at room temperature. Enhanced chemiluminescence was used to visualize
the antibody-antigen interactions and develop the blot using autoradiography.
Autoradiographs were scanned to digital files and were analyzed by measuring the
integrated optical density of each band using Image J software (NIH, Bethesda, MD).
Obtained data was normalized to the total protein loaded in each lane which was
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determined by quantification of each lane after membranes were stained with Amido
Black solution and scanned to digital files.
Flow Cytometry: Flow cytometry was performed using the BD FACS ARIA II machine
located and operated by the UofSC School of Medicine Instrument Resource Facility.
Bone marrow was flushed from both left and right femurs of mice using PBS and passed
through 70μm cell strainers. An aliquot of cells was fixed in 70% EtOH for 24hr at-200C
prior to staining with Ki67 and Propidium Iodide (PI) for cell cycle analysis. Remaining
unfixed cells were resuspended in flow buffer (PBS with 5% FBS) and blocked with FC
block (anti-CD16/CD32) for 30min at 40C. After blocking cells were stained with
macrophage panel (CD11b – FITC, F4/80 – PE, and CD45 – PE/Cy7) for 1hr at 40C.
Cells were then washed twice with sterile PBS and then resuspended in 1mL PBS for
flow cytometric analysis. Analysis was performed using FlowJo_v10.6.2 software by
identifying CD45+ immune cells, then gating for CD11b+ monocytes and F4/80+ to
identify double positive cells as mature macrophages.
Specific Aim #3 will determine the efficacy of dietary emodin on preventing
colorectal cancer.
Rationale: There is emerging evidence that emodin may have anti-tumor
properties. We will use the AOM/DSS and Apcmin/+ models of colorectal cancer to
investigate the potential for emodin to be administered as a preventative agent to patients
at risk for developing colorectal cancer.
Experimental design for specific aim #3. Aim 3 will contain two separate animal
experiments to test the efficacy of emodin as a preventative agent against the
development of colorectal cancer.
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Primary Outcomes
Polyp Count: The total polyp number will be evaluated.
Inflammation: The inflammatory response to 5FU will be evaluated systemically and in
major organs.
Secondary outcomes:
Microbiome: The effect of emodin on the gut microbiome and microbial ecosystem will
be evaluated by 16S rRNA sequencing.
Specific Methodology Aim #3:
Animals: Apcmin/+ mice were purchased from Jackson Laboratories at 4 weeks of age and
were habituated to AIN-76A diet for 1 week prior to the start of the experiment. At 5
weeks of age mice were randomized into two groups: Apcmin/+ + Vehicle (n=8) and
Apcmin/+ + 80 mg/kg emodin (n=8). Mice were euthanized at 16 weeks of age and tissues
were collected. For chemical induction of CRC (AOM/DSS model) C57BL/6J mice from
Jackson Laboratories were randomized into four groups at approximately 12 week of age:
Control (n=5), AOM/DSS + Vehicle (n=20), AOM/DSS + 40 mg/kg emodin (n=20), and
AOM/DSS + 80 mg/kg emodin (n=20). Control mice received a 200μl dose of sterile
PBS and AOM/DSS mice received a 10 mg/kg dose of AOM prepared in sterile PBS.
After one week, AOM/DSS mice received 2% DSS drinking water ad libitum for one
week followed by two weeks of recovery. After two weeks of recovery, AOM/DSS mice
received 1% DSS drinking water ad libitum for one week followed by 2 weeks of
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recovery. Mice were euthanized after 12 weeks of treatment and tissues were collected.
Symptom scores were determined using the same method as in Aim 1.
Emodin Preparation:
Emodin was prepared as described in Aim 2 and administered orally.
Specific Aim #3: will determine the efficacy of dietary emodin on preventing
colorectal cancer.
Table A.4 Animal treatment groups for experiment #2.
Strain

Treatment

Age (Weeks)

N

C57BL/6J

Control + Vehicle

10

5

C57BL/6J

AOM/DSS + Vehicle

10

20

C57BL/6J

AOM/DSS + 40 mg/kg Emodin

10

20

C57BL/6J

AOM/DSS + 80 mg/kg Emodin

10

20

Apcmin/+

Vehicle

4

8

Apcmin/+

80 mg/kg Emodin

4

8

Genotyping: All Apcmin/+ mice were genotyped using a tail snip and DNA PCR. At 4-5
weeks of age; animals will be weaned, numbered, and a small tail snip (~1-2mm)
collected. The tail snip is digested in 200μL of tail digest buffer and 5μL of proteinase K.
Tails are incubated overnight in a water bath set at 55OC. After incubation, samples are
heat shocked at 95OC in a dri-bath for 10 minutes. Heterozygosity of the Apc gene will
be determined via a PCR reaction (Apc forward 5' TGAGAAAGACAGAAGTTA 3',
reverse 5' TTCCACTTTGGCATAAGGC 3'). PCR products are run out on a 5%
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polyacrylamide gel and exposed to UV light. Presence of a band indicates heterozygosity
of the Apc gene.
Polyp count: Intestinal polyps from Apcmin/+ mice were counted by staining in methylene
blue. Formalin fixed intestinal sections from all Apcmin/+ mice were rinsed in deionized
water, briefly stained in 0.1 % methylene blue, and counted by the same investigator who
was blinded to the treatments. Polyps from AOM/DSS mice were counted during surgical
resection without methylene blue. Polyps were counted under a dissecting microscope,
using forceps to pick through the villi and crypts to identify polyps. Polyps were
categorized as small (< 1 mm), medium (1-2 mm), or large (> 2 mm). After polyps were
counted, methylene blue stained intestinal sections were washed with 70% ethanol and
embedded in paraffin for further analysis.
Flow Cytometry: Flow cytometry was performed using the BD FACS ARIA II machine
located and operated by the UofSC School of Medicine Instrument Resource Facility.
Bone marrow was flushed from both left and right femurs of mice using PBS and passed
through 70μm cell strainers. Cells were resuspended in flow buffer (PBS with 5% FBS)
and blocked with FC block (anti-CD16/CD32) for 30min at 40C. Lamina propria was
isolated from whole excised colons using the Miltenyi Biotech Lamina Propria
Dissociation Kit, Mouse (Miltenyi# 130-097-410). After blocking, cells were stained
with macrophage panel (CD11b – FITC, F4/80 – PE, CD206 - APC, CD11c – APC/Cy7,
Ly6C – PerCP/Cy5.5, and CD45 – PE/Cy7) for 1hr at 40C. Cells were then washed twice
with sterile PBS and then resuspended in 1mL PBS for flow cytometric analysis.
Analysis was performed using FlowJo_v10.6.2 software by identifying CD45+ immune
cells, then gating for CD11b+ monocytes and Ly6C+ activated cells to identify F4/80+
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cells as mature macrophages. Mature macrophages were then gated and analyzed for
CD11c and CD206 expression to identify M1- and M2-type macrophages, respectively.
RNA isolation and qPCR:
RNA isolation and qPCR were performed as described in Aim 1.
Histopathology:
Hematoxylin & Eosin staining (H&E)
H&E staining was performed as described in Aim 1.
Western Blotting:
Western blotting was performed as described in Aim 2.
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APPENDIX B
EMODIN PRODUCT INTEGRITY
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Principal Investigator: Alexander T. Sougiannis
Re: 1 F31 AT009820-01
Product Information: Emodin
D. Refined Products
D1. Name the supplier of the product. *
Nanjing Zelang Medical Technology Co., Ltd.
D2. Present data on the characterization of the product (e.g., chemical profile or
fingerprint) as thoroughly as the state of the science allows.
a. Indicate the purity if the product is a single component.
b. Provide concentration of major and minor components if the product is a
mixture.
c. Information from suppliers MUST be confirmed through independent
analysis either by a third-party lab or by the investigator (if they have
appropriate facilities and expertise). Provide conformational data (e.g.
chromatograms and/or spectra) or a plan regarding how this will be
obtained.
Purity: Emodin is a single component with >98% purity.
Independent verification: Nanjing Zelang Medical Technology Co., Ltd. will perform
preliminary identification of Emodin sample using in-house LC-UV-MS techniques.
Nanjing Zelang Medical Technology Co., Ltd. will provide a certificate of analysis
(see Appendix, documents in Chinese and English) with identity and impurity test
results and source information. Emodin will be independently analyzed by the Mass
Spectrometry Center at the University of South Carolina prior to the initiation of any
experimental study (see Appendix). LC-UV-MS and NMR will be performed to
confirm the purity of Emodin and the molecular structure (see Appendix). All
chemicals and reagents used for standardization at the University of South Carolina
will be HPLC-grade.

219

D3. Provide data on the analysis of the product for contaminants/impurities such as
pesticides, heavy metals, and residual solvents.
Product information: Nanjing Zelang Medical Technology Co., Ltd. follows the
guidelines of the China Food and Drug Administration (CFDA) which includes
testing of heavy metals, impurities, and other toxins (see Appendix).
Independent verification: After receiving Emodin, I will send the Emodin powder to
be tested for microbial aflatoxin, heavy metal, and pesticide presence to NP
Analytical Laboratories (St. Louis, MO, USA). Microbial analysis will detect the
presence of total microbial counts, yeast and most counts, gram-negative bacteria, E.
coli, and salmonella. Emodin will also be tested for aflatoxin B1 presence. The
presence of arsenic, cadmium, lead, and mercury heavy metals will be verified.
Additionally, a pesticide screen will be performed.
D4. Provide data on batch-to-batch reproducibility. These data may be required
separately for the agent alone, the vehicle alone, and the final products as
appropriate.
I will use the same batch of Emodin for the entire study, thus I do not expect to
have any problems with batch-to-batch reproducibility. In the case that I need a
new batch of Emodin, special attention will be given to the lot number. Further, I
will perform NMR and LC-UV-MS to confirm the purity and molecular structure
of the new batch. Data presented in the appendix indicates our streamlined
ability to validate the Emodin extract (see NMR and MS appendix).
D5. Present a plan to monitor stability of product samples from all batches used
during the study. The plan should include:
a. How you plan to store the test agents, vehicle, and/or final product
b. What analyses will be conducted, the methods to be used, and how frequently
and by whom the analyses will be done
c. Investigator’s tolerances for chemical and/or biological variability, and what
will be done if variability exceeds those limits. In addition, sufficient material
must be retained from each batch to allow independent analysis, should
NCCIH request samples. Samples should be maintained a minimum of 1
year after all results arising from the study have been published.
Storage: Emodin will be stored at -20 degrees Celsius as a dry powder once it arrives
from the Nanjing Zelang Medical Technology Co., Ltd. Solutions of Emodin extracts
will be prepared at 100mM (27 mg/ml) in DMSO and will be stored at -20 degrees
Celsius.
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Stability Testing: Before conducting a new experiment, or every 3 months, 27 mg/ml
of Emodin powder will be dissolved in DMSO, aliquoted, and stored at -20 degrees
Celsius. An aliquot will be used for Emodin stability testing (anti-inflammatory
capacity) against a freshly prepared aliquot. Remaining aliquots will be stored at -20
degrees Celsius.
After confirming the stability of Emodin using LC-UV-MS, I will verify the antiinflammatory capacity of Emodin utilizing freshly harvested bone marrow derived
macrophages. Briefly, bone marrow derived macrophages will be harvested and
allowed to grow in the presence of 15% L929 conditioned media for 7 days. Cells will
be plated on a 12-well cell culture plate at a density of 0.5x106 cell/ well for 24 hours
to allow for adherence. Then, cells will be treated with Emodin at 0, 50, 100, and 200
μg/ml for 24 hours. After Emodin treatment, cells will be stimulated with LPS at 100
ng/ml for 24 hours. Media and cells will be harvested and assayed for TNFα, IL-6,
IL-1β, IFNγ, and CXCL2 RT-PCR assays. Results should show a dose-response of
Emodin’s ability to decrease TNFα, IL-6, IL-1β, and IFNγ expression in bone marrow
derived macrophages stimulated with LPS. CXCL2 expression will be used as a
negative control, as Emodin does not change CXCL2 expression after LPS treatment.
The PI, Alexander Sougiannis, will perform all stability and cell culture experiments
(see attached paper from Fan laboratory (dissertation committee member)).
Tolerances and Contingency for Variability: Emodin aliquots that show less than
10% variability in anti-inflammatory capacity test will be used for experimental
studies. If Emodin aliquots fail to reduce TNFα, IL-6, IL-1β, and IFNγ expression,
shows greater than 10% variability, or does not show a dose response curve, these
aliquots will not be used in any of the experiments and new Emodin aliquots will be
analyzed prior to any experiments and a new LC-UV-MS fingerprint will be
compared to the original chromatogram. In the event the Emodin fingerprint is not
comparable to the original chromatogram, new Emodin will be ordered from the
Nanjing Zelang Medical Technology Co., Ltd. and the stability protocols will be
performed as described above prior to any experimentation.
Voucher samples: We will store voucher specimens of Emodin, and any new orders
of Emodin (2 x 100g). Emodin will be stored at -20 degrees Celsius as previously
described. The raw material will be confirmed taxonomically by Nanjing Zelang
Medical Technology Co., Ltd. A voucher specimen will be submitted to the University
of South Carolina A.C. Moore Herbarium (http://herbarium.biol.sc.edu//). The A.C.
Moore Herbarium at the University of South Carolina, founded in 1907, contains
over 100,000 specimens making the herbarium the largest in the state of South
Carolina. The majority of material stored is native to the Southeastern United States
and more specifically from South Carolina.
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D6. Provide information relevant to the manufacturing process assuring reasonably
consistent material suitable for scientific study (including process control, as well as
chemical standardization of ingredients).
a. Provide information on the formulation of the final product (e.g. excipients,
solvents, buffers, chow/feed composition).
b. Provide documentation to show product was manufactured under GMP
guidelines.
Final Product Formulation: Nanjing Zelang Medical Technology Co., Ltd. uses
crude material from Rheum palmatum to extract Emodin. As described above
(sections D2, D3, and D5), we will confirm the chemical fingerprint (LC-UV-MS and
NMR) and characterize Emodin upon arrival to ensure we have received a purified
compound.
GMP guidelines: Nanjing Zelang Medical Technology Co., Ltd. follows the
guidelines of the China Food and Drug Administration (CFDA). The Emodin extract
to be used in our studies will be purchased from the Nanjing Zelang Medical
Technology Co., Ltd. and will only be used in animal studies. The extract will be well
characterized (see section D2, D3 and D5) to allow similar human studies to be
performed in a GMP compliant laboratory in the future.
D7. When the product is combined with a diet, a Certificate of Analysis and
specifications for the vehicle will also be necessary to assure purity, consistency,
absence of bioactive components and/or reproducibility of the vehicle. Furthermore,
analysis of the formulated diet may be required to assess consistency, stability, etc.,
of the product in this matrix.
Not applicable. Emodin will be given by oral gavage and will be prepared fresh
on the day of delivery to the animal.
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Figure B1. Certificate of Analysis from Zelang
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Figure B2. Chromatograms of Emodin
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Figure B3. The chemical structure of Emodin.
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